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Abstract 
For a proportion of patients, HBV infection results in chronic disease with severe 
consequences like liver cirrhosis or hepatocellular carcinoma. Approved therapies of 
chronic hepatitis B include administration of antivirally active IFN-α and inhibitors of 
viral reverse transcription. These drugs control replication, but HBV cccDNA, the 
episomal transcription template, persists in most cases. Hence, lifelong therapy is 
required, accompanied by severe side effects and development of drug resistant 
mutants. An alternative and probably safe immunotherapeutic approach for clearance 
of HBV may be achieved by the stimulation of pattern-recognition receptors inducing 
an endogenous type-I IFN response. In this study the cytosolic helicase RIG-I was 
triggered by in vitro transcribed 5’-triphosphated (3p-) dsRNA. Stimulation induced an 
RIG-dependent antiviral type-I IFN response and controlled HBV replication in vitro in 
stable HBV replicating cell lines as well as in HBV infected primary human 
hepatocytes. In vivo, virus replication in HBV transgenic animals was transiently 
controlled when Rig I ligands were complexed and i.v. injected.  
To enhance and prolong the antiviral effect, siRNAs targeting overlapping open 
reading frames of the HBV genome at the 3´-end of multiple HBV-RNAs were 
designed and investigated whether they can be in vitro transcribed and act as RIG-I 
ligands, and thus combine the immune stimulatory potential with HBV specific gene 
silencing. 3p-siRNAs were transfected into HBV replicating cells, induced INF-I and 
IFN-stimulated genes. HBV replication markers were significantly reduced and the 
antiviral effect of 3p-siRNA was superior to siRNA or 3p-RNA alone. Stronger effects 
of 3p-siRNAs on HBV replication were confirmed in HBV infected primary human 
hepatocytes, as well as in vivo. Nevertheless, the gene silencing effect of 3p-siRNA 
seemed to be limited in the mouse model due to insufficient targeting of hepatocytes, 
the HBV host cells. Application of cholesterol coupled siRNA improved hepatocyte 
specific targeting. Furthermore, we showed that 3p-siRNA besides a direct antiviral 
effect additionally induced infiltration of cytotoxic CD8+ T cells to the liver, potentially 
leading to elimination of infected hepatocytes.  
The results of this study demonstrate that HBV-specific 5`-triphosphated siRNAs 
efficiently block HBV replication in vitro and in vivo. Combination of endogenous 
type-I IFN induction by stimulation of RIG-I with HBV sequence-specific gene 
silencing by RNAi in one single molecule could be a promising alternative to the 
actual standard therapeutic approaches against chronic HBV infection. 
 
	   II	  
Zusammenfassung 
Eine Infektion mit dem Hepatitis B Virus führt bei einem Teil der Patienten zu einem 
chronischen Infektionsverlauf mit schwerwiegenden Spätfolgen, wie Leberzirrhose 
oder hepatozellulärem Karzinom. Die gängigen Therapien einer chronischen HBV 
Infektion umfassen IFN-α und Reverse Transkriptase Inhibitoren als Hemmstoff der 
viralen Replikation. Diese Medikamente kontrollieren die Virusreplikation. In den 
meisten Fällen ist es aber nicht möglich, die episomal persistierende virale 
Transkriptionsmatrize (HBV cccDNA) zu eliminieren. Dadurch wird eine lebenslange 
Therapie erforderlich, die von Nebenwirkungen und dem Entstehen von 
arzneimittelresistenten HBV-Mutationen begleitet sein kann. Die Stimulation von 
RIG-I, einer cytoplasmatischen Helikase, kann zu der Freisetzung von endogenem, 
antiviral wirksamen Typ 1 IFN führen und stellt somit einen neuen, therapeutischen 
Ansatz für eine Behandlung der chronischen Hepatitis B dar.  Die Stimulation von 
RIG-I mittels durch in vitro Transkription generierte 5´-triphosphorylierte (3p), 
doppelsträngige RNA führte in stabil HBV exprimierenden Zelllinien, in HBV 
infizierten primären humanen Hepathozyten und in HBV transgenen Mäusen zu einer 
Ausschüttung von Typ 1 IFN, und folglich zu einer Suppression der Virusreplikation. 
Um diesen antiviralen Effekt zu verstärken, wurden siRNAs entworfen, die die 
überlappenden offenen Leseraster des HBV Genoms am 3`-Ende aller viralen RNAs 
als Ziel haben. Es wurde untersucht, ob diese nach in vitro Transkription zur 
Stimulation von RIG-I fähig sind und es somit zu einer Kombination von 
Immunstimulation und Hemmung der viralen Genexpression kommt. Die 
ausgewählten 3p-siRNAs führten in HBV replizierenden Zellen zur Induktion von Typ 
1 IFN und IFN-stimulierter Gene. Sie kontrollierten die HBV Replikation sowohl in 
stabil HBV exprimierenden Zellen, in HBV infizierten primären Hepathozyten, als 
auch in HBV transgenen Mäusen effizienter als die alleinige Applikation von siRNA 
oder 3p-RNA. Im Mausmodel konnte außerdem durch die Kopplung von siRNA an 
Cholesterol ein verbessertes Targeting von Hepatozyten, den HBV-Wirtszellen, 
erreicht werden. Die Injektion von 3p-siRNAs führte in vivo zu Einwanderung von 
zytotoxischen CD8+ T-Zellen in die Leber, die zur Elimination der HBV infizierten 
Zellen beitragen können. Somit kann durch HBV-spezifische 3p-siRNA die HBV 
Replikation in vitro und in vivo effektiv unterdrückt werden. Vereinigt in einer 
Substanz stellt die kombinierte Induktion von endogenem Typ 1 IFN und die 
spezifische Hemmung der viralen Genexpression eine vielversprechende Alternative  
zu den Therapien der chronischen HBV-Infektion dar.  
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1 Introduction 
 
1.1 The Immune System 
 
The immune system is a multifunctional and highly adaptable defense system of 
mammalians to protect the body from different invading pathogenic microorganisms 
and eliminate infective pathogens. It is able to detect a wide variety of agents like 
viruses, bacteria, pathogenic fungi or parasites. Beside the ability to generate a 
variety of cells and proteins capable to recognize and eliminate foreign invaders, the 
immune system is additionally able to recognize and remove disordered and 
damaged cells, which are prone to emerge as malignant tumors. An essential 
assumption of this interacting, elaborate and dynamic network is the ability to 
distinguish infected or degenerated cells from healthy cells and tissues to 
differentiate between self and non-self. 
All components of the immune response are mediated by white blood cells, named 
leukocytes, which derive together with red blood cells (erythrocytes) from one 
common cell type in the bone marrow, the pluripotent hematopoetic stem cell. These 
lymphoid and myeloid progenitor cells differentiate in the bone marrow. The common 
lymphoid progenitors display the precursor of lymphocytes. There are three major 
types of lymphocytes: first, natural killer cells (NK cells); second, B-lymphocytes (B-
cells), which differentiate in the bone marrow and third, T-lymphocytes (T-cells), 
which differentiate in the thymus. The emerging myeloid progenitors are the 
precursor of granulocytes, circulating in the blood, as well as macrophages, dendritic 
cells (DCs) and mast cells entering tissues (Janeway, 2007). 
Immunity, the status of protection from infectious diseases, basically is divided into 
two phylogenetic different stages. The older and less specific component is the 
innate immunity, providing the first line of host defense against invading pathogens. 
The initial and antigen non-specific immune response is rapidly activated to eliminate 
or neutralize the invading organism. This effector response is primarily based upon 
anatomical barriers like skin and physiological barriers such as temperature or pH-
value in the host. Major tasks of innate immunity are activation of NK cells and 
leukocytes, like mast cells, eosinophils or basophils as well as phagocytic cells, such 
as macrophages, neutrophils and DCs. Furthermore the recognition of pathogen 
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specific patterns by non-catalytic receptors, followed by the synthesis of antimicrobial 
mediators like interferons play an important role in innate immune response. 
In contrast to the broad reactivity of the innate immune response, the phylogenetic 
younger and more specific component of the immune system is known as adaptive or 
acquired immunity. The antigen-specific adaptive immune response is activated after 
antigenic challenge to the organism and is established within five to six days after the 
initial exposure to the antigen in the late phase of infection. Repeated exposure to 
the specific antigen generates immunological memory. This fast occurring immune 
response, followed after a secondary encounter with the same specific pathogen, is 
stronger and more efficient and can lead to lifelong protection against the specific 
pathogen. Two types of adaptive immunity are involved in antigen-specific pathogen 
neutralization: first, the cellular immunity mediated by antigen-specific T-lymphocytes 
and their release of various cytokines in response to an antigen. The second 
component of the adaptive immune system is the humoral immunity, mediated by 
secreted antibodies produced by B-cells. 
The rapid and non-specific innate immune response provides the first line of defense 
during the critical period directly after exposure to the pathogen. In addition, it plays a 
crucial role in stimulation of adaptive immunity. The adaptive immune response 
requires some time to arrange a definite and pathogen specific immune response, 
after repeated exposition of the host to microbial pathogens (Janeway, 2007). 
 
 
1.1.1 Adaptive immunity 
 
The adaptive immune system is able to recognize, adapt to and selectively eliminate 
specific foreign microorganisms. Adaptive immunity is divided into a humoral 
response, mediated by B-cells and a cellular response, mediated by T-cells. The 
humoral response of B-cells is based on antibody production and reacts on 
pathogenic organisms and viruses as well as on extracellular free circulating, 
pathogen derived and foreign antigens. Naïve B-cells, that had no previous contact 
with an antigen, circulate in the blood after they left the bone marrow. They express a 
unique antigen-binding receptor on their surface, termed membrane-standing 
immunoglobulin (IgM) or B-cell receptor (BCR). BCRs consist of two identical heavy 
and two identical light polypeptide chains. Every chain contains a constant and a 
Introduction 
	   3	  
variable region. The amino-terminal variable ends of the pairs form a cleft within the 
specific antigen binds (Janeway, 2007).  
The high diversity of BCRs is given by a mechanism called somatic recombination of 
gene segments, which results in the high genetic diversity in the variable regions. 
The number of B-cells that are able to bind to a given antigen is very small. To 
expand this population of B-cells, they are stimulated after antigen binding to divide 
rapidly into a clone with the same antigenic specificity, a process called clonal 
selection. During this process the progeny cells differentiate to effector B-cells. After 
activation the original membrane-standing BCRs are secreted as antibodies. On the 
one hand the antibodies neutralize pathogens or their toxic products by specific 
binding, and thus prevent the access of pathogens to potential target cells. On the 
other hand, phagocytotic cells recognize the constant region of the antibodies and 
ingest the antibody-covered pathogens. After the pathogenic antigen is removed from 
the body most of the effector B-cells undergo apoptosis (Banchereau, Briere et al. 
1994). A small population of naïve B-cells develop into memory B-cells during clonal 
selection by an immunoglobulin-isotype change from IgM to IgG. Memory B-cells 
circulate in the lymphoid organs and mediate lifelong immunity against the specific 
pathogenic antigen (Liu, Zhang et al. 1991).  
The cellular response mediated by T-cells is mainly directed against intracellular 
pathogens. It requires processing and presentation of pathogen-specific antigens by 
infected cells. After T-cells arise in the bone marrow, they migrate to he thymus gland 
to mature under positive and negative selection (Janeway, 2007). During maturation, 
T-cells express a unique antigen-binding receptor on their surface, called T-cell 
receptor (TCR). The TCR differs from BCR in structure, but the high diversity of 
TCRs is also obtained by somatic gene recombination. In contrast to BCRs, which 
can recognize antigens alone, TCRs can only recognize antigenic peptides that are 
bound to cell membrane proteins, called major-histocompatibility-complex (MHC) 
molecules (Klein 1986). This event is termed antigen presentation. T-lymphocytes 
can be differentiated into two well-defined subpopulations by the expression of 
membrane glycoprotein co-receptors beside the TCR, named CD4 and CD8 (CD, 
cluster of differentiation). These co-receptors differentiate both T-cell types in general 
and also determine their interaction with the MHC molecules. CD8+ T-cells interact 
with MHC I and CD4+ T-cells interact with MHC II (Lustgarten, Waks et al. 1991). 
MHC I is expressed by nearly all nucleated cells and presents processed intracellular 
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antigens, for example resulting from virus infection. Furthermore, MHC I and II are  
inherent body-identity markers. MHC II is expressed only by professional antigen-
presenting cells (APCs), like macrophages and DCs, and presents phagocytosed 
antigens of extracellular pathogens to CD4+ T-cells. This phenomenon is known as 
MHC restriction.  
As an exception, internalized extracellular antigens can be transferred to and 
presented by MHC I, a mechanism termed cross-presentation (Bevan 1976). After 
the uptake of extracellular proteins by DCs, macrophages (Brode and Macary 2004), 
B-cells (Hon, Oran et al. 2005) and also liver sinusoidal endothelial cells, LSECs 
(Limmer, Ohl et al. 2000), via receptor-mediated endo- or macropinocytosis, the 
proteins are transferred by an unknown mechanism into the cytoplasm where they 
are processed to peptides by the proteasome. Afterwards, they are transported by 
TAP (transporter associated with antigen processing) into the lumen of the ER, get 
loaded on MHC I (and MHC II) and presented on the cell surface to CD8+ (and CD4+) 
T cells. Thereby, professional APCs are able to present for example antigens from 
different viruses, which are not able to infect APCs (Sigal, Crotty et al. 1999).  
CD4+ T-cells bind antigens presented on MHC II and differentiate upon activation into 
effector T cells with specific effector functions and cytokine profiles. They essentially 
participate to humoral and cellular immunity, as well to initiation and development of 
immunological memory. During the adaptive immune response against HBV 
infection, HBV-specific CD4+ T-cells induce and maintain a CD8+ T-cell response and 
activate B-cells (Rehermann 2003). CD4+ T-cells are separated into T-helper cells 
(TH) and T-regulatory cells (Tregs). The population of TH-cells is subdivided into TH1-, 
TH2-, TH17- and TH22-helper cells with specific roles in host defense against certain 
pathogens and in organ-specific autoimmunity. TH1-cells activate macrophages, 
support antigen specific proliferation of CTLs and stimulate B-cells to produce 
opsonizing immunoglobulins, leading to phagocytosis of antibody-marked pathogens. 
TH2-cells assist the humoral immune response by B-cells activation to produce 
neutralizing antibodies (Ridge, Di Rosa et al. 1998). Another subset of TH-cells highly 
produce interleukin-17 (IL-17) and are designated TH17-cells. Their role, together 
with other inflammatory cells, in induction of tissue inflammation during host defence 
and organ-specific autoimmunity is under discussion (Korn, Oukka et al. 2007). 
Recently, a previously uncharacterized IL-22-and TNF- α producing T-helper cell 
population has been described (Trifari, Kaplan et al. 2009). These peripheral 
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lymphocytes, subject to be named TH22-cells, are primarily found in epithelial tissue 
and are involved in inflammatory and wound healing processes. A supposed 
contribution to HBV infection has to be elucidated.  
A small subpopulation of CD4+ T-cells, named regulatory T cells (Tregs) provide 
regulatory functions in adaptive immunity. Tregs additionally express surface markers 
such as CD25, CD45 or FoxP3. It was shown, that they regulate immune-
inflammatory aspects during viral infections (Suvas, Azkur et al. 2004) and may play 
a regulatory role in viral resistance during chronic HBV infection (Peng, Li et al. 
2008). CD8+ T-cells recognize intracellular or phagocytozed (by cross-presentation) 
antigens presented on MHC I complex and differentiate under the influence of TH cell-
derived cytokines to cytotoxic T lymphocytes (CTLs). CTLs kill infected or malignantly 
transformed cells. During an HBV infection CTLs specific for different HBV epitopes 
remove infected hepatocytes from the liver by lysis. Additionally, they may control an 
infection also on a non-cytolytic level by secreting antiviral cytokines (Guidotti, 
Ishikawa et al. 1996). 
Nevertheless, most of the microorganisms, which entered a healthy individual are 
already cleared within a few days by distinct defense mechanisms of the innate 
immunity. Before the adaptive immune response eradicates foreign pathogens, the 
innate immune system is able to repress a pathogenic invasion by distinct features. 
 
 
1.1.2 Innate immunity 
 
The less specific and initial acting part of the immune response is the innate immune 
system, which often leads to the destruction of pathogens during the first days of 
infection without the help of the adaptive immune response. This complex system 
unifies different types of defensive barriers during a first contact of the host with a 
nonspecific microbial pathogen (Kuby, 2000).  
First, the skin and mucosal membranes, as well as low pH-value in the stomach and 
digestive enzymes provide a protective anatomic, mechanical and chemical barrier 
between the internal and the external milieu. Once a pathogen passed this first 
barrier through a breached or wounded skin, the internal epithelial surface or body 
fluid exchange, the body possesses further physiological barriers. Normal body 
temperature or fever response inhibits the growth of some pathogens. Moreover,  
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chemical barriers, for example antiviral acting interferons, are produced by virus-
infected cells. Bactericidal peptides like defensins are produced or released by 
phagocytes after the ingestion of microorganisms, which represent the endocytotic 
barrier of the innate immune system.  
After a pathogenic microorganism crossed the anatomic barrier of epithelial cells and 
escaped all physiological barriers, the pathogen is able to start replication in the 
affected tissue of the host. Normally, the site of infection is immediately recognized 
and invaded by various cells that internalize (endocytose) and dissolve the foreign 
macromolecules. Circulating phagocytes, such as monocyte derived macrophages or 
neutrophils, phagocytose, kill and digest microorganism during beginning and acute 
phase of inflammation. Macrophages and neutrophils recognize pathogens via 
pattern recognition receptors (PRRs) on their cell surface and are able to discriminate 
between pathogen-associated molecular patterns (PAMPs) and those of the host.  
Once bound, microorganisms are engulfed and degraded in endosomes and 
lysosomes. The generated peptides can be presented by MHC class II to CD4+ T-
cells, a process connecting innate and adaptive immune response. Macrophages are 
localized especially in connective tissues, in the mucosa of the gastrointestinal tract, 
in the lung, in the spleen and also in the liver. In the liver the specialized 
macrophages are called Kupffer cells, where they remove large numbers of dying 
cells from the blood. Contact to the pathogen initiates the activation of macrophages 
to release chemical mediators, cytokines and chemokines (chemoattractant), which 
indicate an inflammation in the tissue. Neutrophils circulate in the blood stream and 
migrate, attracted by macrophage-derived cytokines, a process called chemotaxis, to 
the site of infection (Janeway, 2007).  
DCs are the key players of antigen presentation to T-cells. Immature phagocytotic 
DCs migrate to peripheral tissues, where they continuously and unspecifically take up 
extracellular material via macropinocytosis. Additionally they selectively recognize 
and ingest pathogens through receptor-mediated endocytosis (Banchereau, Briere et 
al. 2000). After uptake and degradation of a microorganism, the expression and 
presentation of MHC and co-stimulatory molecules on the cell surface is up-
regulated. DCs are now able to effectively present antigens on their surface, activate 
T-cells and stimulate the innate and adaptive immune response via secretion of 
cytokines like IL-6, IL-12, Il-18, IFN-α and IFN-γ (Banchereau, Briere et al. 2000). 
The DCs, now called mature, migrate to the local lymphoid tissue, where they 
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activate naïve T-cells. Thereby, following T-cell development can be driven in 
different directions. IL-12 and IFN-γ expressed by DCs lead to the differentiation of 
CD4+ T-cells into TH1-helper cells. (Lanzavecchia and Sallusto 2001). Uptake of 
extracellular pathogens by DCs and presentation via MHC II mediates development 
of CD4+ T-cells into TH2-helper cells (Moser and Murphy 2000). DCs also present 
phagocytosed and cross-primed antigens from viruses, bacteria and also tumors to 
CD8+ T-cells via MHC I, which thereupon become CTLs (Janssen, Lemmens et al. 
2003).  
The main pathway by which DCs get activated, mature and present antigens to naïve 
T-cells, is the recognition of PAMPs by PRRs. DCs display the key cell type coupling 
PRR-mediated innate immune recognition and initiation of adaptive immune 
response. Consequently, the innate immune response is not completely non-specific. 
The system is able to discriminate between self and broad variety of foreign 
pathogens (Janeway and Medzhitov 2002).  
 
 
1.1.3 Pathogen-associated molecular patterns: PAMPs 
 
The variety of pathogens that can be recognized is given through highly conserved 
structures, a broad spectrum of microbial components, and known as pathogen-
associated molecular patterns (PAMPs) or microbe-associated molecular patterns 
(MAMPs). PAMPS are essential for the survival of the microorganism and therefore 
difficult for the microorganism to alter. A prototypical PAMP is bacterial 
lipopolysaccharide (LPS) of gram-negative bacteria, a component of their outer 
bacterial cell wall. Other PAMPs are for example bacterial flagellin, peptidoglycan, 
unmethylated bacterial CpG-DNA, or nucleic acid variants of viruses, such as double-
stranded RNA (dsRNA) or double-stranded DNA (dsDNA) (Fig. 1). 
 
 
1.1.4 Pattern-recognition receptors: PRR 
 
Pattern-recognition receptors (PRR) are the key players in innate immune host 
defense. They are tagged by the PAMPs, which leads to induction and activation of 
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inflammatory and antimicrobial innate immune responses (Medzhitov 2001). Different 
PRRs react with specific PAMPs (Fig. 1). The binding activates specific signaling 
pathways, which lead to altered gene expression and to distinct antipathogenic 
responses. PRRs can be subdivided into four different families: a) Toll-like receptors 
(TLR) b) RIG-I-like receptors (RLR) c) C-type lectin receptors (CLR) and d) NOD 
(nucleotide binding and oligomerization domain) -like receptors (NLR) (Palsson-
McDermott and O'Neill 2007). 
Toll-like receptors are probably the most important family of PRRs. Their name 
originates from Toll, a receptor that was primarily identified in Drosophila (Hashimoto, 
Hudson et al. 1988). Subsequent studies revealed that Toll also play an essential 
role in insect innate immunity (Lemaitre, Nicolas et al. 1996). In the following, 
homologues of Toll were identified in mammals. To date 10 members of the human 
TLR family have been identified. TLRs, which are type I transmembrane 
glycoproteins are expressed by various immune cells including macrophages, DCs, B 
cells and specific types of T-cells, but also by non-immune cells such as fibroblasts 
and epithelial cells (Akira, Uematsu et al. 2006). The receptors are able to detect 
PAMPs derived from fungi, parasites, bacteria or viruses via an extracellular leucine-
rich repeat (LRR) sequences and transmit signals through the cytoplasmic Toll-
interleukin (IL)-1 receptor (TIR) domain. They can be divided in several subfamilies 
by different aspects and characteristics. One characteristic is that each subfamily of 
TLRs recognizes related PAMPs: TLR1, 2 and 6 predominantly recognize lipids, 
TLR5 flagellin and TLR9 bacterial and viral CpG-DNA. TLR3, 7 and 8 are triggered 
by viral nucleic acids (Barton 2007). TLR4 recognizes a collection of different ligands 
with totally different structures, such as lipopolysaccharide (LPS), viral proteins, 
fibronectin or heat-shock proteins. Another aspect for discrimination is that certain 
TLRs are expressed on the cell surface (TLR1,2,4,5 and 6), others are found in 
intracellular compartments such as endosomes (TLR3,7,8 and 9). Initially, TLRs were 
described to be involved in bacterial pathogen recognition (TLR1,2,4,5,6 and 9), but 
they also play a crucial role in the host response to viruses. Endosomal TLR3, 7 and 
8 recognize viral nucleic acids, which requires internalization to the endosome, 
before induction of an antiviral response is possible. In contrast viral glyoproteins 
interact with TLR 2 and 4 on the cell surface before or during viral entry (Akira and 
Takeda 2004; Akira, Uematsu et al. 2006; Thompson and Locarnini 2007).  
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Fig. 1.1: Toll like receptors (TLRs), cytosolic helicases and their different ligands. Illustration 
modified after (Chaudhuri, Dower et al. 2005) 
 
 
The second family of PRR identified to be involved in the recognition of viral nucleic 
acids beside TLRs are the retinoic acid-inducible gene–I (RIG-I)-like receptors (RLR). 
RLR comprise RIG-I (retinoic acid inducible gene-I), MDA-5 (melanoma 
differentiation associated gene 5) and LGP-2 (laboratory of genetics and physiology 
2) (Yoneyama, Kikuchi et al. 2004; Rothenfusser, Goutagny et al. 2005; Yoneyama, 
Kikuchi et al. 2005; Gitlin, Barchet et al. 2006). All RLRs are ubiquitously expressed 
cytosolic helicases. RIG-I and MDA-5 survey the cytoplasm for viral RNA and 
recognize different RNA viruses. Additionally, MDA-5, as well as TLR3 are 
preferentially triggered by poly(I:C) (polyinosinic:polycytidylic acid), a synthetic 
analogue of short double-stranded RNA (Alexopoulou, Holt et al. 2001; Gitlin, 
Barchet et al. 2006; Kato, Takeuchi et al. 2006). RLR binding of viral nucleic acids 
lead to the induction of an antiviral interferon type-I response, as further described in 
chapter 1.2.2 and 1.2.3. Although LGP-2 is able to recognize dsRNA, it lacks a 
downstream signaling domain and functions as negative regulator of RIG-I (Saito, 
Hirai et al. 2007).  
Another antimicrobial defense line of PRRs beside TLRs and RNA helicases are 
cytoplasmic DNA sensors that recognize viral or bacterial (B-form) DNA and induce 
IFN type-I (Ishii, Coban et al. 2006). DAI (DNA-dependent activator of IFN-regulatory 
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factors) was identified as a possible DNA receptor (Takaoka, Wang et al. 2007), but 
DAI knockout mice showed no abnormal DNA induced IFN production (Ishii, 
Kawagoe et al. 2008). Recently AIM2 (absent in melanoma 2), a PYHIN (pyrin and 
HIN domain-containing protein) family member, was identified as a receptor for 
cytosolic dsDNA recognition, which potently activates innate immunity via the 
inflammasome (Takaoka, Wang et al. 2007; Fernandes-Alnemri, Yu et al. 2009; 
Hornung, Ablasser et al. 2009).  
Membrane-bound C-type lectin receptors detect extracellular fungal PAMPs 
(Willment and Brown 2008). The cytosolic NOD-like receptors exhibit a characteristic 
C-terminal LRR and an internal nucleotide-binding domain (NBD). NLRs are known 
to detect cytoplasmic bacterial PAMPs. This leads to the activation of cytokine 
expression including IL-1β (Inohara, Chamaillard et al. 2005; Martinon, Gaide et al. 
2007).  
 
 
1.2 Cytosolic helicase RIG-I 
 
1.2.1 Structure of RIG-I, the retinoic acid inducible gene-I  
 
RIG-I, the retinoic acid inducible gene-I (also known as DDX58), was originally 
identified and named by the ability to be induced by retinoic-acid during differentiation 
of acute promyelocytic leukemia cells (Sun, 1997). Subsequently, RIG-I was 
described to be stimulated after transfection of synthetic dsRNA poly(I:C) and thereby 
activate IRF-regulated reporter gene expression (Yoneyama, Kikuchi et al. 2004). 
Expression of RIG-I can be enhanced by retinoic acid, interferon and viral infection. 
RIG-I is a member of the DExD/H box RNA helicase (dsRNA unwinding) family 
(Yoneyama, Kikuchi et al. 2005). The human RIG-I gene encodes for a protein of 925 
amino acids and 115 kDa that comprises two characteristic caspase recruitment 
domain (CARD)-like motifs at its N-terminus, and a C-terminal RNA binding domain 
(Fig. 2) (Cui, Eisenacher et al. 2008). CARD as the signaling domain is responsible 
for activation of a downstream signaling cascade, the C-terminal region containing 
several conserved helicase motifs and a repression domain (RD) (Yoneyama, 
Kikuchi et al. 2005), is responsible for RIG-I function. The C-terminal repressor 
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domain is involved in inhibition of RIG-I activation in the absence of stimulating viral 
RNAs (Saito, Hirai et al. 2007). The C-terminal domain (CTD), aa792-925, which is 
part of the RD-domain, is responsible for the recognition of specific viral RNAs (Cui, 
Eisenacher et al. 2008; Takahasi, Yoneyama et al. 2008). The helicase domain 
comprises an adenosine-triphosphate (ATP)-binding lysine residue. Substitution of 
lysine to alanin renders RIG-I into a dominant negative inhibitor form, which indicates 
that RIG-I requires ATP to activate signaling (Yoneyama, Kikuchi et al. 2004). 
 
                           
                   
Fig. 1.2: Schematic representation of RIG-I. N-terminal CARD (caspase recruitment domain) motifs 
are responsible for downstream signaling after binding of RNA to helicase domain and C-terminal 
domain (CTD), including the repressor domain. Modified after (Yoneyama and Fujita 2009) 
 
 
1.2.2 RIG-I activation 
 
RIG-I recognizes a specific set of RNA viruses, such as Flaviviridae, 
Paramyxoviridae, Orthomyxovirida and Rhabdoviridae (Kato, Takeuchi et al. 2006). 
All this viruses affiliate a common feature, an RNA genome modified by 
phosphorylation. Recent studies showed that RIG-I distinguishes viral RNA from the 
broad amount and variety of cellular RNAs by the recognition of 5`-triphosphates 
(Hornung, Ellegast et al. 2006; Pichlmair, Schulz et al. 2006). This oligonucleotide 
modification arises from RNA synthesis by various viruses already mentioned above. 
The variation of 5`-triphosphorylation is not found on cellular RNA due to several 
modifications. Although cellular primary transcripts contain 5`-triphosphate, just like 
the viral transcripts, they undergo several various modifications. The mRNA acquires 
a 7-methylguanosine CAP structure at its 5`-end; tRNA undergoes 5`-cleavage and 
series of nucleotide base modifications. Primary transcripts of ribosomal RNA are 
directly complexed with ribosomal proteins to form ribonucleoproteins, and are 
therefore masked. Modification of 5`-triphosphated RNA like artificial capping or base 
modifications abolished detection by RIG-I (Hornung, Ellegast et al. 2006). 
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Thus, RIG-I is the key sensor of negative strand RNA viruses in the cytosol of cells. 
RNA containing a triphosphate at the 5`-end activates RIG-I, but the exact structure 
of RNA supporting 5`-triphosphate recognition, the requirement of 5`-triphosphate 
group and the existence of RNA stimulating RIG-I in the absence of a 5´-triphosphate 
group remain controversial. Until now, there are six proposed RIG-I ligands, capable 
for the induction of an IFN type-I (IFN-I, IFN-α and -β) response (Schlee, Hartmann et 
al. 2009). Beside single-stranded (ss) and double-stranded (ds) RNA with 5`-
triphosphate groups, short (23 - 30 bp) dsRNA with 5`-monophosphate and 
triphosphorylated ssRNA with A- and U-rich sequence at the 3`-end, as well as 
intermediate (300 – 2000 bp) and short (23 - 30 bp) dsRNAs without 5`-triphosphate 
efficiently stimulate RIG-I. Nevertheless, sequence unspecific dsRNAs, prepared by a 
technique called in vitro transcription (IVT), preferentially activate RIG-I (Kato, 
Takeuchi et al. 2006), a characteristic that is utilized in this work. For this purpose, an 
ssDNA template is transcribed by a T7 RNA polymerase into dsRNA. During this 
procedure the 5`-ends of the RNA-oligonucleotide become triphosphorylated.  
A model of possible RIG-I activation by Yoneyama and Fujita (Yoneyama and Fujita 
2008) proposes, that RIG-I is inactivated in the absence of stimulating RNA by 
intramolecular interaction between C-terminal repressor domain (RD) and caspase 
recruitment domain (CARD) (Fig. 3). After the transfer of 5`-triphosphorylated dsRNA 
(5`ppp-dsRNA or shortly 3p-RNA) or the appearance of viral RNA as a result of viral 
infection in the cytoplasm of the cell, RIG-I detects the RNA motifs via basic cleft like 
structure of the C-terminal domain (CTD). Stable complex of RNA and RIG-I via CTD 
activates intrinsic ATPase, which leads to an ATP-dependent conformational change 
of RIG-I, rather than ATP-dependent RNA unwinding by the helicase function of RIG-
I (Takahasi, Yoneyama et al. 2008). Due to the conformational change of RIG-I the 
N-terminal CARD domain is exposed for interaction with downstream adaptor 
molecules. Alternatively, it was shown that RIG-I primarily could form a dimer or 
oligomer via RD (Fig. 3) in response to 3p-RNA interaction (Cui, Eisenacher et al. 
2008). The consequently activated RIG-I is predicted to directly interact with 
interferon beta promotor stimulator-1 (IPS-1), located in the outer membrane of 
mitochondria and also known as mitochondrial antiviral signaling (MAVS), CARD 
adaptor inducing interferon beta (CARDIF) or virus-induced signaling adaptor (VISA) 
(Kumar, Kawai et al. 2006). IPS-1 consists of two domains characterized as an N-
terminal CARD-like domain sharing homology with those of RIG-I, and a C-terminal 
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effector domain. IPS-1 associates with RIG-I via the CARD domain and provides a 
link between RIG-I and downstream signaling molecules (Fig. 3 and 4). 
 
 
            
 
Fig. 1.3: Model of RIG-I activation. In the absence of stimulating RNA, RIG-I is present in an 
inactivated form by intramolecular interaction between C-terminal repressor domain (Inohara, 
Chamaillard et al.) and caspase recruitment domain (CARD) or a linker region of the helicase domain. 
In the presence of stimulating RNA in the cytoplasm, such as transferred 5`-triphosphorylated dsRNA 
(3p-RNA) or viral RNA, RIG-I detects this non-self RNA via basic cleft-like structures of the C-terminal 
domain (CTD). The detection of RNA induces an ATP-dependent conformational change and forming 
of a dimer, which allows CARD to interact with the mitochondrial downstream adaptor protein 
interferon beta promotor stimulator-1 (IPS-1), which itself include a CARD domain and links 
downstream signaling. Modified after (Yoneyama and Fujita 2009). 
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1.2.3 RIG-I signaling 
 
The RIG-I signaling cascade converges at the expression of activating transcription 
factors such as nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-
κB) and Interferon regulatory factors (IRFs). These factors are translocated to the 
nucleus, where they bind to the promotor region of IFN-I and other proinflammatory 
cytokines, in order to activate their transcription. Besides NFκB especially IRF-3 and 
IRF-7 are phosphorylated due to a viral induced signal and activate antiviral immunity 
(Sato, Suemori et al. 2000) (Fig. 4).  
More precisely, binding of activated RIG-I to IPS-1 via CARD-CARD interaction 
induces a complex downstream signaling cascade. First, IPS-1 is essential for RIG-I 
specific induction of IFN-I, demonstrated in IPS-1 KO cells, which show an impaired 
IFN-I induction after RIG-I specific stimulation (Kumar, Kawai et al. 2006; Sun, Sun et 
al. 2006). IPS-1 encodes beside an N-terminal CARD domain additionally a 
transmembrane domain at its C-terminal effector side and a proline-rich region (PRR) 
in the middle of the protein. The expression in the outer mitochondrial membrane 
suggests an essential role of mitochondria in RIG-I mediated signaling. It has been 
shown that tumor necrosis factor (TNF) receptor-associated factors (TRAF) 3, an E3 
ligase for Lys63-linked polyubiquitination, directly interacts with the PRR of IPS-1 
(Oganesyan, Saha et al. 2006), as well as TRAF 2 and TRAF 6 (Xu, Wang et al. 
2005).  The signaling cascade proceeds on one hand via the recruited TRAF family 
member associated NF-κB activator (TANK), which transmits the signal to 
downstream protein kinases, inhibitor of NF-κB (IκB) kinase (IKK) family members. 
The canonical IKK complex, consisting of IKK-α, IKK-β and the regulatory subunit of 
NF-κB essential modulator (NEMO), also termed IKK-γ, phosphorylates IκB. 
Subsequently, proteasome-dependent degradation of IκB allows functional NF-κB to 
translocate to the nucleus (Karin and Ben-Neriah 2000) and induces the transcription 
of proinflammatory cytokines like IL-1, IL-6 and TNF-α (Dinarello 2000) (Fig. 4, left 
part of cascade). In contrast, TANK recruits binding of non-canonical IKKs, TANK-
binding kinase 1 (TBK1) and IKK-ι (also termed IKK-ε), which themselves activate the 
signal-dependent phosphorylation of IRF-3 and IRF-7 to form a functional homodimer 
or heterodimer (Fitzgerald, McWhirter et al. 2003; Sharma, tenOever et al. 2003). 
Following translocation of IRFs into the nucleus allows transcription factor activity and 
the induction of IFN-I (Fig. 4, right part of cascade). The interaction between the PRR 
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region of IPS-1 and TRAF-3 is essential for the activation of both, canonical and non-
canonical IKK complexes, whereas TRAF-2 / -6 is responsible for NF-κB activation 
(Xu, Wang et al. 2005).  
As a regulatory element NAK-associated protein 1 (NAP1) is involved in the non-
canonical IKK activation of IRFs (Sasai, Shingai et al. 2006). NEMO, which is known 
to be a regulatory subunit of the canonical IKK complex, also plays a role in the non-
canonical IKK complex formation and activation of IRFs (Zhao, Yang et al. 2007), 
pointing to a crosstalk between both IKK complexes during RIG-I signaling. Already 
upstream in the signaling cascade, Fas-associated death domain (FADD) and 
receptor interacting protein 1 (RIP1), which are both death domain-containing 
proteins, are involved in the IPS-1 signaling complex (Kawai, Takahashi et al. 2005). 
They interact with the C-terminal part of IPS-1 and activate the NF-κB inducing 
pathway via the activation of caspase-8 and caspase-10 (Takahashi, Kawai et al. 
2006). Additionally, tumor necrosis factor receptor (TNFR) -associated DD (TRADD) 
complexes with IPS-1, TRAF-3, TANK, RIP1 and FADD, which leads to the activation 
of NF-κB and IRF-3 (Michallet, Meylan et al. 2008).  
It remains unclear why IRF-3 is activated via IPS-1 containing signaling, but not via 
TNFR-mediated signaling. Possibly, mediator of IRF-3 activation (MITA), localized 
like IPS-1 on the outer mitochondrial membrane, is a critical scaffold protein for IRF-3 
activation. MITA interacts directly with IPS-1 and regulates the recruitment of TBK1 to 
the IPS-1 complex on mitochondria (Zhong, Yang et al. 2008). Other molecules are 
responsible for post-translational modifications of RIG-I signaling. The tripartite motif 
protein 25 (TRIM25), an E3 ubiquitin ligase, specifically interacts with the CARD-
domain of RIG-I and conjugates ubiquitin to RIG-I CARD, which results in a marked 
increase in RIG-I downstream signaling activity (Gack, Shin et al. 2007). The 
modification of RIG-I is essential for the interaction with IPS-1 and subsequent 
signaling. A negative regulator of RIG-I mediated signaling is NLRX1, a member of 
the NLR family. NLRX1 is also expressed on the outer membrane of mitochondria 
and negatively regulate IPS-1 activity by direct interaction between the IPS-1 CARD 
domain and NLRX1 (Moore, Bergstralh et al. 2008). This negative regulation is 
necessary, because prolonged and unwanted activation of antiviral signaling via RIG-
I and IPS-1 might be harmful for host survival.  
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Fig. 1.4: RIG-I-mediated signaling cascade and its regulation. Activated RIG-I interacts directly 
with mitochondrial IPS-1 and transmits the signal through the indicated signaling molecules, resulting 
in the activation of the transcription factors NF-κB and interferon-response factors (IRF) 3 and 7 
(detailed described in the text). Translocation to the nucleus allows transcription factor activity and the 
induction of proinflammatory cytokines and interferon type-I. Black arrows and blue lines indicate 
positive or negative regulation of the signal, respectively, by cellular proteins. Modified after 
(Yoneyama and Fujita 2009). 
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1.3 Interferon class I 
 
1.3.1 The interferon type-I system 
 
The detection of determined PAMPs by PRRs initiates effective antimicrobial 
machinery. The recognition of pathogenic nucleic acids by TLR3, 7, 8 and 9, RIG-I 
and MDA-5, as well as bacterial LPS by TLR4, induce an inflammatory response and 
the production of different cytokines. The antimicrobial key cytokine produced after 
stimulation of RIG-I is interferon type-I (IFN-I). IFN was initially identified as a soluble 
factor secreted by virus-infected cells, acting as an inhibitor of viral replication (Isaacs 
and Lindenmann 1957). Beside its antiviral activity, other major biological activities 
include antitumor and immunomodulatory effects.  
The IFN-I family comprises of one INF-β and 13 IFN-α subtypes in humans (plus 
IFNκ, IFNε, IFNο, IFNτ and IFNδ) (Roberts, Liu et al. 1998). The IFN-I system 
includes two different signaling cascades. First, an IFN-I producing signal, which is 
induced by PRR dependent recognition of specific oligonucleotides and second, an 
IFNα/β receptor (IFNAR) mediated signal, which is activated by released IFN-I itself 
(Randall and Goodbourn 2008). When IFN-I is released out of the cell, IFN α/β is 
bound autocrinic and paracrinic by the heterodimeric transmembrane receptor 
IFNAR, which is broadly expressed by nearly every cell type, and consists of two 
subunits, IFNAR-1 and IFNAR-2 (Gaboriaud, Uze et al. 1990). Interaction of IFN-I 
with IFNAR on the cell surface leads to the activation of the Janus-Kinase (Jak)-
signal transducer activator of transcription (STAT) pathway (Darnell, Kerr et al. 1994). 
The intracellular domains of the IFNAR subunits are associated with Janus protein 
tyrosine kinases (Jak PTKs or JAK), namely Tyk2 and Jak1. Binding of IFN-I to 
IFNAR results in cross-activation of these Jak kinases through a conformational 
change, bringing the two JAKs close enough to phosphorylate each other. After 
autophosphorylation the JAKs phosphorylate their downstream substrates, which are 
two members of the family of signal transducers and activators of transcription 
(STATs), named STAT1 and STAT2 (Darnell, Kerr et al. 1994). The tyrosine-
phosphorylated and activated STAT1 and STAT2 dissociate from the IFNAR receptor 
and form together with another transcription factor member, IRF-9, the heterotrimeric 
complex ISGF3. The complex translocates to the cell nucleus and subsequently 
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binds to its specific DNA sequence, the IFN-stimulated regulatory element, ISRE 
(Kessler, Veals et al. 1990). The IFN-stimulated activation of the promotor results in 
the transcriptional induction of more than 300 target genes, so called IFN-stimulated 
genes, ISGs (Der, Zhou et al. 1998). A few of these ISGs implicate antiviral effects, 
also against HBV (detailed explained in chapter 1.5.4), encoding for example for 
PRRs, transcription factors or candidates with immediate antiviral activity, which 
include proteins that regulate post-transcriptional and post-translational events.  
 
 
1.4 Hepatitis B virus 
 
1.4.1 Classification 
 
The Hepatitis B virus (HBV) is a small and enveloped desoxyribonucleic acid (DNA) 
virus, which is highly species- and liver specific. HBV replicates only in hepatocytes 
and belongs to the family of hepadnaviridae (hepatotrop associated DNA viruses) 
(Gust, Burrell et al. 1986). The replication of the DNA genome occurs via a 
ribonucleic acid (RNA) intermediate by reverse transcription in the cytoplasm of host 
liver cells. Therefore the virus also belongs to pararetroviruses. HBV is divided into 
four major serotypes (adr, adw, ayr, ayw) to distinguish between different variations 
in between subspecies of HBV (Magnius and Norder 1995). The differentiation is 
based on antigenic epitopes presented by the envelope proteins. Furthermore, HBV 
is divided into eight genotypes (A-H), according to diverse overall nucleotide 
sequence variations of the HBV genome (Kramvis, Kew et al. 2005). The genotypes 
differ by at least 8% of their sequence, which has been associated with 
anthropological history and exhibit distinct geographical distributions (Norder, 
Courouce et al. 1992). For example, type A is prevalent in Europe, North America 
and Africa (Norder, Hammas et al. 1993), genotype D has a worldwide distribution 
but predominates in the Mediterranean area (Lindh, Andersson et al. 1997). Type A 
and D are also predominant in Germany (Vieth, Manegold et al. 2002). The 
differences in between the genotypes A-H significantly affect the disease severity, 
the response to distinct treatment therapies and possible vaccination strategies 
against the virus. 
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1.4.2 HBV history and research 
 
Lürmann made the earliest record of an epidemic caused by HBV in 1885 in Bremen, 
Germany (Lürmann A., 1885). Almost a century later Blumberg discovered in 1965 
the `Australian antigen`, afterwards known to be the Hepatitis surface antigen, 
HBsAg, in the blood of Australian aboriginal people (Blumberg, Melartin et al. 1966). 
Subsequently, he identified the antigen as the infectious agents of viral hepatitis 
(Blumberg, Sutnick et al. 1969), a discovery made him receive the Nobel prize of 
Medicine in 1977. Finally, Dane discovered the virus particle in 1970 by electron 
microscopy (Dane, Cameron et al. 1970). In 1979, the genome of the virus has been 
sequenced (Galibert, Mandart et al. 1979). A vaccine against human hepatitis B is 
available since 1981. After completion of 3 required vaccinations, 95% to 100% of 
recipients achieve adequate protection in preventing HBV infection. 
Human HBV infects only humans and humanoid primates, such as Chimpanzees 
(Vaudin, Wolstenholme et al. 1988), Gibbons (Norder, Ebert et al. 1996) and Gorillas 
(Grethe, Heckel et al. 2000). Close relatives of human HBV, which also belong to the 
genus of orthohepadnaviridae and specifically infect different animal populations, are 
the Woodchuck hepatitis B virus (Summers, Smolec et al. 1978), the Beechey 
Ground squirrel hepatitis B virus (Marion, Oshiro et al. 1980) and the New World 
Woolly Monkey hepatitis B virus (Lanford, Chavez et al. 1998). Another genus of 
hepadnaviridae is called avihepadnaviridae, hepatitis B viruses that infect birds, 
including snow goose hepatitis B virus (Schettler 1971), Peking duck hepatitis B virus 
(Mason, Seal et al. 1980) and heron hepatitis B virus (Sprengel, Kaleta et al. 1988).  
There is a lack of appropriate animal models for investigations of interaction between 
virus and host in HBV research due to the high species specificity of HBV. The 
animal models already mentioned above are little characterized, difficult to keep and 
rather expensive. For this reason, up to date, HBV-transgenic mice serve as a model 
for chronic HBV infection (Chisari, Pinkert et al. 1985; Guidotti, Matzke et al. 1995). 
Additionally, the transduction of mice with adenoviral vectors for hepatocyte-specific 
expression of a complete HBV-genome reflects some characteristics of an acute 
HBV infection accompanied by liver inflammation and followed by elimination of HBV 
replication (Ren and Nassal 2001; Sprinzl, Oberwinkler et al. 2001; Isogawa, Kakimi 
et al. 2005). Surprisingly, hepatocytes of tupaia belangeri, a tree shrew, which is not 
related with primates, are infectable with human HBV (Walter, Keist et al. 1996; Yan, 
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Su et al. 1996). The tupaia hepatocytes can repopulated a mouse liver in immune 
deficient mice, whose endogenous hepatocytes were destroyed by a liverspecific 
urokinase treatment (Dandri, Burda et al. 2005). But this infection model is inefficient 
and self-limiting.  
The repertoires of cells, which can be infected with human HBV, and therefore are 
suitable as cell-culture model, are limited by the viral hepatotropism. Human 
hepatoma cell lines, such as HuH7 (Nakabayashi, Taketa et al. 1982) and HepG2 
(Hirayama, Kohgo et al. 1993), are not infectable with HBV apart from some rare 
clones for example HepG2-BV cell line (Bchini, Capel et al. 1990), but are a useful 
tool to investigate intracellular aspects of viral replication. For this purpose the HBV 
genome is transferred into the cells by transient transfection or adenoviral vectors. 
Nevertheless, HepaRG cells, a cell line that exhibits hepatocyte-like morphology and 
express specific hepatocyte functions, is susceptible to HBV infection. Differentiation 
and infectability are maintained only when these cells are cultured in the presence of 
corticoids and dimethyl sulfoxide (Gripon, Rumin et al. 2002). Stably HBV transfected 
hepatoma cell lines, such as HepG2 2.15 expressing genotype A HBV (Sells, Zelent 
et al. 1988) and HepG2 H1.3 expressing genotype D HBV (Jost, Turelli et al. 2007; 
Protzer, Seyfried et al. 2007), replicate from several copies of integrated HBV 
overlength genomes. These cells additionally allow the production of high titers of 
HBV, suitable for infection of HepaRG cells and primary human hepatocytes (PHH) 
(Schulze-Bergkamen, Untergasser et al. 2003). PHHs are isolated from surgical liver 
resections and are a useful tool to investigate early steps of HBV replication after 
acute infection with HBV. Interestingly, HepG2 H1.3 cells and HBV infected PHH 
additionally express covalently closed circular HBV-DNA (cccDNA). This supercoiled 
HBV-DNA form accumulates and persists as an episome in the nucleus of 
hepatocytes, serving as the viral transcription template during natural infection. 
 
 
1.4.3 Liver structure 
 
The liver (greek hēpar) is the central organ of metabolism in the human body. It can 
be divided into two lobes or 8 segments and has a wide range of functions, such as 
plasma protein synthesis (e.g. coagulation factors), utilization of nutritional 
components (e.g. glycogen and fat storage), cholesterin and bilic acid synthesis, as 
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well as detoxification. Nutrients, absorbed from the intestine into blood, catabolism 
products of the spleen and pancreatic hormones reach the liver by the portal vein. 
The liver predominantly consists of mostly multinucleated parenchymal cells, the 
hepatocytes (Fig. 2.27). Extended capillaries, so called liver sinusoids, are blood 
vessels located between hepatocytes that provide liver cells with oxygen-rich blood 
from the hepatic arteries and with nutrient-rich blood from the portal vein. The blood 
is then taken up by central veins, which join the liver vein, and finally delivered back 
to the circulation. Sinusoids are flanked by liver endothelial cells (LSECs) and contain 
specialized macrophages of the liver, so called Kupffer cells. The room between 
LSECs and hepatocytes, the space of Disse (named after Joseph Disse), contains a 
third type of non-parenchymal cells; vitamin A containing and fat-storing stellate cells 
named Ito cells. Nevertheless, HBV replication only takes place in the the 
hepatocytes.  
 
 
                  
             
                  
Fig. 1.5: Formation of liver cells. Modified after K. Esser.  
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1.4.4 Epidemiology of HBV infection 
 
Despite the availability of an HBV vaccine, infection rates of HBV increase constantly 
worldwide, especially in developing countries. The WHO estimate worldwide two 
billion infected people and more than 360 million chronic carriers, with high risk to 
develop liver cirrhosis and HCC. Approximately 700 000 people die each year due to 
the acute or chronic consequences of hepatitis B (WHO, 2008). Infection with HBV 
occurs by exchange of body fluids through blood or sexual contacts with an infected 
person and proceeds in between adults by horizontal transmission or from an 
infected mother to a newborn by vertical transmission (Ganem 1982). People with 
high risk of HBV infection therefore include parental drug users, people with multiple 
sex partners and infants born to HBV-infected mothers. After an acute phase of 
infection with HBV, some patients develop a chronic state with a lifelong infection. 
The two primary adverse outcomes of chronic HBV infection are liver cirrhosis and 
primary hepatocellular carcinoma (HCC); either of both can lead to a liver related 
death (Beasley, Hwang et al. 1981).  
HBV infection, acute or chronic, holds variable manifestations (Fig. 5). During the 
acute state, HBV infection can manifest as a subclinical or icteric hepatitis and rarely 
in 0.1% to 0.5% of patients, as acute fulminant hepatitis with acute liver failure. 
Chronic HBV infection can be asymptomatic or can be manifested by symptoms and 
signs of cirrhosis or hepatocellular carcinoma or both. Subsequent course of disease 
after primary HBV infection is individual and depends on age and general immune 
status of the patient. After primary infection with HBV the acute phase of infection 
starts with an incubation period without any symptoms (asymptotic) that ranges from 
four to six weeks. During the acute phase of infection approximately one third of all 
patients proceed asymptotic and develop neutralizing immunity. Thus, the majority of 
patients show after an asymptomatic incubation time symptoms like fatigue, malaise, 
anorexia or flu-like symptoms until jaundice may become apparent. Afterwards, the 
patients develop an acute liver inflammation (hepatitis). In 95% of infected adults the 
virus is cleared after an acute infection, only 5% of infected adults, but 20-50% of 
infants in early childhood (one to five years) and even 90% of infected perinatals 
develop a chronic state of infection (McMahon, Alward et al. 1985).  
Dependent on different phases of chronic infection, the annual rate of progression to 
cirrhosis in untreated patients has been estimated to be 2 – 9 % (Yim and Lok 2006). 
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HBV is a non-cytopathic virus, but strongly carcinogen. Severe liver damage is due to 
a strong inflammatory response against the virus (Chisari and Ferrari 1995 a; Chisari 
and Ferrari 1995 b) and the risk of hepatocellular carcinoma is 100 times higher in 
patients with HBV infection than in uninfected ones (Pungpapong, Kim et al. 2007).  
 
                     
 
Fig. 1.6: Clinical development of HBV infection in adults.  
 
 
About half of the world’s population has had contact with HBV, but HBV prevalence 
varies drastically worldwide (Fig. 6). Regions with low prevalence, where less than 
2% of the population is chronic HBsAg carrier, are developed countries in Central 
Europe, in North America, in southern parts of South America, as well as Australia. 
Decreasing numbers of between 0.4% and 0.7% (~500.000) of the population in 
Germany live with chronic hepatitis B (Robert Koch Institut, Epidemiologisches 
Bulletin 2004). Intermediate infection rates (2 -7% HBsAg positive) are found in East 
Europe, Middle East, Russia, India, North Africa and in southern parts of Brazil. High 
prevalence is given in developing countries like in Africa south of the equator, in 
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Southeast Asia, or in China, where hepatitis B is endemic and about 10% of the 
population is HBV positive (WHO, 2008).  
 
      
 
Fig. 1.7: Hepatitis B prevalence 2005. Worldwide distribution of chronic HBsAg carriers 
 
 
1.4.5 Morphology and structure of HBV 
 
Electron microscopy (EM) imaging of purified preparations of HBV from serum of 
patients shows that infected hepatocytes secret three different types of particles (Fig. 
7). First, infectious virions with a diameter of 42 - 47 nm, known as Dane particles 
and second two different types of subviral particles, which are not infectious (Dane, 
Cameron et al. 1970). Infectious virions contain a single copy of a partially double-
stranded DNA genome of ~3.2 kilo base (kb) pairs, which is covalently linked via a 
terminal protein (TP) domain at the 5`-end of the negative strand to the viral 
polymerase (P) (Bartenschlager and Schaller 1992). The viral genome is packaged 
into a icosahedral nucleocapsid of about 27 nm diameter, composed of 180 or 240 
homodimeric subunits of the viral core protein, which is arranged with triangulation 
numbers of T = 3 or T = 4 (Crowther, Kiselev et al. 1994). There are evidences, that 
cellular proteins, including chaperones and protein kinases are also packaged inside 
of nucleocapsids (Hu, Toft et al. 1997). The capsid itself is surrounded by a host 
derived lipid bilayer. Integrated into the lipid membrane are three different viral 
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surface proteins, expressed by the viral genome, the large (L-), the middle (M-) and 
the small (S-) protein (Neurath, Kent et al. 1985). All three surface proteins are 
anchored in the lipid membrane by a hydrophobic C-terminus with four 
transmembrane α-helices (Berting, Hahnen et al. 1995). The L-protein is expressed 
at levels of about 5 – 15 % compared to S-protein on the surface of Dane particles, 
the M-protein at levels of about 1 – 2 % compared to S-protein (Robinson, 1995). 
The secreted non-infectious subviral particles (SVP) are divided into spherical SVP 
(or spheres) and filamentous SVP (or filaments) with a diameter between 15 and 22 
nm and consist exclusively of surface proteins (Ganem and Prince 2004). Spheres 
represent, for a protein complexed particle uncommon, octahedral symmetry with a 
diameter of approximately 20 nm and comprise basically of S-protein and marginal 
M-protein. The enclosed lipids of spherical SVPs appear not to be located in a typical 
semifluid lipid bilayer, but rather in an immobilized form on the surface (Satoh, Imai et 
al. 2000; Gilbert, Beales et al. 2005). Filaments consist of all three surface proteins, 
L-, M- and S-protein, and are variable in size (Fig. 7). The SVPs contain neither viral 
capsids nor viral DNA and are therefore not infectious. Nevertheless they are highly 
immunogenic. The pathological role of SVPs is still unclear. Titers of Dane particles 
in the blood of patients can range from less than 104 / ml to more than 109 / ml. In 
contrast, filamentous SVP can be present in 100 fold excess, spherical SVPs even in 
10 000 fold excess (Ganem and Schneider 2001). For this reason, SVPs might be 
responsible for capturing anti-HBV antibodies, produced naturally in the body, which 
are preferentially directed against the S-protein. Through the neutralization of the 
antibodies the virions might be protected against an immune response of the host 
(Rehermann and Nascimbeni 2005). The HBV surface antigen HBsAg, predominantly 
exposed on SVPs and used as a serological marker, reaches concentrations of 500 
mg / ml in the blood of HBV patients (Hoofnagle 1981). 
All three surface proteins of HBV are translated from one open reading frame. They 
differ by distinct in-frame starting codons of initiation; the carboxyterminal ends are 
identical 
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Fig. 1.8: Structures of hepatitis B virus particles. a) Electron microscopy (EM) from HBV carrier 
plasma and b) schematic presentation of human HBV particles structures. The infectious Dane 
particles (1.) with a diameter of ~42 nm are composed of a host derived lipid bilayer with integrated 
HBV surface proteins (L-, M- and S-protein). This envelope covers the nucleocapsid, composed of 
viral core proteins. The nucleocapsid harbors the 3.2kb HBV DNA genome, covalently linked via the 
terminal protein (TP) to the viral polymerase (Dandri, Burda et al.). The non-infectious subviral 
particles (SVP), filaments (2.) and spheres (3.), differ in structure, size and HBV surface-protein 
composition. SVPs contain neither viral capsids nor viral DNA. Images modified after a) (Gerlich and 
Kann) and 2005 b) (Glebe and Urban 2007)  
 
 
1.4.6 Genomic organization and protein function of HBV  
 
The HBV genome present in virions is a 3.2 kb partially double-stranded relaxed, 
circular DNA (rcDNA) molecule and the smallest known full replicative mammalian 
viral genome (Fig. 8). Therefore, the genome has a very complex organization with 
multiple overlapping open reading frames (ORFs). Every nucleotide in the HBV-
genome encodes for one of the HBV-proteins.  
The viral polymerase is covalently attached via the terminal protein (TP) to the 5`-end 
of the full-length antisense minus-strand, which is complementary to the viral mRNA. 
The 3`-end of the sense plus-strand is of variable length, hence a part of the viral 
genome is single stranded (ss). After infection of the cell the viral DNA translocates 
into the nucleus, where plus-strand of the rcDNA molecule is repaired, resulting in 
circularized cccDNA. The cccDNA serves as a template for the viral pre- (pg-) and 
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subgenomic (sg) messenger RNAs (mRNAs). The small and compactly organized 
HBV genome consists of four overlapping ORF on the (-)-antisense DNA-strand 
(Schlicht and Schaller 1989). The ORF preC/Core encodes for the precore protein 
(HBeAg) and the core protein (C), ORF preS1/preS2/S encodes for the surface 
proteins (L, M and S), ORF polymerase encodes for the viral polymerase (Pol) and 
the ORF X encodes for the viral X protein (X). The transcription of viral mRNAs is 
regulated by four promotors, the preC/C-, preS1 (L)-, preS2 (S)- and the X-promotor. 
Starting at these different promotor sites, transcription in all cases ends at one 
common polyadenylation (polyA) signal, resulting in one pregenomic and three 
subgenomic viral mRNAs (Cattaneo, Will et al. 1984). Two internal enhancer 
elements (Enh1/Enh2) differently influence the promotors. Enh1 increases 
transcription of all four promotors, whereas the liver-specific Enh2 (Hu and Siddiqui 
1991) only upregulates the transcription-rate of preS2/S (Ganem and Schneider 
2001).  
Once formed, the cccDNA in the nucleus serves as a template for the transcription of 
four groups of viral RNA. First these are the 3.5 kb pre-core mRNA (pre-C) and 
pregenomic (pg) RNAs. PreC mRNA (also named e mRNA in Fig. 8) is translated to 
produce a precore protein that is further proteolytically cleaved into e antigen 
(HBeAg). HBeAg is not a component of viral and subviral particles, but is secreted 
from infected liver cells. The function of HBeAg is widely undefined, but it has been 
implicated as an immune tolerogen, whose function is to promote a persistent 
infection (Milich and Liang 2003). Viral replication levels correlate with HBeAg levels 
in the serum of patients and HBeAg level is therefore used as serological marker. 
The 3.5 kb pgRNA transcript is bi-functional. On the one hand it serves as mRNA for 
the translation of viral capsid protein and the DNA polymerase, initiated at different 
startcodons. On the other hand pgRNA serves as a template for reverse 
transcriptional synthesis of the viral genome and is afterwards packaged together 
with the complex of viral polymerase and terminal protein into the nucleocapsid. The 
core protein has the intrinsic property to self-assemble into capsid structure (Zhou 
and Standring 1992) and contains a cluster of aminoacids at the C-terminus with 
RNA-binding activity to get in contact with the pgRNA (Hatton, Zhou et al. 1992).  
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Fig. 1.9: The HBV genome. a) Schematic organization of the HBV genome: The inner red and blue 
circles represent the partially double-stranded HBV genome, which displays the viral relaxed circular 
(rc) HBV DNA form, with polymerase (pol) and terminal protein (TP) as green circles, enhancer 
(Enh1/Enh2) and direct repeat (DR1/DR2) elements as boxes. PreC- (e-), Pre- and subgenomic 
mRNA transcripts are illustrated in black outer circles. PreC mRNA encodes for the precore protein 
(HBeAg), the pregenomic mRNA encodes for core protein and polymerase, subgenomic L-, M- and 
SHBs (large, medium and small hepatitis B surface) mRNAs for the envelope proteins. Triangles 
indicate transcription starts, the yellow square symbol the encapsidation signal (ε) and blue lined 
areas the post-translational regulatory element (PRE). The colored arrows inside the scheme depict 
the four open reading frames (ORFs) and the translated viral products: prec/core (HbeAg), core 
(capsid-protein), polymerase, preS2, preS1 and S (surface proteins L, M and S), and X (X-protein). 
Modified after (Gerlich and Kann 2005). 
 
 
The viral polymerase is functional divided into three domains. The terminal protein 
domain, which is involved in encapsidation and initiation of minus-strand synthesis; 
the reverse transcriptase (RT) domain, which catalyzes viral genome synthesis; and 
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the ribonuclease H (RNAseH) domain, which degrades pgRNA and facilitates 
replication. The three subgenomic RNAs include exclusively mRNA functions. The 
sgRNAs of 2.4 kb and 2.1 kb are the transcsripts for translation of all three viral 
surface envelope proteins L, M and S, and HBsAg, respectively. The mRNA of all 
surface proteins is transcribed from one ORF with different internal start-codons and 
all proteins share the S- protein sequence leading to identical C-termini. The M-
protein is extended by the preS2 domain at the N-terminus, the L-protein is extended 
by the preS2- plus the pres1 domain (Fig. 8). The surface proteins are synthesized at 
the endoplasmatic reticulum (ER), where they get integrated into the ER-membrane 
and thus build up the viral envelope. The sgRNA of 0.7 kb encodes for the X protein 
(HBx). HBx is indispensable for viral infection in vivo and influences multiple cellular 
gene functions necessary for virus survival, including signal transduction, 
transcriptional activation and inhibition of protein degradation (Bouchard and 
Schneider 2004). Moreover, HBx is controversially discussed to be involved in the 
mediation of HBV associated cancer. On the level of transcribed mRNA additional 
regulatory elements are found. Present on all mRNA is the post-transcriptional 
regulatory element (PRE), which suppresses splicing of the transcribed RNAs 
(Huang and Liang 1993). Additional posttranscriptional regulation elements within the 
HBV genome are the two direct repeats (DR1 and DR2) at the 5`-end of the plus-
strand, which are required for plus-strand specific DNA synthesis during replication 
(Seeger, Ganem et al. 1986). 
 
 
1.4.7 Replication of HBV 
 
The replication of hepadnaviridae occurs similar to retroviruses via a RNA-
intermediate that is packaged into the viral capsid in the cytoplasm of the host cell 
and afterwards reversely transcribed into viral DNA (Fig. 9). Therefore, HBV is also 
known as a pararetrovirus (Ganem and Schneider 2001). The replication of HBV is 
strongly restricted to hepatocytes of the host organism due to the liver tropism. Early 
steps of HBV infection, such as the attachment of the viral particle on the cell surface, 
the entry and release of the capsid into the cytoplasm and the transport of the viral 
genome into the nucleus of the host cell are not completely clarified. Nevertheless, 
actual data suggest that the N-terminal region of the L-protein is responsible for 
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attachment to the cell surface, followed by receptor-mediated endocytosis via still 
unknown receptor(s) (Tai, Suk et al. 2002). The binding of HBV to specific cellular 
receptor(s) is thought to trigger	   the actin-independent and microtubule-dependent 
entry of the virion into hepatocytes by endocytosis (Schmitt, Glebe et al. 1999; Funk, 
Mhamdi et al. 2004). These findings support the idea of endocytosis since 
endosomes are transported via microtubules towards the perinuclear region.	  
Presumably, the viral capsid is released into the cytoplasm from endosome upon 
fusion of the viral envelope and endosomal membranes, a process that might be 
induced by low pH and proteolytic cleavage of envelope proteins (Lu, Block et al. 
1996). After this uncoating event near the cell surface the intra-cytosolic translocation 
of the nucleocapsid to the nucleus is facilitated by the interaction with microtubules. 
Delivery of the rcDNA into nucleus is mediated by close contact of the viral capsid 
and the nuclear-pore complex (NPC) via interaction of a nuclear localization signal 
(NLS) at the C-terminus of the core protein and nuclear import receptors importin α 
and β. (Kann, Sodeik et al. 1999). Exposure of the NLS is regulated and depends on 
phosphorylation of the capsid protein (Kann, Schmitz et al. 2007). Size restrictions 
indicate that the complete disassembly of the capsid and the release of the viral 
genome into the nucleus occur in the nuclear basket of NPC (Andreyev, Norman et 
al. 2001). After entry of the viral genome into the nucleus the gap in the plus-strand 
of the partially double-stranded rcDNA molecule is repaired and completed by cellular 
enzymes, resulting in a supercoiled HBV genome with cccDNA form. Mechanisms 
and enzymes involved in this process are intensively investigated. The cellular RNA-
polymerase II promotes transcription from the cccDNA template to synthesize pre- 
and subgenomic RNAs. Afterwards, the RNA transcripts are transported into the 
cytoplasm without any splicing events (Kock and Schlicht 1993), where translation 
into viral surface proteins L, M and S as well as the X-protein based on subgenomic 
RNAs takes place. The translation of the surface proteins is mediated by ribosomes 
of the ER. The surface proteins get integrated into the ER membrane and obtain 
modifications like glycosylation and myristoylation, indispensable for proper protein 
folding (Helenius 1994) and infectivity of the virion (Glebe and Urban 2007). Free 
ribosomes promote the translation from preC-RNA to “pre-C protein” that is further 
proteolytically processed into HBeAg (Ganem and Schneider 2001). They also 
mediate the translation from the pgRNA to obtain viral polymerase and the capsid-
protein core. 
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Fig. 1.10: The replication cycle of HBV. HBV virions attach to the cell surface of the hepatocyte via 
an unknown receptor. During the entry step the nucleocapsid gets uncoated and is released into 
cytoplasm of the cell. The partially double-stranded DNA genome is imported into the nucleus, where 
cellular enzymes repair the plus-strand gap, leading to the formation of cccDNA. The episomal viral 
cccDNA genome is transcribed into viral pre- and subgenomic RNAs. After the export of the RNAs into 
the cytoplasm, translation into viral proteins takes place. The pregenomic RNA gets encapsidated and 
reverse transcribed into the HBV DNA genome. The viral genome of mature nucleocapsids is either 
re-imported into the nucleus or the capsid buds into the ER, where it receives its envelope containing 
the HBV surface proteins. Virions and subviral particles are transported through the ER/Golgi network 
to the cell surface and get secreted. 
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Additionally, the pgRNA represent the viral genome and is packaged in the viral 
capsid in the cytoplasm of the HBV-infected cell (Beck and Nassal 2007). Therefore, 
the complex of viral polymerase and terminal protein initially interacts with a stem-
loop structure (encapsidation-signal ε) at the 5`-end of the pgRNA and gets 
covalently linked to the pgRNA (Bartenschlager and Schaller 1992). The 
encapsidation of the pgRNA-protein-complex is initiated by the attachment of core-
protein-dimers to ε (Pollack and Ganem 1994), followed by self-assembling of the 
capsid. After completion of the newly synthesized capsid, the viral polymerase 
promototes reverse transcription of the pgRNA (Fig. 10). Binding of the DNA 
polymerase protein complex to ε at the 5`-end of pgRNA additionally initiate reverse 
transcription. A tyrosin residue of the terminal protein primes viral DNA minus-strand 
synthesis for extension of three nucleotides (Wang and Seeger 1992). Subsequently, 
polymerase and covalently attached nascent DNA is translocated to the 3`-end copy 
of DR1 and minus strand DNA synthesis continues by copying pgRNA. 
Simultaneously, the positive orientated RNA of the RNA/DNA-hybrid is eliminated by 
the RNAseH activity of the reverse transcriptase, (Fig. 10 a) (Walton, Wu et al. 
2001). When the polymerase reaches the 5`-end of pgRNA, an RNA oligomer that 
contains DR1 sequence is left uncleaved and subsequently translocated and 
annealed to DR2 (Fig. 10 b, left). This short RNA-oligonucleotide at the 5`-end 
serves as a primer (Lien, Aldrich et al. 1986) for plus-strand synthesis, initiated at 
DR2 (Beck and Nassal 2007). Several cis-elements appear to promote close 
proximity of the DR regions (Fig. 10 b, right). After the copy of the 5`-end of DNA 
minus-strand during synthesis the growing 3´-end of the DNA plus-strand switches to 
the 3`-end on the DNA minus-strand, which lead to circularization of the HBV 
genome and enables further elongation (Fig. 10 c) (Lien, Petcu et al. 1987). 
Extension of the DNA plus-strand on the DNA minus strand template creates the 
partially double-stranded relaxed, circular DNA (rcDNA) genome (Fig. 10 d).  
development of hepatocellular carcinoma. 
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Fig. 1.11: Schematic illustration of rc-DNA synthesis by reverse transcription. a) During (-)-DNA 
synthesis and completion, the DNA primer, still linked to TP, is extended from DR1* to the 5´-end of 
pgRNA. The pgRNA is simultaneously degraded by the RH domain, except for its capped 5´ terminal 
region including 5´ DR1 b) The RNA primer translocates to DR2, and is extended to the 5´-end of (-)-
DNA. c) The growing 3´-end of the (+)-DNA switches to 3´ -end (-)-DNA, enabling further elongation 
and circularization. d) Elongation on the (-)-DNA template creates rcDNA genome e) Double-stranded 
linear (dsL) DNA synthesis due to failed primer translocation to DR2, called "in situ priming". Modified 
after (Block, Guo et al. 2007). 
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A minor DNA form of double-stranded linear (dsl) DNA originates when the RNA 
primer failed to translocate from DR1 to DR2 (Fig. 10 e). This process is called “in 
situ” priming and occurs in around 1 - 5% of naive human HBV replication (Nassal 
1992). Dsl-DNA arises by in situ primimg or by non-homologous recombination (Yang 
and Summers 1995) can be integrated directly into the host DNA. It is assumed, that 
presence of foreign viral DNA in the host genome, together with expression of viral 
proteins such as X protein may trigger the subsequent 
When rcDNA is formed, the mature viral capsids can follow to different pathways. 
Some of them translocate through the cytoplasm back to the nucleus. The rcDNA is 
re-imported into the nucleus (Tuttleman, Pourcel et al. 1986) and converted into more 
cccDNA molecules (Wu, Coates et al. 1990), a way to increase cccDNA levels in the 
absence of re-infection of cell. This viral strategy operates very efficiently in the early 
stages of infection to build up and amplify the cccDNA pool, which is essential for 
HBV-transcription and replication (Werle-Lapostolle, Bowden et al. 2004). In stably 
infected hepatocytes of chronic HBV carriers, the nucleus may contain between 30 
and 50 copies of cccdDNA. The number of cccDNA molecules in vitro varies 
drastically. Stably HBV expressing HepG2 H1.3 cells contain approximately between 
4 - 10 copies of cccDNA per cell. (Illing, IMMIH, Cologne, Diploma thesis). Other 
mature viral capsids bud to the ER-lumen, by which they get enveloped with a lipid 
bilayer that contains the modified viral surface proteins integrated into the ER 
membrane (Huovila, Eder et al. 1992). Afterwards virions and SVPS pass the Golgi 
and the trans-golgi-network (TGN) and are then further transported to the plasma 
membrane in microtubule independent endosomal vesicles, distinct from the 
transcytotic pathway, to bud out of the cell by exocytosis and efficiently infect 
neighboring cells and new hosts. It is likely that sphingolipids (lipid rafts) are utilized 
for this transport, similar to other enveloped viruses like influenza (Scheiffele, 
Rietveld et al. 1999).  
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1.4.8 HBV specific immune response 
 
Analysis and determination of early events in human HBV specific immune responses 
are difficult, because HBV infected patients are screened for the first time after the onset 
of clinical symptoms, which means four to six weeks after primary infection. However, 
the following clinical courses and serologic profiles of acute and chronic hepatitis B differ 
in several aspects (Fig. 11). The typical course of acute and self-limiting hepatitis B (Fig. 
11a) is initiated with detectable HBV-DNA in the serum four weeks after primary 
infection, with low concentrations about 102 to 104 genome equivalents per ml blood 
(Rehermann and Nascimbeni 2005). HBsAg arises four weeks after primary exposure to 
the virus, followed by HBeAg and antibody responses against the viral core protein (anti 
HBc) two weeks later, which primarily disclose an IgM-isotype during early progress 
(Hoofnagle 1981). Viremia is established with high viral titers of about 109 to 1010 viral 
particles per ml (Ribeiro, Lo et al. 2002) and studies with chimpanzees revealed that 75 
– 100% of hepatocytes are infected at this time point (Kajino, Jilbert et al. 1994). 
Additionally, after 5 to 15 weeks after primary infection, alanine aminotransferase (ALT) 
levels in the serum rise during the acute phase and jaundice may appear, indicating a 
cytotoxic liver-inflammation and the begin of an adaptive immune response. ALT is 
secreted by apoptotic hepatocytes and is used as a clinical marker for the degree of liver 
damage. HBeAg is usually cleared early at the peak of clinical illness, whereas HBV 
DNA and HBsAg persists in the serum for the duration of symptoms and are cleared with 
recovery. In 95% of infected adults the virus is cleared after an acute infection, 
accompanied by the formation of HBc-, HBs- and HBeAg specific IgG antibodies, 
providing protective immunity (Rehermann and Nascimbeni 2005).  
Patients who develop chronic hepatitis B show similar initial patterns of serological 
markers with appearance of HBV DNA, HBs- and HBeAg, as well as anti HBc (Fig. 11b). 
The subsequent course and severity of chronic hepatitis B is quite variable (Ganem and 
Prince 2004). In contrast to acute infection, the chronic progression is characterized by 
lack of anti HBsAg specific IgG antibodies and a late and weak HBeAg specific antibody 
response. Also typical for chronic hepatitis B are variably high but persistent HBV DNA 
and ALT levels and a persisting production of HBsAg, which remains detectable for 
years, if not for life after primary exposure to HBV (Ganem and Schneider 2001).  
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Fig. 1.12: Clinical courses and serologic profiles of a) acute resolving and b) chronic hepatitis B. 
Relative amounts and appearance of viral replication (HBV DNA), HBV proteins (HBs- and HBeAg), HBV 
specific antibodies (anti-HBc, - Hbs, -HBe), liver injury (alanine aminotransferase, ALT) and symptoms 
during time-courses of a) acute, self-limiting and b) chronic hepatitis B infection. Modified after (Liang 
2009). 
 
 
The course of HBV infection strongly depends on the adaptive T-cell immune response 
of the host (Wieland, Thimme et al. 2004). Cytotoxic T-cells are responsible on the one 
hand for elimination of the virus during acute and self-limiting hepatitis B and on the 
other hand for liver injury during chronic HBV-infection (Thimme, Wieland et al. 2003). 
Patients with acute but resolving hepatitis B develop a strong, polyclonal and virus 
specific T-cell response (Bertoletti, Ferrari et al. 1991). The T-cell response in patients 
with a chronic course in contrary is weak, monoclonal and virus non-specific (Penna, 
Chisari et al. 1991; Webster, Reignat et al. 2004). Cell lysis and turnover repopulate the 
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liver with new and uninfected cells. However, a chronic liver inflammation and following 
massive regenerative processes may also lead to mutagenesis that could promote 
development of DNA damage and consequently HCC formation (Chisari and Ferrari 
1995). Additionally, it has been shown that an HBV-specific T-helper cells response is 
absent during chronic HBV infection (Ferrari, Penna et al. 1990), but regulatory T-cells 
(Tregs) have a suppressive impact on T-cell response, supporting persistence of HBV 
(Stoop, van der Molen et al. 2005).  Other in vivo studies suggested that HBV core-
antigen specific B-cells respond in a T-cell independent fashion along with production of 
neutralizing antibodies to prevent infection of new hepatocytes (Cao, Lazdina et al. 
2001).  
To prevent elimination HBV was thought to widely circumvent innate immune response 
and is therefore considered as a “stealth” virus. For instance, a study of experimental 
HBV infection of chimpanzees suggested that infection, per se, might induce no or little 
innate response in hepatocytes (Wieland, Thimme et al. 2004). However, several studies 
over three decades of research indicate that HBV is able to counteract the innate 
immune response by inhibition of several actors of the IFN-signaling pathway or down-
regulation of functional TLR expression (Twu, Lee et al. 1988; Foster, Goldin et al. 1993; 
Visvanathan, Skinner et al. 2007; Wu, Xu et al. 2007; Xie, Shen et al. 2009). In contrast, 
recent analysis of patients revealed early development of NK and CD56+ natural T (NT) 
cell response during early stages of HBV infection (Fisicaro, Valdatta et al. 2009). 
Furthermore, it has been shown that HBV induces IL-6 production in primary human liver 
cells and that IL-6 inhibits transcription of HBV (Hösel et al., 2009, in press). These 
controversial results indicate that HBV is not a stealth virus at all and that the innate 
immune system is able to sense HBV and allow timely induction of adaptive immune 
response. 
Nevertheless, HBV developed like other viruses different escape mechanisms to evade 
elimination by the immune system of the host. An important role in chronic course is 
proposed for the high quantity of produced SVPs. They contain high amounts of strongly 
immunogenic HBsAg-monomers and are produced in 104 - 106 fold excess over virions. 
Therefore they might be responsible for capture of HBsAg specific antibodies, thus mask 
infectious particles and prevent them from neutralization (Mangold and Streeck 1993; 
Rehermann and Nascimbeni 2005). Moreover high amounts of secreted HBeAg seem to 
participate to tolerating effects of HBV-specific T-cell (Milich and Liang 2003). HBV also 
seems to attenuate the expression of MHC I on hepatocytes, required for effective 
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presentation of HBV specific antigens on the cell surface to stimulate cytotoxic T-cell 
response (Chen, Tabaczewski et al. 2005). Another escape mechanism of HBV to evade 
an immune response is the outgrowth of mutated viruses. But this phenomenon occurs 
very rarely during acute and chronic HBV infection (Rehermann, Pasquinelli et al. 1995; 
Whalley, Brown et al. 2004). “Escape” variants of HBV, such as the G145R mutant with 
alterations in the S-protein, are frequently found in vaccinated individuals with 
breakthrough infections (Kalinina, Iwanski et al. 2003) or in graft infected liver transplant 
recipients under passive immunoprophylaxis with polyclonal hepatitis B hyperimmune 
globulin (HBIG) (Protzer-Knolle, Naumann et al. 1998). 
 
 
1.5 Therapeutic approaches 
 
1.5.1 Approved and novel inhibitors for antiviral therapy against HBV 
 
Prophylactic vaccination against hepatitis B, available since 1981, provides efficient 
protection from HBV infection and its consequences. Acute hepatitis B infection does 
not usually require treatment, because 95% of adults clear the infection 
spontaneously. Early antiviral treatment is required in less than 1% of patients, 
whose infection develop into a fulminant hepatitis or who are immuno-compromised. 
Therapy of patients chronically infected with HBV mirrors the main effort for 
development of antivirals, which made significant improvements during the last 
decade. Approved and novel inhibitors potentially target all steps of viral replication 
(Fig. 12). Chronic hepatitis B hallmarks of candidates for therapy are active viral 
replication in the hepatocytes, positive HBV surface antigen levels for more than six 
months (Ganem and Prince 2004) and variable, but persistent HBV titers in the blood 
for more than twenty weeks (Robinson, 1996).  
Approved treatments (Fig. 12, in red) include orally administered nucleos(t)ide 
reverse transcriptase inhibitors (NRTIs), also called nucleos(t)ide analogues. Their 
application inhibits viral replication and improves clinical outcome, including reduction 
of hepatocellular carcinoma (Liaw, Sung et al. 2004). There are currently licensed 
four NRTIs; Lamivudine (or Epivir), Telbivudine (Tyzeka), Entecavir (Baraclude) and 
Adefovir (Hepsera). Additionally, Emtricitabine and Tenofovir are approved in patients 
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co-infected with the human immunodeficiency virus	   (HIV) and HBV. Treatment of 
chronic HBV patients with NRTIs is well tolerated and strongly suppresses HBV 
replication, but require long-term application, which is limited by the increasing risk 
for the development of drug-resistant mutants. Due to spontaneous viral genome 
variability, pharmacological pressure may select for the viral species that exhibit the 
best replication capacity in this new treatment environment. Mutations that might lead 
to NRTI resistance are located in the viral polymerase gene. 
Alternative to a monotherapy with one of the RT-inhibitors, IFN-α is used for antiviral 
therapy alone or in combination with lamivudine and enables in 10 - 15% an 
elimination of HBV (Marcellin, Lau et al. 2004). IFN-α treatment relies on distinct 
antiviral effects with anti-proliferative and immunoregulatory properties, including the 
stimulation of the immune system by T-cell response activation (Guan 2000). 
Previously, treatment of chronic HBV patients with standard IFN-α required an 
injection every second day. To date, stabilized pegylated (PEG) IFN-α (Pegasys) is 
approved and has to be injected only once weekly (Barnard 2001). The treatment 
efficacy is limited, also dependent on the individual and on the genotype of the virus 
(Kao, Wu et al. 2000). Only in 30% of chronically infected patients, treated for one 
year with PEG IFN-α, the therapy is associated with a sustained antiviral effect 
(Marcellin, Lau et al. 2004; Lau, Piratvisuth et al. 2005). Moreover, treatment with 
IFN-α is attended by occurrence of severe side effects, such as anemia, 
thrombocytopenia, neuropenia and depression. In addition, the available drugs rarely 
clear the infection, but they potentially stop viral replication and minimize liver 
damage.  
Nevertheless, the single HBV replication cycle steps (Fig. 12, in blue) implicate and 
encourage the development of novel inhibitors (Fig. 12, in orange). First, viral entry 
represents a target for antiviral compounds. It was shown that myristoylated peptides, 
identical to the pre-S1 domain of the large viral envelope protein, which interacts with 
the cellular receptor, are able to inhibit viral entry in vitro (Glebe, Urban et al. 2005). 
The next possible target step in viral replication, the cccDNA formation, is the most 
ambitious aspect in the development of new antivirals. The major reason for needful 
life-long treatment of chronic patients with approved drugs is that these not 
necessarily eliminate cccDNA. The cccDNA may persist over decades, even after 
serological clearance of viral infection. The discovery of compounds specifically 
inhibiting cccDNA formation remains a major goal of HBV research.  
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There were several approaches to target HBV genome transcription or the viral 
transcripts themselves, using small interfering RNAs (siRNAs), antisense 
oligonucleotides or ribozymes, often limited by the delivery of such nucleic acids to 
hepatocytes in vivo (von Weizsacker, Wieland et al. 1997; Klein, Bock et al. 2003; 
Shlomai and Shaul 2003). Phenylpropenamide derivates were shown to inhibit 
nucleocapsid formation by inhibition of pgRNA packaging in vitro, also in lamivudine 
resistant HBV strains (Delaney, Edwards et al. 2002). Heteroaryldihydropyrimidines 
are able to inhibit viral capsid formation and increase degradation of the core protein 
(Deres, Schroder et al. 2003). Furthermore, IFN-α also affects stability of the viral 
nucleocapsid (Schultz, Summers et al. 1999; Wieland, Guidotti et al. 2000). The next 
step, viral reverse transcription can be efficiently inhibited, as already mentioned, by 
nucleos(t)ide analogues (Zoulim 2004) or antisense oligonucleotides (Robaczewska, 
Narayan et al. 2005). Moreover, several studies showed that iminosugars interfere in 
the correct folding of viral envelope proteins and therefore disturb proper virion 
packaging morphogenesis (Block and Jordan 2001). Strategies to support defective 
immune responses against HBV include treatment with IFN-α or PEG-IFN-α to 
stimulate and activate an HBV specific T-cell response, as mentioned above, as well 
as the development of DNA or recombinant protein vaccines (Zhang, Jiang et al. 
2008; Rapicetta, D'Ugo et al. 2009). Furthermore, it was shown that modified primary 
human T-cells, which express chimeric TCRs directed against HBV surface proteins, 
efficiently lyse HBV replicating and cccDNA-positive cells (Bohne, Chmielewski et al. 
2008). Additionally, several studies revealed that modulations of TLR-signaling and 
response efficiently inhibit HBV replication in vitro and in vivo (Isogawa, Robek et al. 
2005; Wu, Lu et al. 2007). 
Finally, as ultimate salvation for patients, who already developed liver failure by HBV-
related cirrhosis, HCC or both, often only orthotropic liver transplantation remains 
(Todo, Demetris et al. 1991), accompanied with high risk for graft re-infection or graft 
rejection. 
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Fig. 1.13: New targets of antiviral therapy. Approved inhibitors (red) and novel inhibitors in 
development (orange) of hepatitis B life cycle (blue). All steps of HBV replication are potential targets 
of antiviral therapy, except the inhibition of cccDNA formation. Modified after (Zoulim and Lucifora, 
2006). 
 
 
1.5.2 Combinatorial treatment of HBV 
 
Nevertheless, the variety and efficacy of already approved monotherapies, such as 
nucleos(t)ide analogues and IFN-α are strongly limited. Their application along with 
severe side effects and treatment of patients is time-consuming and associated with 
high costs. For that reasons, the development and improvement of novel antiviral 
therapies are indispensible. More efficient therapies with combined antiviral activity 
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acting simultaneously on several steps of the HBV life cycle are preferentially 
required. Immunotherapeutic strategies that combine HBV-specific and HBV-
nonspecific treatments are a promising approach, which additively and 
advantageously act along with avoidance of HBV resistance during treatment. It has 
been demonstrated that induction of antiviral cytokines by stimulation of TLR-9 with 
CpG-oligonucleotides (HBV-nonspecific) paired with the application of polymerase 
inhibitor lamivudine (HBV-specific) represents a promising combination to suppress 
HBV replication in vitro (Vincent, Lucifora et al. 2009).  
The immunotherapeutic and combinatorial antiviral approach aspired in this study is 
to affiliate induction of antiviral innate immunity by stimulation of RIG-I (HBV-
nonspecific) with siRNA mediated gene silencing, targeting free cytosolic HBV 
pgRNA (HBV-specific). Lately, it has been shown, even though in another context, 
that 5`-triphosphorylated siRNA (3p-siRNA) efficiently turns gene silencing and RIG-I 
activation against melanoma (Poeck, Besch et al. 2008). Potential induction of 
antiviral IFN-I via RIG-I stimulation in combination with HBV-sequence specific siRNA 
silencing by 3p-siRNA appears to be a powerful tool for combinatorial treatment of 
chronic hepatitis B. 
 
 
1.5.3 Antiviral activity of IFN-I against HBV  
 
IFNs and interferon-stimulated genes (ISGs) are key components of the innate 
immune response, and therefore are the first line of defense against virus infection, 
as well as potent inhibitors of viral replication (Fig. 13). We hypothesized that IFN-I 
induction by 3p-(si)RNA stimulation of RIG-I exhibits antiviral activities against HBV 
replication. First, IFN-α/β (and IFN-γ) inhibit HBV-replication in a proteasom 
dependent way by an unknown mechanism (Robek, Wieland et al. 2002; Zhang, 
Protzer et al. 2004). An IFN-induced increase in ubiquitination of proteins required for 
viral particle assembly or maturation could lead to their degradation by the 
proteasome, thus limiting viral replication. Second it was shown, that IFN-I inhibits the 
formation and/or promotes the destabilization of immature HBV RNA-containing 
capsids in HBV transgenic (tg) mice (Wieland, Guidotti et al. 2000). 
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Fig. 1.14: Principles and antiviral activity of IFN-I system. a) Schematic summary of the antiviral 
IFN-I system and b) fluorescence microscopy of IFN-I activity. The image show cells infected with 
parainfluenza virus (PIV5) and 24h later stained with antibodies to the viral nucleocapsid protein (virus 
antigen, yellow) and to the cell nuclei, (DAPI, blue). Virus infection (and also 3p-RNA stimulation) 
induces a cell (a+b, left) to synthesize IFN-I, which acts autocrine or paracrine via the Jak-STAT 
pathway on the induction of interferon stimulated genes (ISGs). These ISGs code for antiviral acting 
proteins responsible for the inhibition of virus multiplication in neighboring cells (a+b, right). IFN may 
also act in an autocrine manner on the IFN producer cell.	   Modified after a) (Samuel 2001) and b) 
(Randall and Goodbourn 2008) 
 
 
Furthermore, IFN-I stimulates the expression of distinct ISGs, which efficiently 
suppress HBV replication. For example, induced IFN-I directly enhances the 
expression of PRRs, such as RIG-I, in turn resulting in increased pattern (3p-
(si)RNA) recognition. But ISGs also code for other antiviral effector proteins believed 
to affect virus multiplication within single cells (Fig. 14). 2`-5` oligoadenylate 
synthetase (2`-5` OAS) activates the endoribonuclease RNAse L leading to RNA 
degradation. IFN-I, induced via activation of RIG-I or TLR3, activates the latent form 
of 2`-5` OAS that synthesizes 2`-5`-linked phosphodiester bonds to polymerize ATP 
into oligomers of adenosine (Rebouillat and Hovanessian 1999). These unique 2`-5` 
oligomers again specifically activate the latent form RNAse L. The enzyme RNAse L 
is constitutively expressed as an inactive monomer. Upon binding of 2`-5`- oligomers, 
generated by OAS proteins, homodimerization take place. The active dimeric enzyme 
then degrades viral RNA and cellular RNAs, including cellular rRNA, by cleaving on 
the 3`-end of UpXp-sequences (Silverman 2007). Viral RNA degraded by RNAse L is 
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able to activate the cytoplasmic PRRs like RIG-I itself or MDA-5, resulting in 
enhanced ISG induction again (Floyd-Smith, Slattery et al. 1981).  
IFN-I also induces the expression of guanosine-hydrolysing GTPases, probably the 
best characterized and most efficient antiviral effector protein. But only the human 
GTPase MxA (myxovirus resistance protein A) demonstrates antiviral activity, also 
potentially inhibiting HBV replication at a posttranscriptional level (Gordien, 
Rosmorduc et al. 2001). MxA has a large N-terminal GTPase domain, a central 
interacting domain (CID) and a C-terminal leucine zipper (LZ). The CID and the LZ 
domain are required to recognize the main viral target, which are nucleocapsid-like 
structures. Following stimulation with IFN-I, MxA accumulates in the cytoplasm on 
intracellular membranes, such as the ER, as oligomers via association between CID 
and LZ domains. Upon virus infection, the oligomers bind viral nucleocapsids or other 
viral components to degrade them. Interestingly, MxA proteins do not interact with 
HBV nucleocapsids, but inhibit the nucleocytoplasmic export of HBV mRNA via the 
PRE sequence (Gordien, Rosmorduc et al. 2001). 
Another validated IFN-inducible, dsRNA dependent effector is the protein kinase R 
(PKR), which belongs to a small family of kinases that respond to environmental 
stress to regulate protein synthesis. PKR is found predominantly as a monomer in the 
cytoplasm and associated with ribosomes (Thomis, Doohan et al. 1992). IFN-I leads 
to activation of PKR by dimerization through autophosphorylation. Following 
activation, PKR catalyzes the phosphorylation of the α-subunit of translation initiation 
factor eIF-2α. This results in impairment of the limiting guanine nucleotide exchange 
factor eIF-2β that catalyzes the recycling of GDP, required for translation. For this 
reason, the activation of PKR by IFN-I leads to the inhibition of viral and cellular 
mRNA translation (Samuel 2001).  
Accessory IFN-I induced antiviral acting proteins are members of the APOBEC 
family. APOBEC3G (A3G) and APOBEC3C (A3C) are cellular cytidine deaminases 
with a broad spectrum of antiretroviral activity (Mangeat, Turelli et al. 2003; Harris 
and Liddament 2004). Both contain an N-terminal RNA-binding domain and one 
(A3C: C-terminal) or two, respectively (A3G: N- and C-terminal) deaminase domains 
(Harris and Liddament 2004). The larger A3G protein (384aa), by chance entrapped 
into preassembled capsids by HBV-RNA binding, is thought to inhibit subsequent 
steps of capsid formation and HBV DNA synthesis in vitro (Rosler, Kock et al. 2005). 
The smaller A3C protein (190aa), readily packaged into replication-competent 
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capsids, may deaminate newly synthesized HBV-DNA. The C-to-U editing could 
results in enhanced hypermutation of HBV DNA (Baumert, Rosler et al. 2007). 
However, it was recently suggested, that induction of APOBEC proteins is not 
responsible for the control of HBV by IFN-I (Turelli, Liagre-Quazzola et al. 2008). 
 
 
 
 
Fig. 1.15: Anti-HBV functions of IFN-I inducible proteins. Among IFN-I induced proteins thought to 
affect HBV replication within single cells are OAS synthetase and RNAse L nuclease, which mediate 
RNA degradation; MxA protein GTPase, which appear to inhibit nucleocytoplasmic export of HBV 
mRNA; PKR kinase, which inhibits translation initiation through phosphorylation of protein synthesis 
initiation factor eIF-2α; and APOBEC A3C and A3G, which edit newly synthesized HBV-DNA and may 
block capsid formation, respectively. IFN-I induced expression of MHC class I antigens might 
contribute to the antiviral multiple-cell response. Modified after (Samuel 2001). 
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1.5.4 Antiviral activity of HBV-sequence specific siRNA  
 
Application of siRNA potentially mediates HBV-sequence specific gene silencing by 
targeting the pgRNA. Several studies demonstrated that siRNA mediated gene 
silencing show potent antiviral effects against HBV (Shlomai and Shaul 2003; 
Morrissey, Lockridge et al. 2005; Peng, Zhao et al. 2005). The genomic organization 
in overlapping ORFs and multiple RNAs make the virus particularly susceptible to 
RNA interference (Mahato, Cheng et al. 2005).  
RNA interference (RNAi) is a natural process by which canonical siRNA duplex 
directs sequence-specific post-transcriptional gene silencing of homologues genes 
(Almeida and Allshire 2005). The siRNA binds to its complementary mRNA and 
triggers its elimination. This evolutionary highly conserved mechanism controls gene 
activity in most eukaryotic cells and protects the genome against invasion by distinct 
viruses. Potent knockdown of a gene of interest with high sequence-specificity 
provided RNAi as a powerful tool for studying gene function and is already used for 
treatment for various diseases. RNAi takes place post-transcriptionally in the 
cytoplasm (Zeng and Cullen 2002) and is an ATP-dependent and translation 
independent process. siRNAs are 9 - 27 bp dsRNA molecules with a characteristic 
overhang of two nucleotides at the 3´-end on both strands. Each strand has a 5` 
phosphate group and a 3` hydroxyl group. In mammalian cells this structure is the 
result of processing by the RNAse III nuclease named Dicer (Zhang, Kolb et al. 
2004). Dicer converts either virus derived long dsRNA, cellular microRNA (miRNA), 
responsible for gene regulation or short hairpin RNAs (shRNA) used in expression 
vectors, into siRNAs. Therefore, dicer catalyzes the first step in the RNAi pathway 
and then delivers the siRNA to the RNA-induced silencing complex (RISC) (Tang 
2005).  
Exogenous siRNA can be directly introduced into target cells by various transfection 
methods (Fig. 15). The delivered siRNA binds independent of Dicer to RISC, which 
contains the splicing protein Argonaute 2 (Ago2). After the siRNA is loaded onto 
RISC, Ago 2 unwinds the siRNA, cleaves both strands and releases the sense or 
“passenger” RNA strand in an ATP dependent process (Meister, Landthaler et al. 
2004). This leads to activation of RISC, loaded with the single stranded antisense or 
“guide” RNA molecule. Afterwards the siRNA/RISC complex associates with the 
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target mRNA. Target mRNA molecules complementary to the antisense siRNA 
strand are recognized and then cleaved by Ago2 (Tang 2005). 
Chemical modifications and incorporation of siRNA into cationic liposomes are widely 
used to improve siRNA stability, cellular uptake and gene silencing effectivity in 
RNAi-based therapy (Soutschek, Akinc et al. 2004; Wolfrum, Shi et al. 2007). 
 
 
               
 
Fig. 1.16: RISC-model of siRNA mediated gene silencing. Binding of the RNA-induced silencing 
complex RISC follows delivery of siRNA into the cell. RISC component Ago-2 mediates ATP 
hydrolysis dependent siRNA unwinding, cleavage of the siRNA strands and maturation of RISC. 
Mature RISC loaded with the siRNA “guide” strand associates with the complementary target mRNA 
sequence and cleaves it. Modified after RNAi gene silencer, Santa Cruz Biotechnology, Inc.. 
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1.6 Aims of the study: Hypothetical activity of 3p-siRNA against HBV 
 
As said before, chronic HBV infection is the major cause of liver cirrhosis and primary 
liver cell carcinoma. These long-term consequences of persistent HBV infection 
represent a severe health problem leading to high mortality worldwide. Approved 
clinical therapies of chronic hepatitis B include administration of antiviral active IFN-α, 
as well as nucleos(t)ide analogues, which inhibit viral reverse transcription. These 
drugs can control replication effectively, but HBV cccDNA, the episomal replication 
template, persists in most cases, generating a relapse of infection after the therapy 
has been ceased. Hence, lifelong therapy is required, often accompanied by severe 
side effects and development of drug resistant mutants (Dienstag 2009). Therefore, 
new combinatorial treatment concepts targeting multiple steps in HBV replication 
cycle are urgently required for antiviral HBV therapy.  
It is known that induction of IFN-I by stimulation of TLRs results in strong suppressive 
antiviral effects on HBV replication (Isogawa, Robek et al. 2005). Moreover, distinct 
hepatoma cell lines are susceptible to IFN-I induction by stimulation of the cytosolic 
helicase RIG-I (Preiss, Thompson et al. 2008) and thus, HBV replication can be 
controlled in vitro (Guo, Jiang et al. 2009). In addition, it was shown that RIG-I is 
stimulated by in vitro transcribed 5`-triphosphated RNA (3p-RNA), leading to a potent 
IFN-I expression (Hornung, Ellegast et al. 2006). 
Accordingly, we wanted to analyze, whether stimulation of the cytosolic helicase RIG-
I by in vitro transcribed 3p-RNA may induce an endogenous antiviral active type-I IFN 
response, suppressing HBV replication. Moreover, it was shown that 5`-
triphosphorylated siRNA (3p-siRNA) efficiently combines gene silencing and RIG-I 
activation in treatment of melanoma (Poeck, Besch et al. 2008). Consequently, 
suitable HBV sequence-specific siRNAs were sought to be in vitro transcribed to 
additionally act as RIG-I ligands, combining induction of antiviral active IFN-I by RIG-I 
stimulation with HBV-sequence specific gene silencing. Therefore, the following study 
addressed the question, whether an alternative immunotherapeutic approach for 
successful treatment of HBV could be achieved by application of in vitro transcribed 
3p-siRNA to efficiently suppress HBV replication. It was investigated, whether 3p-
siRNA could lead on the one hand to siRNA mediated gene silencing of HBV by 
RNAi (Model, Fig. 16, left side), combined on the other hand with the activation of 
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the RIG-I signaling cascade, followed by the induction of antiviral acting IFN-I and 
ISGs (Model, Fig. 16, right side).  
 
 
 
 
Fig. 1.17: Schematic model of HBV specific gene silencing and IFN-I signaling activation by RIG-I 
stimulation with 3p-siRNA and resulting antiviral effects on HBV replication in hepatocytes. 
Delivery of 3p-siRNA into HBV infected hepatoytes might have on the one hand a specific antiviral 
effect on HBV replication by RNAi (left).  On the other hand cytosolic helicase RIG-I binds distinct viral 
RNAs, but also in vitro transcribed 3p-siRNA (stimulation). Binding of 3p-siRNA should lead to 
activation of IFN-I signaling cascade via different adaptor molecules. Transcription factors IRF3/7 
induce production of IFN-I. IFN-I exhibits antiviral effects against HBV via unknown, probably 
intracrinic acting mechanisms. Furthermore, IFN-I is secreted from the cell and binds auto- or 
paracrinic to IFNAR1 receptor, which leads to activation of JAK-STAT pathway and therefore to the 
induction of IFN-stimulated genes (ISGs) (signaling). ISGs code for several antiviral active proteins, 
which provide immune stimulated antiviral effects against HBV replication (right). Modified after 
(Bowie and Unterholzner 2008). 
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2 Results 
 
 
2.1 Hepatocellular expression profile of RIG-I 	  	  
HBV replication is IFN-I sensitive. Activation of the innate immune system by 
stimulation of the ubiquitous cytosolic helicase RIG-I results in a strong induction of 
endogenous IFN-I potentially suppressing HBV replication. Liver derived cell lines are 
useful tools to investigate the influence of therapeutic approaches for suppression of 
HBV replication in vitro. Human hepatoma cells such as HuH7 are not permissive for 
HBV, but are suited to analyze HBV replication. Stably HBV expressing hepatoma 
cells like HepG2 2.15 and HepG2 H1.3 mimic a chronic HBV infection in vitro. In 
contrary, HBV infected primary human hepatocytes (PHHs) simulate acute HBV 
infection.  
To find a suitable in vitro model for this study it was first investigated, whether the 
cytosolic helicase RIG-I is present in different hepatoma cell lines and primary human 
hepatocytes. Previous IFN-I stimulation of cells is known to increase the expression 
of RIG-I (Bowie and Unterholzner 2008). Therefore, presence of cytosolic RIG-I was 
compared by Western blot analysis, with and without previous addition of IFN-I into 
the supernatant of the cells.  
Both, the hepatoma cell line HuH7 and its subline HuH7.5 contained comparable 
RIG-I levels, strongly increased after stimulation with IFN-I (Fig. 2.1 a). Also the 
stably HBV producing cell lines HepG2 H1.3 and HepG2 2.15 strongly expressed the 
cytosolic helicase, although at different levels (Fig. 2.1 b). PHHs also showed RIG-I 
expression, compared to HepG2 H1.3 cells even at higher levels (Fig. 2.1 c). In all 
cell types the expression of RIG-I could be enhanced by previous addition of 
exogenous IFN-I.  
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Fig. 2.1. RIG-I expression in hepatoma cell lines and primary human hepatocytes. Comparison of 
RIG-I expression levels in a) Hepatoma cells HuH7 and HuH7.5  b) stably HBV expressing hepatoma 
cells HepG2 H1.3 and HepG2 2.15 c) stably HBV expressing hepatoma cells HepG2 H1.3 and primary 
human hepatocytes (PHHs). Cells were cultured for 36 hours with and without previous addition of 
exogenous IFN type I (1000 U / ml). Total cell lysates were prepared and RIG-I expression was 
determined by Western blot analysis with ß-actin as loading control. a) and c) 40 µg b) 50 µg total cell 
lysate was applied per lane.  
 
 
2.2 Applicability of 3p-RNA 
 
2.2.1 Induction of IFN-β by 3p-RNA 
 
IFN-I production can be induced by different RNA-oligonucleotides serving as RIG-I 
ligands (Schlee, Hartmann et al. 2009). The exact structure of the RNA stimulating 
RIG-I, predominantly supported by 5`-triphosphate recognition, remains controversial. 
However, it was reported that short dsRNA generated by in vitro transcription (IVT) 
induces IFN-I in cell lines (Kim, Longo et al. 2004). Subsequently, it was shown that 
in vitro transcribed 3p-RNA strongly induces IFN-I by stimulation of RIG-I (Hornung, 
Ellegast et al. 2006). The 3p-RNA used in this study consists of a dsRNA-
oligonucleotide of 23 nucleotides with an overhang of one nucleotide at the 5`-
position, both 5`-ends are coupled with triphosphate groups due to in vitro 
transcription by T7 polymerase.  Quantity and potency of IFN-β induction by 3p-RNA 
differed drastically between different 3p-RNA in vitro transcriptions. Therefore, a dual-
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luciferase assay was used to determine the potency of each 3p-RNA to induce IFN-β. 
This assay was performed with human embryonic kidney cells (HEK 293), a cell line, 
which well compensates necessary transfections and allows high transfection 
efficiency (Aiello, Guilfoyle et al. 1979). Therefore, HEK 293 cells were firstly 
transfected with two plasmids. One construct contained a Firefly-luciferase cassette 
under control of an IFN-β promotor as a reporter gene. The second construct 
included a Renilla-luciferase cassette with a constitutive promotor and was used as 
an internal control to determine transfection efficiency. On the following day cells 
were transfected with 3p-RNA from four different in vitro transcriptions (#1 - 4) to be 
tested. It is known that IFN-I expression peaks 6 - 18 hours after treatment with 3p-
RNA in vitro (Hornung, Ellegast et al. 2006). Therefore, HEK cells were lysed 12 
hours after stimulation with 3p-RNA, Firefly-luciferase substrate (Luciferin) was 
added to the lysate and IFN-β dependent activity of the Firefly-luciferase was 
quantified by measuring luminescence. After quantifying the firefly luminescence the 
reaction was stopped and simultaneously the renilla luciferase reaction was initiated 
by addition of its substrate (Coelenterazien). Accordingly, the quotient of Firefly- and 
Renilla luciferase expression correlated with induced IFN-β expression. Cells 
expressing both luciferase constructs but not transfected with 3p-RNA served as 
mock control (Fig. 2.2). 
 
                                                                                             
 
Fig. 2.2: RIG-I expression in HEK 293 cells and induction of IFN-β by 3p-RNA prepared of 
different in vitro-transcriptions. a) RIG-I expression levels in HEK 293 cells with and without 
previous addition of exogenous IFN type I (1000 U / ml). 50 µg total protein lysate per lane b) HEK 
293 cells were transfected with dual luciferase constructs and treated with several 3p-RNA 
preparations of different in vitro transcriptions (IVT). Luminescent signals (relative light units, RLU) of 
Firefly- and renilla luciferase, respectively, were determined in a luminometer. Data are shown as 
mean ± SD, n=3.  
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The dual luciferase assay showed different levels of IFN-β induction by 3p-RNA after 
four different in vitro transcriptions. 3p-RNA of IVT #1 and #3 revealed only minor and 
3p-RNA of IVT #4 medial IFN-β induction, whereas 3p-RNA generated by IVT #2 
exhibited the strongest potency to induce IFN-β and was thereby favoured for further 
experiments. The results show the variability of IFN-β stimulation by 3p-RNA 
generated in several in vitro transcriptions, which was normalized before application 
of 3p-RNA in further experiments. 
                              
 
2.2.2 Induction of IFN-β by 3p-RNA in HuH7 cells 
 
To determine the potency of 3p-RNA to induce IFN-I in different hepatoma cell lines, 
HuH7 and HuH7.5 cells were transfected with 3p-RNA (0.5 µg / ml) and IFN-β 
expression levels were determined after 12h by quantitative RT-PCR (qRT-PCR) 
(Fig. 2.3). Poly(I:C) (0.05 µg / ml) was transfected as a positive control. Poly (I:C), 
polyinosinic-polycytidylic acid, is a synthetic analogue of dsRNA that induces a 
potent IFN type I response triggering another ubiquitous cytosolic helicase, the 
human melanoma differentiation associated gene-5 (MDA-5) (Gitlin, Barchet et al. 
2006) as well as the endosomal TLR 3 (Kulka, Alexopoulou et al. 2004). Inert (non-
stimulating) polyA-RNA (polyriboadenosine) was used as negative control (Ctrl-RNA). 
Cells treated only with transfection reagent Hiperfect served as mock control.  
 
             
             
Fig. 2.3: IFN-I induction by 5´-triphosphorylated dsRNA in HuH7 cell lines. a) HuH7 cells and b) 
HuH7.5 cells were treated with 3p-RNA, Ctrl-RNA (polyA-RNA; negative control) and poly(I:C) 
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(polyinosinic:polycytidylic acid, a synthetic analog of double-stranded RNA; positive control). Mock 
cells were treated with transfection reagent Hiperfect. IFN-ß levels were analyzed by quantitative RT-
PCR relative to GAPDH and normalized to mock treated cells 12 hours p. tr.. Data are shown as mean 
± SD, n=3. 
 
 
HuH7 cells treated with 3p-RNA or poly(I:C), respectively, showed only IFN-β 
induction at background levels 12 hours after transfection (Fig. 2.3 a). HuH7.5 cells, 
a subline of HuH7 cells, exhibit no measurable IFN-β expression at all after 
transfection of the appropriate ligands (Fig. 2.3 b). Other groups have already shown 
that Huh7 cells are inadequate for production of IFN-I caused by minor TLR 3 
expression and by an defect on RIG-I receptor level (Li, Chen et al. 2005; Preiss, 
Thompson et al. 2008) The results show that the human hepatoma cell line HuH7 as 
well as its subline HuH7.5 are devoid of proper signaling after stimulation of RIG-I by 
3p-RNA or intracellular TLR3 by poly(I:C) transfection, respectively, and hence were 
not suitable for further in vitro experiments. 
 
 
2.2.3 Three different HBV models 
 
Other hepatoma derived cell lines display different PRR expression patterns 
compared to HuH7 cells, such as HepG2 cells, which are known to be impaired in 
TLR3 dependent, but competent for RIG-I dependent IFN-I signaling (Preiss, 
Thompson et al. 2008). Additionally, a stably HBV expressing cell line was preferred 
for cell culture experiments. Available stably HBV expressing HepG2 cells, such as 
HepG2 H1.3 (Jost, Turelli et al. 2007; Protzer, Seyfried et al. 2007) and HepG2 2.15 
(Sells, Chen et al. 1987) replicate HBV at higher levels than comparable HBV 
producing HuH7 cells (Bohne, Chmielewski et al. 2008). In order to use the optimal 
stably HBV expressing cell line for this work, initially HepG2 H1.3 were preferred over 
HepG2 2.15 cells due to their enhanced expression of RIG-I (Fig. 2.1 b). Moreover, 
HepG2 H1.3 cells also express, in comparison to HepG2 2.15 cells, episomal 
cccDNA as an additional and sensitive marker of HBV replication (Fig. 2.4, Southern 
blot (SB) analysis kindly provided by D.Webb).  
Primary human hepatocytes (PHHs) are another useful in vitro system to investigate 
early steps of HBV replication after acute infection with HBV. Nevertheless, their 
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availability is restricted because they are isolated from fresh liver specimen. PHHs 
expressed cytosolic RIG-I at levels comparable to HepG2 H1.3 cells (Fig. 2.1 c) and 
also establish a nuclear cccDNA pool. According to that reason, the stable HBV 
expressing hepatoma cell line HepG2 H1.3 as well as HBV infected PHHs were 
considered as optimal tools for further in vitro investigations (Fig. 2.4).  
To investigate the different aspects of antiviral RIG-I stimulation by 3p-RNA in vivo, 
two distinct HBV transgenic (tg) mouse strains were available. On the one hand, 
HBV1.3 tg mice and on the other hand HBV1.3 –xfs tg mice containing a frameshift 
mutation within the X-gene (Weber, Schlemmer et al. 2002). We found that HBV1.3 –
xfs tg mice replicate HBV at 10 times higher levels (107 -108 virions per ml serum) 
than HBV1.3 tg mice. Therefore, HBV1.3 –xfs mice were used in all following in vivo 
studies (Fig. 2.4). 
 
             
    
Fig. 2.4: Potential induction of antiviral IFN-I by 3p-RNA in 3 HBV-model systems. Three different 
HBV models were used to test 3p-RNA for potential induction of an antiviral IFN-I response against 
HBV. Stably HBV expressing hepatoma cell line HepG2 H1.3 and HBV infected primary human 
hepatocytes (PHHs) were used as in vitro models, HBV tg mice were used as an in vivo model.  
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2.2.4 Cytotoxicity of 3p-RNA 
 
After the choice of the best model systems, potential toxicity of 3p-RNA was analyzed 
for liver cells and HBV tg mice, respectively. Therefore, different amounts of 3p-RNA 
were transfected into HepG2 H1.3 cells and cell viability was determined by an XTT-
based assay over a period of 16 days (Fig. 2.5 a). No obvious toxicity at a 
concentration of up to 0.5 µg per ml medium was observed. Furthermore, 3p-RNA 
complexed with jetPEI was injected intravenously (i.v.) at day 0 and day 3 into the tail 
vein of HBV tg mice (Hornung, Ellegast et al. 2006). PolyA-RNA was used as 
negative control (Ctrl-RNA). Mice treated with the RNA delivery agent jetPEI served 
as mock control. Alanine aminotransferase (ALT) levels, a marker for cytotoxic liver 
damage, were determined in the sera of mice 6 hours after the two injections and at 
day 6, respectively (Fig. 2.5 b). 3p-RNA injected at a concentration of 25 µg per 
application showed no cytotoxic effects after both injections until day 6 in comparison 
to mock treated mice. Surprisingly, significantly elevated ALT levels were observed in 
a few mice treated with Ctrl-RNA over time.  
According to these results, 3p-RNA was applied at 0.5 µg per ml medium in all 
following in vitro experiments. Due to its known toxicity, poly(I:C) was transfected at 
lower concentrations of 0.05 µg per ml medium throughout the study. 25 µg 3p-RNA 
per mouse and application were injected twice at day 0 and day 3 in all further in vivo 
experiments throughout the study. 
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Fig. 2.5: Cytotoxicity of 3p-RNA in vitro and in vivo. a) HepG2 H1.3 cells were transfected with 
different doses of 3p-RNA and cell viability was monitored by XTT-cell-viability-test at indicated time 
points. Data are shown as mean ± SD, n=3. b) HBV tg mice (n=3) were intravenously injected twice 
(at d0 and d3) with 25 µg of 3p-RNA or Ctrl-RNA (polyA-RNA; negative control), respectively, per 
mouse and application. Mock (HBV tg) mice were treated with RNA delivery agent jetPEI. Serum 
alanine aminotransferase (ALT) levels were determined 6 hours after the first injection at day 0 and 6 
hours after the second injection at day 3, respectively, as well as at day 6. 
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2.3 Functionality of 3p-RNA as RIG-I ligand in HBV replicating liver cells 
 
2.3.1 IFN induction by 3p-RNA and activation of interferon-stimulated genes in 
vitro and in vivo 
 
After exclusion of cytotoxic effects, 3p-RNA dependent induction of IFN-β and IFN-γ, 
as well as activation of interferon-stimulated genes such as 2`-5`-oligoadenylate 
synthetase (OAS) and IFN-inducible protein 10 (IP-10), respectively, were 
determined in all three models. The IFN-I induced expression of 2`-5`-OAS 
(Hovanessian 1991) leads to the activation of the latent endoribonuclease RNaseL, 
which is able to effectively degrade viral RNA (Hassel, Zhou et al. 1993). Moreover, 
IFN-I and IFN-II (IFN-γ) stimulate the expression of IP-10 (also named CXCL10), a 
chemokine that is secreted predominantly by monocytes, endothelial cells and 
fibroblasts. PRR stimulation with ligands such as LPS or poly(I:C) also induces 
expression of IP-10, which functions as a chemoattractant for the recruitment of 
effector T cells, macrophages, NK cells and DCs in vivo (Luster, Unkeless et al. 
1985; Dufour, Dziejman et al. 2002). 
HepG2 H1.3 cells and HBV-infected (MOI 100) PHHs were transfected with 3p-RNA, 
poly(I:C) as positive control and inert polyA-RNA as negative control (Ctrl-RNA). 
Cells treated with the transfection reagent Hiperfect were used as mock control. In 
addition, 3p-RNA or Ctrl-RNA, respectively, was injected intravenously into the tail 
vein of HBV tg mice with. Mice treated with nucleic acid delivery reagent jetPEI 
served as mock control. Expression of IFNs and interferon-stimulated genes 2`-5`-
OAS and IP-10 were determined on mRNA level by qRT-PCR at indicated 
timepoints.  
Transfection of both, 3p-RNA or poly(I:C), respectively, exhibited induction of IFN-β 
(Fig. 2.6 a) and IFN-I dependent 2`-5`-OAS (Fig. 2.7 a) in HepG2 H1.3 cells. The 
expression of both remained at high levels until day 3 and was still detectable until 
day 6 after transfection. Accordingly, HBV infected PHHs also revealed strong 
induction of IFN-β at day 1 after stimulation with 3p-RNA or poly(I:C), respectively 
(Fig. 2.6 b), as well as IFN-I induced expression of 2`-5`-OAS, which decreased over 
time (Fig. 2.7 b). Both cell types showed no induction of IFN-β after Ctrl-RNA or 
mock transfection.  
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Injection of 3p-RNA in HBV tg mice resulted in a very fast and potent IFN-I response, 
which dropped markedly until day 3 and was not detectable at day 6 after 
administration (Fig. 2.6 c). Despite high amounts of IFN-α in the sera of mice 
determined 6 hours after application of 3p-RNA, only residual expression of 2`-5`-
OAS was found at day 6 after application (Fig. 2.7 c).  
 
                
     
 
Fig. 2.6: IFN-I induction by 5´-triphosphorylated dsRNA in vitro and in vivo. a) HepG2 H1.3 cells 
b) HBV infected PHHs and c) HBV tg mice were treated with indicated RNA-oligonucleotides. Mock 
(HepG2 H1.3 and PHH) Hiperfect; mock, (HBV tg mice) jetPEI. IFN-ß mRNA expression was analyzed 
by quantitative RT-PCR relative to GAPDH mRNA levels and normalized to mock treated cells at 
indicated timepoints. Serum IFN-α levels of HBV tg mice were determined by cytokine bead assay at 
indicated time points. Data are shown as mean ± SD, n=3. 
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Fig. 2.7: IFN-I dependent induction of 2`-5`-oligoadenylate synthetase (OAS). a) HepG2 H1.3 
cells b) PHHs and c) HBV tg mice were treated with indicated RNA-oligonucleotides and 
hepatocellular 2`-5`-OAS mRNA levels were determined at indicated timepoints by quantitative RT-
PCR relative to GAPDH and normalized to mock treated cells or animals, respectively. Data are 
shown as mean ± SD, n=3.  
 
 
The results clearly showed that application of 3p-RNA led to a strong induction of 
IFN-I and is followed by expression of 2`-5`-OAS in vitro and in vivo. 
In contrast, IFN-γ expression could not be detected in any model system, at any 
timepoint. Nevertheless, transfection of 3p-RNA or poly(I:C), respectively led to the 
expression of IP-10 in HepG2 H1.3 cells (Fig. 2.8 a) and in PHHs (Fig. 2.8 b). Ctrl-
RNA or mock transfected cells exhibited no IP-10 expression at any timepoint. 
Remarkably, 3p-RNA injected HBV tg mice showed no residual IP-10 expression at 
day 6, independent of treatment (Fig. 2.8 c).  
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These results show that IP-10 expression was strongly induced, at least in the cell 
culture systems, after application of 3p-RNA and in the absence of IFN-γ. Type II 
interferon (IFN-γ) was not induced or, if so, to minor extends. 
 
 
                  
 
Fig. 2.8: IFN dependent induction of IP-10. a) HepG2 H1.3 cells b) PHHs and c) HBV tg mice were 
treated with indicated RNA-oligonucleotides and analyzed at indicated timepoints for mRNA 
expression of IP-10 by quantitative RT-PCR relative to GAPDH and normalized to mock treated cells 
or animals, respectively. Results of a) are representative of three different experiments, data of b) and 
c) are shown as mean ± SD, n=3.  
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2.3.2 RIG-I dependent IFN-β induction by 3p-RNA  
 
To confirm the contribution of RIG-I in 3p-RNA induced IFN-I expression, RIG-I 
expression was knocked down by transient transfection of a RIG-I specific siRNA in 
HepG2 H1.3 cells and PHHs (Fig. 2.9). RIG-I expression was determined on protein 
levels at several time points after siRNA treatment. The most prominent reduction of 
about 80% was observed 72 hours after siRNA transfection (Fig. 2.9 a). In parallel, it 
was investigated, whether the auto- and paracrinic acting IFN-pathway via the 
interferon-α/β-receptor (IFNAR) was also required for the antiviral induction of IFN-I 
by 3p-RNA. Functional active human IFNAR consists of two subunits, IFNAR-1 and 
IFNAR-2 (Gaboriaud, Uze et al. 1990). Therefore, the expression of the interferon-
α/β-receptor in HepG2 H1.3 cells was inhibited by using an IFNAR specific siRNA. 
RIG-I specific - and an HBV sequence specific siRNA (Ctrl siRNA) were used as 
negative controls. Knockdown-efficiency of IFNAR-I was determined on mRNA level 
by quantitative real-time PCR (qRT-PCR). Expression of IFNAR was significantly 
reduced by 70% upon RNAi knockdown after 72 hours in comparison to Ctrl siRNA 
treated cells (Fig. 2.9 b). According to these results, HepG2 H1.3 cells were 
stimulated 72 hours after treatment with siRNAs against RIG-I or IFNAR-1, 
respectively, with 3p-RNA to stimulate IFN-I signaling. Unstimulated cells transfected 
previously with Ctrl siRNA served as negative control. In fact, significantly reduced 
IFN-β levels were observed in HepG2 H1.3 cells in which RIG-I had been knocked 
down. However, the cells with IFNAR knockdown only showed a minor reduction on 
IFN-β expression (Fig. 2.9 c). Confirming results were obtained in PHHs (Fig. 2.9 d). 
These data indicate that RIG-I is strictly required for 3p-RNA induced IFN-β 
response, while a positive fee-back via IFNAR-pathway seems to play a minor role. 
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Fig. 2.9: RIG-I dependent IFN-β induction by 3p-RNA. HepG2 H1.3 cells (a-c) and PHHs (d) were 
transfected with siRNA against RIG-I, IFNAR-1 or with Ctrl-siRNA (HCV-sequence specific siRNA). a) 
HepG2 H1.3 cells treated with αRIG-I siRNA were lysed at indicated timepoints and analyzed for RIG-I 
expression by Western blot analysis with ß-actin as loading control. 30 µg total cell lysate was applied 
per lane. b) HepG2 H1.3 cells treated with indicated siRNA were lysed 72 h p. tr. and IFNAR-1 
expression was determined by quantitative RT-PCR c) HepG2 H1.3 cells and d) PHHs were 
transfected with indicated siRNAs. After 72 h indicated cells were transfected with 3p-RNA and after 
12 h analyzed for IFN-ß expression by quantitatitative RT-PCR. RT-PCRs are relative to GAPDH and 
normalized to Ctrl siRNA treated cells. Data are shown as mean ± SD, n=3 (*P<0.05, t-test). 
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2.4 Antiviral effects of 3p-RNA induced IFN-I on HBV 
 
2.4.1 Antiviral effects of 3p-RNA treatment in vitro 
 
To test the therapeutic potential of 3p-RNA on HBV replication, first the antiviral 
effects of transfected 3p-RNA (0.5 µg / ml) were determined in stably HBV 
expressing HepG2 H1.3 cells. Therefore, the cells were transfected with indicated 
RNA-oligonucleotides. After treatment accumulated HBV-DNA levels of progeny virus 
released into the supernatant of cells were measured at three different timepoints by 
qRT-PCR (Fig. 2.10). Released HBV-progeny DNA levels were comparable at day 1 
after application. At day 3, HepG H1.3 cells treated with 3p-RNA secreted less virions 
relative to ctrl-RNA and mock controls. At day 6 after transfection the media of cells 
transfected with 3p-RNA contained strongly reduced (1.5 log scales) HBV-DNA 
levels, but not after treatment with Ctrl-RNA (polyA-RNA) (Fig. 2.10 a). Additionally, 
affected HBeAg and HBsAg secretion were determined by ELISA, HBeAg was about 
50% and HBsAg about 40% reduced, compared to untreated cells (Fig. 2.10 b). 
 
  
 
Fig. 2.10: Suppression of HBV replication by IFN-I induction after application of 3p-RNA in 
HepG2 H1.3 cells. HepG2 H1.3 cells were treated with 3p-RNA, Ctrl-RNA (polyA-RNA; negative 
control) or poly (I:C) (positive control). Mock cells were treated with transfection reagent Hiperfect. a) 
Quantiative RT-PCR analysis of HBV-DNA levels at day 1, day 3 and day 6 p. tr., respectively. b) 
Enzyme immunoassay of HBV-antigen levels (HBsAg and HBeAg) in supernatant of 3p-RNA treated 
HepG2 H1.3 cells at 6 days p. tr.. One representative of three different experiments is shown. 
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Second, the antiviral effect of 3p-RNA was examined in HBV infected PHHs. The 
primary cells were analyzed for HBV-replication markers at day 6 after treatment 
(Fig. 2.11). Both, 3p-RNA and poly(I:C) treated PHHs exhibited a significant 10-fold 
reduction of secreted virions compared to untreated cells (Fig. 2.11 a). Antigen levels 
in the supernatant were significantly reduced (Fig. 2.11 b). In addition, quantification 
of pgRNA levels by qRT-PCR disclosed a significant reduction of HBV-RNA in PHHs 
after application of 3p-RNA (Fig. 2.11 c). Antiviral effects were as strong as those of 
poly(I:C). 
 
            
 
Fig. 2.11: Stimulation of RIG-I by 3p-RNA suppressed HBV replication in primary human 
hepatocytes. HBV infected PHHs were treated with indicated RNA-oligonucleotides. Mock cells were 
treated with transfection reagent Hiperfect. a) Quantiative PCR analysis of HBV-DNA levels and b) 
enzyme immunoassay of HBV-antigen levels (HBeAg, HBsAg) in the supernatant of PHHs at day 6 p. 
tr. c) Quantitative RT-PCR ofpregenomic RNA levels at day 6 p. tr. relative to GAPDH and normalized 
to mock treated cells. Data are shown as mean ± SD, n=3 (**P<0.01, ***P<0.001, t-test). 
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The results clearly demonstrate a strong immuno-stimulatory, antiviral activity of 3p-
RNA against HBV by induction of IFN-I via RIG-I stimulation. Analyzed HBV-
replication markers were significantly reduced in both HepG2 H1.3 cells and HBV 
infected PHHs. 
 
 
2.4.2 Antiviral effects of 3p-RNA treatment in vivo 
 
Next, the antiviral effects of 3p-RNA were examined in HBV tg mice. Ctrl-RNA and 
jetPEI injected mice served as negative controls. HBV replication markers such as 
progeny HBV-DNA and HBV-antigens levels in the sera as well as HBV-RNA levels 
in the livers of HBV tg mice were determined at day 6 p. inj. (Fig. 2.12).  
HBV tg mice showed a 1.6 log reduction of HBV-DNA levels in the blood after 3p-
RNA injection compared to Ctrl-RNA or mock treated mice (Fig. 2.12 a). 
Furthermore, HBsAg levels were significantly reduced (Fig. 2.12 b). HBeAg, at 
comparable levels at the day of application, was significantly reduced at day 6 
compared to untreated mice or basal levels at day 0 (Fig. 2.12 c). 3p-RNA 
application also reduced pregenomic HBV-RNA (Fig. 2.12 d). RT-PCR results were 
confirmed by Northern blot analysis of pooled liver RNA within the different groups. It 
showed a reduction of both HBV-RNA forms, pgRNA and sgRNA after injection of 3p-
RNA compared to untreated mice (Fig. 2.12 e). GAPDH served as loading control 
and indicated that loaded RNA amount of 3p-RNA treated mice was lower than of 
mock treated mice, suggesting even stronger differences in HBV-RNA levels. 
The data confirm the potent therapeutic effectivity of 3p-RNA by induction of antiviral 
IFN-I leading to strong suppression of HBV replication in vivo. 
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Fig. 2.12: Stimulation of RIG-I by 3p-RNA suppressed HBV replication in HBV tg mice. HBV tg 
mice were treated with 3p-RNA or si-Ctrl (HCV-sequence specific siRNA; negative control) or with 
nucleic acid delivery reagent jetPEI as mock control. a) Quantiative PCR analysis of HBV-DNA levels 
and b) HBsAg levels in serum of HBV tg mice at day 6 p. inj. and c) HBeAg levels in serum at the day 
of application (day 0) and day 6 p. inj. (EIA) d) Quantiative RT-PCR analysis of intrahepatic 
pregenomic RNA levels relative to GAPDH, normalized to mock treated mice and e) Northern blot of 
pooled liver RNA (n=4/group) that reflect the effect of 3p-RNA on pre- and subgenomic RNA levels at 
day 6 after treatment with indicated RNA-oligonucleotides. GAPDH as loading control. 25 µg pooled 
total RNA was applied per lane. Data are shown as mean ± SD, n=4 (*P<0.05, **P<0.01, ***P<0.001, 
t-test). 
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2.5 HBV sequence specific 3p-siRNA as RIG-I ligand 
 
2.5.1 Design of HBV-sequence specific siRNAs 
 
To enhance the therapeutic efficiencycy against HBV it was intended to combine the 
antiviral immune regulatory effect of RIG-I stimulation with an RNAi mediated gene-
silencing effect on cytosolic HBV-RNAs. Therefore, three different HBV-sequence 
specific siRNAs of 19 nt were designed, which target three different regions at the 3`-
end of the HBV-RNAs within the overlapping ORFs of HBV (Fig. 2.13). The siRNA si-
1.1 targets a region of the HBV genome within the overlapping ORFs of the X-protein 
and the precore protein (processed to HBeAg), and was predicted to affect all HBV-
mRNAs (Fig. 2.13, orange arrows). The siRNA si-1.2 targets an alternative region 
within the X-protein ORF, but, as si-1.1, all HBV-mRNAs transcripts. Another 
alternative HBV-genome target region, the ORF of the polymerase, is targeted by 
siRNA si-1.3, which potentially affects all HBV mRNA transcripts except for the 0.7 kb 
transcript of the X-protein. All HBV targeting sequences are conserved among all 
HBV genotypes, except the rare genotype F. Genotype D HBV is present in HepG2 
H1.3 cells and in the HBV tg mice used in this study. In contrast, primary hepatocytes 
were infected with HBV genotype A before treatment, originated and purified from 
stably HBV expressing hepatoma cell line HepG2 2.15. 
To combine the antiviral effect of siRNA mediated HBV gene silencing and 
endogenous IFN-I induction via RIG-I stimulation, DNA templates for HBV-sequence 
specific siRNAs were reverse transcribed by in vitro transcription and thereby 
coupled to triphosphate groups at both 5`-ends. The resulting RNA-oligonucleotides 
were named 3p-1.1, 3p-1.2 and 3p-1.3, according to their unphosphated siRNA 
counterparts. 
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Fig. 2.13: HBV-sequence specific siRNA targeting. The HBV-sequence specific siRNAs named si-
1.1, si-1.2 and si-1.3 were designed to target the ORFs of the X-protein or the polymerase within the 
3`-end region of the mRNA transcripts near the polyadenylation signal, indicated by orange arrows. 
 
 
2.5.2 Functionality of 3p-siRNA as RIG-I ligand  
 
Subsequently, the ability of 3p-siRNA to induce an antiviral IFN response was tested. 
Therefore, HepG2 H1.3 cells were transfected exemplarily with 3p-1.2, 
(triphosphorylated, HBV-sequence specific siRNA), its non-phosphorylated 
counterpart si-1.2 (HBV-sequence specific siRNA) or si-Ctrl (inert HCV-sequence 
specific siRNA). Mock cells were treated with transfection reagent Hiperfect (Fig. 
2.14). Only HepG2 H1.3 cells transfected with 3p-1.2 showed an induction of IFN-β 
after 12 hours determined on mRNA level by quantitative RT-PCR. Cells treated with 
si-1.2 or si-Ctrl, respectively, revealed no or only marginal IFN-β expression in 
comparison to mock treated cells (Fig. 2.14 a). Next, IFN-I induction levels of all 
three triphosphorylated siRNAs (3p-1.1, 3p-1.2 and 3p-1.3) were compared. 
Therefore, IFN-I stimulated 2`-5`-OAS levels were determined 8 days after 
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transfection of the 3p-siRNAs in HepG2 H1.3 cells (Fig. 2.14 b) and in HBV infected 
PHHs (Fig. 2.14 c). Cells treated with transfection reagent Hiperfect were used as 
mock controls. All three 3p-siRNAs induced 2´-5`-OAS in both in vitro models; in 
HepG2 H1.3 cells at comparable levels, in PHHs less pronounced and at variable 
strength. 
 
          
 
Fig. 2.14: HBV sequence specific 5`-triphosporylated siRNAs served as RIG-I ligands. a) HepG2 
H1.3 cells were transfected with control siRNA (HCV-sequence specific siRNA), si-1.2 (unphosphated 
HBV-sequence specific siRNA) or 3p-1.2 (triphosphorylated HBV-sequence specific siRNA). Mock 
cells were treated with transfection reagent (Hiperfect). 12h after treatment the cells were tested for 
IFN-ß induction by quantitative RT-PCR relative to GAPDH and normalized to mock treated cells. Data 
are shown as mean ± SD, n=3. b+c) HepG2 H1.3 cells and HBV infected PHHs were transfected with 
3p-siRNAs (3p-1.1, 3p-1.2 or 3p-1.3), mock cells were treated with transfection reagent Hiperfect. 
Cells were analyzed by quantiative RT-PCR at day 8 p. tr. for mRNA expression of interferon-inducible 
2´-5`-oligoadenylate synthetase (OAS) relative to mRNA GAPDH, normalized to mock treated cells. 
One representative of three different experiments is shown. 
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This data clearly elucidate that HBV sequence specific triphosphated siRNAs were 
suitable as RIG-I ligands, competent for induction of IFN-I, as determined by IFN-I 
induced 2`-5`-OAS expression in both in vitro models. 
 
 
2.5.3 Antiviral effects of 3p-siRNA treatment in vitro  
 
To elucidate the therapeutic efficiency of the modified RIG-I ligands, the effects of 
applied 3p-siRNAs on HBV-replication markers were determined at day 8 after 
transfection in HepG2 H1.3 cells and HBV infected PHHs (Fig. 2.15). All three 3p-
siRNAs had a significant impact on HBV-progeny release of HepG2 H1.3 cells 
(Fig.2.15, a) and PHHs (Fig.2.15, b). 3p-1.2 reduced virion secretion in HepG2 H1.3 
cells about 1 log (Fig. 2.15 a). All 3p-siRNAs reduced HBV-DNA release from HBV-
infected primary cells more than 0.75 log scales (Fig. 2.15 b). Furthermore, the 
antiviral effects of 3p-siRNAs on HBV-antigen levels (HBeAg and HBsAg) were 
examined by ELISA assays (Fig. 2.15 c + d). All three 3p-siRNAs led to a clear 
reduction of secreted HBeAg in HepG2 H1.3 cells, on average around 50% (Fig. 2.15 
c) and in HBV infected PHHs of approximately 35% (Fig. 2.15 d). HBsAg levels were 
also significantly reduced in HepG2 H1.3 cells by all three 3p-siRNA, but most 
drastically for 80% by the application of 3p-1.2 (Fig. 2.15 c). In HBV infected PHHs 
3p-siRNAs showed a minor effect on HBsAg, with reduction of approximately 40% 
(Fig. 2.15 d).  
HepG2-H1.3 cells and HBV infected PHHs additively express episomal HBV-
cccDNA. This supercoiled HBV-DNA accumulates and persists in episomal form in 
the nucleus and serves as viral transcription template during HBV infection. 
Examined cccDNA levels were decreased after application of 3p-siRNAs in both, 
HepG2 H1.3 cells (Fig. 2.15 e) and in PHHs (Fig. 2.15 f). 
Taken together, these results indicate that 3p-siRNAs efficiently suppress HBV-
replication on HBV-DNA and HBV-protein level. Furthermore, nuclear HBV cccDNA 
levels were reduced by 3p-siRNA application in both cell types. 
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Fig. 2.15: HBV-sequence specific 3p-siRNAs suppressed HBV replication in vitro. HepG2 H1.3 
cells and HBV infected PHHs were transfected with different 3p-siRNAs (3p-1.1, 3p-1.2 or 3p-1.3) and 
analyzed at day 8 p. tr.. Mock cells were treated with transfection reagent (Hiperfect). Supernatants of 
HepG2 H1.3 cells and PHHs were analyzed for (a+b) HBV-DNA levels by quantiative PCR, 
normalized to mock treated cells and for (c+d) HBeAg by enzyme immunoassay and HBsAg levels by 
ELISA. Data are shown as mean ± SD, n=3 (*P<0.05,**P<0.01, ***P<0.001, t-test). Additionally, 
quantiative RT-PCR analysis of cccDNA levels relative to mitochondrial DNA normalized to mock 
treated cells was performed (e+f). Data are representative of three different experiments. 
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As already said, PHHs were infected with genotype A HBV, secreted from stably 
HBV expressing HepG2 2.15 cells. To confirm the therapeutic efficiency of 3p-
siRNAs on genotype A HBV, HepG2 2.15 cells were treated directly with the different 
3p-siRNAs (Fig.2.16). At day 6 after application IFN-I dependent 2`-5`-OAS induction 
was determined on mRNA level by qRT-PCR (Fig. 2.16 a).  
 
 
       
 
Fig. 2.16: HBV-sequence specific 3p-siRNAs suppressed genotype A HBV replication in HepG2 
2.15 cells. HepG2 2.15 cells were transfected with different 3p-siRNAs (3p-1.1, 3p-1.2 or 3p-1.3) and 
analyzed at day 6 p. tr.. Mock cells were treated with transfection reagent (Hiperfect). a) 2´-5`-OAS 
induction was tested on mRNA level by qRT-PCR relative to GAPDH mRNA and normalized to mock 
treated cells. Supernatants of HepG2 2.15 cells were analyzed for b) progeny HBV-DNA levels by 
quantitative PCR and for c) HBeAg levels by enzyme immunoassay. d) pgRNA levels were 
determined by quantitative RT-PCR. Data are shown as mean ± SD, n=3 (*P<0.05, ***P<0.001, t-test). 
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None of the transfected 3p-siRNAs revealed any, or only residual, expression of 2´-
5´-OAS at day 6 after transfection in HepG2 2.15 cells, possibly due to already 
strongly reduced 2`-5`-OAS expression at this timepoint, but more likely through 
absence of IFN-I induction, which coincidences to the reduced sensitivity of HepG2 
2.15 cells against IFN (Guan, Lu et al. 2007). Nevertheless, apparently independent 
of IFN-I induction, progeny HBV-DNA levels were decreased on average around 60% 
(Fig. 2.16 b). HBeAg levels (Fig. 2.16 c) and pgRNA levels (Fig. 2.16 d) were also 
significantly diminished after transfection of 3p-siRNAs.  
These results indicate despite lacking IFN-I response an effective suppression of 
HBV replication by RNAi mediated gene silencing also on genotype A HBV. 
 
 
2.5.4 Comparison of 3p-RNA and 3p-siRNA treatment in vitro 
 
To analyze whether immunostimulation and RNAi-mediated gene silencing acts 
synergistically to suppress HBV replication, the primarily used 3p-RNA was 
compared with the 3p-siRNAs in HepG2 H1.3 cells. Therefore, HepG2 H1.3 cells 
were transfected with the original RIG-I ligand 3p-RNA, the 3p-siRNAs 3p-1.1, 3p-1.2 
and 3p-1.3 and si-Ctrl RNA, respectively. HepG2 H1.3 cells treated with transfection 
reagent Hiperfect served as mock control. The effects on HBV replication were 
analyzed within an expanded timeframe at day 4 and day 8 post transfection, 
determining intracellular HBV-DNA levels by Southern blot analysis (Fig. 2.17 a), 
episomal HBV cccDNA levels by qRT-PCR (Fig. 2.17 b) and HBV-protein levels by 
Western blot analysis (Fig. 2.17 c).  
Indicated bands of the Southern blot analysis represented different HBV-DNA forms 
such as rcDNA, linear and single-stranded HBV-DNA, as well as replicative 
intermediates of variable size (Fig. 2.17 a). Detection of integrated HBV genomes 
served as a loading control. Intracellular HBV-DNA levels were strongly reduced at 
day 4 after treatment with the original 3p-RNA. Intriguingly, all three 3p-siRNAs 
displayed a slightly more pronounced reduction in HBV-DNA levels compared to 3p-
RNA at this timepoint. Surprisingly, also si-Ctrl RNA treatment slightly reduced 
hepatocellular HBV-DNA levels in comparison to mock control (Fig. 2.17 a, left). The 
antiviral effect of the original 3p-RNA ligand nearly disappeared at day 8 after 
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treatment, whereas the effect on intracellular HBV-DNA levels by all 3p-siRNAs 
persisted (Fig. 2.17 a, right).  
Accordingly, a superior antiviral effect of 3p-siRNA compared to 3p-RNA alone could 
be shown on HBV cccDNA levels (Fig. 2.17 b). The displayed quantitative PCR 
products of cccDNA, relative to mitochondrial DNA as loading control, indicated a 
potent reduction of the episomal HBV-DNA form at day 4 after treatment by both, 3p-
RNA and all 3p-siRNAs in comparison to mock control. However, again si-Ctrl had 
some effect (Fig. 2.17 b, left), probably to its low, but clearly detectable 
immunostimulatory activity (Fig. 2.14 a). On day 8 3p-siRNA still decreased cccDNA 
levels, whereas 3p-RNA had no effect anymore (Fig. 2.17 b, right). This difference in 
antiviral activity was confirmed by Western blot analysis of the large HBV envelope 
protein (Fig. 4c upper panel). In addition, the HBV core-protein was only slightly 
affected by 3p-RNA at day 4, whereas all three 3p-siRNAs had a post-translational 
effect on core-protein expression at this timepoint. Core-protein expression was 
completely restored in 3p-RNA treated cells at day 8, but still decreased in cells 
treated with 3p-1.2 and 3p-1.3 (Fig. 4c lower panel). 
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Fig. 2.17: 3p-siRNA combined RIG-I stimulation and siRNA mediated gene silencing in vitro. 
HepG2 H1.3 cells were treated with indicated RNA-oligonucleotides and analyzed 4 days and 8 days 
after treatment. Mock (cells treated with transfection reagent Hiperfect), 3p-RNA (in vitro transcribed 
5`-triphosphated dsRNA), si-Ctrl (HCV-sequence specific siRNA) served as negative control, 3p-1.1, 
3p-1.2 and 3p-1.3 (in vitro transcribed 5´-triphosphated HBV-sequence specific siRNA). a) Southern 
blot analysis of intracellular HBV-DNA in HepG2 H1.3 cells. 20 µg total DNA was applied per lane. b) 
Agarosegel of PCR products using cccDNA specific primers. Mitochondrial DNA PCR served as 
control. c) Western blot analysis of intracellular HBV L- and core protein expression. ß-actin was 
detected as loading control. 15 µg total cell lysate was applied per lane. 
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The results indicate comparable antiviral effects of the original RIG-I ligand 3p-RNA 
and the modified 3p-siRNAs on HBV replication at early time-points (day 4 after 
transfection) in HepG2 H1.3 cells. In contrast, an enhanced and prolonged antiviral 
effect of 3p-siRNAs was detected at later time-points (day 8 after tarnsfection). 
 
 
2.5.5 Long-term treatment of HBV by 3p-siRNA in vitro 
 
To prove the sustained antiviral effects of 3p-siRNAs, the antiviral efficiency of 3p-
RNA was compared with the most promising 3p-siRNA (3p-1.2) and its 
unphosphated counterpart si-1.2 over a period of 16 days in HepG2 H1.3 cells (Fig. 
2.18). Poly (I:C) served as positive control, mock cells were treated with transfection 
reagent Hiperfect. Therapeutic effects were monitored in terms of progeny HBV-DNA 
release by quantitative PCR (Fig. 2.18 a) and HBeAg secretion by ELISA (Fig. 2.18 
b). Analysis started 12 h after treatment, followed by day 4 and subsequently every 
second day until day 16. The medium of cells was changed every second day from 
day 4 onwards. The early antiviral response until day 6 was comparable between all 
oligonucleotides at progeny HBV-DNA and HBeAg levels. Nevertheless, both, 3p-1.2 
as well as its synthetic counterpart si-1.2 controlled HBV-DNA synthesis over time. 
3p-1.2 was significantly superior to si-1.2 from day 10 onwards (Fig. 2.18 a). HBeAg 
level reduction by 3p-1.2 was significantly superior to 3p-RNA or si-1.2 from day 8 
onwards. Accordingly, 3p-1.2 showed a prolonged antiviral response than si-1.2 and 
3p-RNA alone. Probably, IFN-I mediated reduction of HBV replication by 3p-RNA and 
3p-1.2 diminished over time. Therefore, 3p-RNA and 3p-1.2, as well as poly(I:C) as 
IFN-I inducing positive control, were equally active at early timepoints. But 3p-RNA 
and poly(I:C) lost their antiviral activity at later timepoints due to the absence of gene 
silencing activity. 
Taken together, the results indicate that the combination of immuno-stimulation and 
gene silencing in one single molecule displayed superior antiviral activity than each 
mechanism alone in vitro. 
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Fig. 2.18: Longterm effects of 3p-siRNA on HBV replication in vitro. a) Quantiative PCR analysis 
of progeny HBV-DNA and b) enzyme immunoassay of HBeAg levels in supernatant of HepG2 H1.3 
cells until day 16 after treatment with indicated RNA-oligonucleotides; mock cells were treated only 
with transfection reagent Hiperfect. The experiments were performed in triplicates and results were 
given as mean ± SD. Significant differences were shown between si-1.2 and 3p-1.2 treated cells 
(*P<0.05,**P<0.01, ***P<0.001, t-test) . 
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The experiments showed a slight increase in HBV-DNA levels after treatment with 
3p-1.2 or si-1.2 over more than 12 days in HepG2 H1.3 cells. Accordingly, a reduced 
or hampered binding of siRNA to HBV-DNA due to mutations selected by RNAi 
induced selection pressure was excluded. For this, the intrinsic siRNA binding site of 
si-1.2 was sequenced in secreted virions at day 10 and day 16 (Fig. 2.19 b + c). 
HBV-DNA sequence of mock treated cells at day 0.5 after application served as 
control (Fig. 2.19 a). The correct sequence of the control was verified by comparison 
with the known HBV genome sequence. None of the analyzed DNA fragments 
revealed any mutations inside the HBV-genome sequence targeted by si-1.2 or 3p-
1.2, neither at day 10 nor at day 16 after transfection.  
 
                               
                                     
Fig. 2.19: Direct sequencing analysis of siRNA binding site within the HBV-DNA genome of 
secreted virions. DNA was extracted from supernatant of HepG2 H1.3 cells treated with si-1.2 or 3p-
1.2 at day 10 and day 16 after transfection. Si-1.2 binding site spanning fragment of HBV-DNA was 
amplified by PCR and analyzed by direct sequencing.  
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2.5.6 Antiviral effects of 3p-siRNA treatment in vivo 
 
Next, the ability of 3p-1.2 and 3p-RNA to induce an antiviral IFN-I response was 
compared in vivo (Fig. 2.20). Therefore, 3p-1.2, 3p-RNA and si-1.2, respectively, 
were injected intravenously twice (day 0 and day 3) into HBV tg mice and sera of 
mice were tested 6 h after injection for IFN-α by ELISA assay. Mice treated with 
HCV-sequence specific siRNA (si-Ctrl) served as negative control (Fig. 2.20 a). Both 
ligands 3p-1.2 and 3p-RNA triggered a fast IFN-α response at comparable levels, 
whereas si-1.2 treated and control mice showed no response. 
Next, the impact of 3p-RNA was compared with the antiviral effect of 3p-siRNAs on 
HBV replication in HBV tg mice. Therefore, mice were injected with 3p-RNA, 3p-1.1 
and 3p-1.2, as well as their non-phosphorylated counterparts si-1.1 and si-1.2, 
respectively. Si-Ctrl treated mice served as negative control. HBV replication levels 
were determined by Southern blot analysis of pooled, intrahepatic HBV-DNA, isolated 
at day 6 after treatment. HBV genome integrates served as a loading control. HBV-
DNA of HepG2 H1.3 cells, treated with or without the HBV-sequence single-cutter 
EcoRI, served as a control for different HBV-DNA forms (Fig. 2.20 b). Consistent with 
the in vitro data at day 6, mice treated with 3p-RNA, siRNA and 3p-siRNA showed a 
clear reduction on HBV-DNA replication in comparison to the control group (si-Ctrl). 
Nevertheless, 3p-RNA seemed to reduce HBV DNA levels superior to 3p-siRNA or 
siRNA at this timepoint. 
The results confirm a rapid IFN-I induction by 3p-1.2 comparable to 3p-RNA in vivo. 
Moreover, mice treated with 3p-siRNA, 3p-RNA or siRNA, respectively, showed a 
drastic reduction of intracellular HBV-DNA levels at day 6 after treatment.  
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Fig. 2.20: 3p-siRNAs were functional as RIG-I ligands in vivo. a) IFN-α concentration in serum of 
HBV tg mice treated with indicated RNA-oligonucleotides, measured by ELISA 6 h after first injection 
at day 0. Data are shown as mean ± SD, n=4. b) Southern blot analysis of pooled (n=5) intrahepatic 
HBV-DNA (75 µg total DNA was applied per lane) of HBV tg mice 6 days after treatment with indicated 
RNA-oligonucleotides. HBV genome integrates in HBV tg mice served as loading control. HBV-DNA of 
HepG2 H1.3 cells, treated with or without the HBV-sequence single-cutter EcoRI, served as a control 
for different HBV-DNA forms.  
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2.5.7 Long-term treatment of HBV by 3p-siRNA in vivo 
 
The antiviral efficiency of both RNA-oligonucleotides was compared over an 
extended time period of 15 days. Therefore, HBV tg mice were injected intravenously 
with 3p-RNA, 3p-1.2, si-1.2 or si-HCV (si-Ctrl) as negative control, respectively. 
Therapeutic effects against HBV were monitored at day 6, day 9 and day 15 after 
application by determination of hepatocellular HBV pgRNA levels and progeny HBV 
DNA levels in the serum of mice by qRT-PCR (Fig. 2.21), as well as by cytoplasmic 
HBV core-protein staining in liver sections (Fig. 2.22).  
Mice treated with si-1.2 exhibited a slight decrease of pgRNA levels at day 6 and day 
9. 3p-RNA or 3p-1.2 treatment, respectively, led to a significant and comparable 
reduction of pgRNA at day 6. However, 3p-1.2 that combines HBV-specific gene 
silencing and immune stimulatory properties, showed a significantly stronger effect 
on HBV pgRNA than 3p-RNA and si-1.2 alone at day 9. Of note, no effect on pgRNA 
was detectable anymore at day 15 (Fig. 2.21 a). 
HBV DNA levels in the sera of the mice were comparable in all groups at day 0, the 
day of application. Mice treated with si-1.2 showed only a minor reduction of HBV 
viremia, and the effect had disappeared at day 9. In contrast, both, 3p-RNA more 
than 3p-1.2 injected mice showed a significant drop of HBV viremia at day 6 and day 
9 after treatment in comparison to control group, consistent with Southern blot data 
(Fig. 2.20 b). Furthermore, HBV viremia remained reduced until day 15 in comparison 
to control mice. (Fig. 2.21 b). 
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Fig. 2.21: Combined antiviral efficiency of 3p-siRNA in vivo. a) Quantitative PCR analysis of HBV 
DNA levels in serum of HBV tg mice at day 0, 6, 9, 12 and 15, respectively, after treatment with 
indicated RNA-oligonucleotides. b) Quantiative PCR analysis of hepatocellular pgRNA levels in HBV 
tg mice at day 6, 9 and 15, respectively, after treatment with indicated RNA-oligonucleotides, relative 
to mRNA levels GAPDH, normalized to mice treated with control siRNA.Results are shown as mean ± 
SD, n=4 (*P<0.05, **P<0.01, ***P<0.001, t-test). 
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To investigate the antiviral effect of 3p-RNA and 3p-1.2 on protein expression, the 
Pathology of Helmholtz Zentrum München additionally performed a HBV core-
antigen staining of the liver tissue of treated animals (Fig. 2.22). Two different core-
antigen staining patterns were observed. First, core-protein that assembles in the 
nucleus of HBV positive hepatocytes by an unknown mechanism remained 
unaffected by treatment. This phenomenon occurs frequently in HBV mouse models 
and results in a nuclear core staining (N), which was observed in 90 - 95% and at 
comparable intensity in all samples. In addition, cytoplasmic core-staining (CP) was 
detected, predominantly located in the area of central veins (CV). Mice treated with 
si-1.2 exhibited little effect, whereas 3p-RNA treatment led to a drastic reduction of 
cytoplasmic core-protein at day 9. Strongly decreased levels of cytoplasmic core-
protein were also observed in mice injected with 3p-1.2, even though not as drastic 
as in 3p-RNA treated mice (Fig. 2.22 a). Cytoplasmic HBV core-antigen staining at 
day 15 was not affected anymore in si-1.2 treated mice, but slightly diminished in 
both, 3p-RNA and 3p-1.2 treated mice with superior effects of 3p-1.2 (Fig. 2.22 b). 
 
 
 
Fig. 2.22: HBV-core antigen staining in liver of RNA-oligonucleotide treated HBV tg mice. HBV 
tg mice were injected with indicated RNA-oligonucleotides. Liver tissue was analyzed by HBV core-
antigen staining at a) day 9 and b) day 15 after treatment. N: nuclear positivity; CP: cytoplasmic 
positivity; CV: central vein; PV; portal vein. Results are representative for n=5 mice per group, 2 mice 
per group were analyzed. 
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The in vivo results confirmed that the combinatorial antiviral effect of 3p-1.2 was 
superior to siRNA or 3p-RNA. 
 
 
2.6 Liver directed targeting of RNA-oligonucleotides in vivo 
 
As already shown, HBV-sequence specific siRNAs acted on cytosolic HBV RNAs in 
HBV replicating hepatocytes in vitro and in vivo. For that, RNAi inducing 3p-1.2 and 
si-1.2 had to reach the hepatocytes. Within the in vitro systems efficient targeting was 
given by direct transfection. In the in vivo system, in contrast, the RNA-
oligonucleotides were injected into the tail vein of HBV tg mice and had to reach the 
hepatocytes via bloodstream transport. In order to protect them from degradation and 
enhance efficient liver targeting, all RNA-oligonucleotides were complexed prior to 
injection with “in-vivo-jetPEI”, a reagent that protects and delivers nucleic acids to 
various tissues via the intravenous route, also to the liver. Nevertheless, in vivo 
experiments indicated a lower impact on HBV replication by non-phosphorylated si-
1.2, indicating an insufficient delivery into hepatocytes.    
 
 
2.6.1 Targeting specificity of applied RNA-oligonucleotides  
 
To determine the delivery efficiency of RNA-oligonucleotides into the liver and to 
specify other targeted organs, HBV tg mice were injected intravenously with 
complexed si-1.2 or 3p-1.2, respectively. After isolation of liver, spleen, kidney, heart 
and gastric lymphatic glands 6 hours after injection, IFN-β expression was 
determined on mRNA levels in respective organs by qRT-PCR (Fig. 2.23). 
Interestingly, mice treated with unphosphated si-1.2 showed a strong IFN-β induction 
in isolated lymph nodes and in the spleen. No or minor IFN-β expression was 
detectable in the liver, kidney and heart, respectively, after application of si-1.2. 
Accordingly, 3p-1.2 injected mice revealed a potent IFN-β expression in gastric 
lymphatic glands and at reduced levels also in the spleen. No IFN-β induction was 
observed neither in the kidney nor in the heart or in the liver. 
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Fig. 2.23: IFN-β expression in different organs of si-1.2 and 3p-1.2 treated HBV tg mice. HBV tg 
mice were injected intravenously with jetPei complexed si-1.2 and 3p-1.2, respectively. 6 hours after 
injection IFN-β expression was determined in different isolated organs on mRNA level by qRT-PCR 
relative to GAPDH, normalized to IFN-β values in the liver of mice treated with si-1.2. Results are 
shown as mean ± SD, n=2. 
 
 
The results demonstrate that both complexed si-1.2 and 3p-1.2 were predominantly 
delivered into gastric lymph nodes and into the spleen after systemic administration, 
where they efficiently induced IFN-β, likely via TLR3 or RIG-I stimulation. No or only 
minor amount of injected RNA-oligonucleotides ended up in the liver. 
To confirm and visualize these results, mice were injected intravenously with jetPEI 
complexed si-1.2, which was fluorescently labeled at the 5`-end of the plus-strand 
with Alexa 488 via a biotin residue. Liver, spleen, kidney and lung were isolated 6 
hours after injection, thin sections of isolated organs were prepared and Alexa 488 
localized by fluorescence microscopy (Fig. 2.24). Comparing the examined organs, 
only a small amount of applied fluorescently labeled si-1.2 localized to the liver, but at 
least partially in double-nucleated hepatocytes (solid white arrows). Most of it, 
however, accumulated and clotted in undefined areas of the liver (dashed white 
arrows), likely in LSECs or Kupffer cells. Most of the intravenously applied siRNA 
ended up in the spleen. Rare single fluorescence signals could also be detected in 
the kidney and in the lung.  
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Fig. 2.24: Targeting efficiency of fluorescently labeled and complexed si-1.2 to different organs. 
Mice were injected intravenously with fluorescently labeled (Alexa 633) si-1.2., previously complexed 
with jetPEI. Organs were analyzed for siRNA distribution 6 hours p. inj., indicated by white arrows. 
Solid arrows point to siRNA distribution in hepatocytes, dashed arrows to aggregates in undefined 
structures, likely Kupffer cells or LSECs. Results are representative for n=2 / group.  
 
 
The results validated that most of the complexed and intravenously injected RNA-
oligonucleotides predominantly ended up in the spleen and only a low amount 
reached the liver. 
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2.6.2 Liver-specific targeting of RNA-oligonucleotides 
 
Targeting and delivery of siRNAs into specific cell types is a major problem in RNAi 
treatment. To improve the RNAi-based effect of 3p-siRNA mediated combinatorial 
therapy of HBV, the hepatocellular uptake of siRNA had to be improved. Several 
possibilities for enhanced liver specific delivery were considered. A promising 
approach included the application of the siRNA by an alternative injection technique. 
The hydrodynamic injection (HDI) technique was already used to efficiently deliver 
nucleic acids to the liver (Klein, 2003 #668;Giladi, 2003 #1753;Morrissey, 2005 
#764;Huang, 2006 #1781}. By hydrodynamic injection the siRNA is rapidly injected in 
a large volume under high pressure intravenously into the tail vein of the mice. To 
compare the efficiency of RNA-oligonucleotide delivery by classical intravenious 
injection and hydrodynamic injection, mice were injected by both injection techniques 
with naked (not complexed with jetPEI) si-1.2, which was previously fluorescently 
labeled at the 5`-end of the plus-strand with Alexa 488. Liver, spleen, kidney were 
isolated 6 hours after injection and siRNA-coupled Alexa 488 was localized in 
different organs by fluorescence microscopy (Fig. 2.25). Fluorescently labeled siRNA 
applied by classical intravenous injection predominantly accumulated in the spleen. A 
small amount of applied si-RNA reached the liver, but was primarily localized outside 
of the hepatocytes. Additionally, injected siRNA was detectable to a minor extent in 
the kidney of the mice. (Fig. 2.25 a). In contrast, hydrodynamic injection led to an 
increased targeting of the siRNA to hepatocytes, especially to hepatocytes located in 
an area near sinusoidal blood vessels. Less siRNA was delivered to the spleen and 
only minor amounts to the kidney (Fig. 2.25 b). 
The results indicate an enhanced delivery of naked siRNA to the liver and especially 
into hepatocytes by hydrodynamic injection in comparison to classical intravenous 
injection. Nevertheless, the structure and vitality of the liver seemed to be negatively 
affected by hydrodymaic injection. 
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Fig. 2.25: Targeting efficiency of fluorescently labeled naked siRNA to different organs by 
intravenious injection and hydrodynamic injection. Mice were treated with naked (uncomplexed) 
fluorescently labeled (Alexa 633) si-1.2. by a) classical intravenous injection or b) hydrodynamic 
injection (HDI). Organs were analyzed for siRNA distribution 6 hours p. inj.. Results are representative 
for n=2 / group. 
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An alternative method to enhance the delivery efficiency of the nucleic acid to the 
liver is the linkage of a targeting ligand to the siRNA. Bioconjungation of the siRNA to 
cholesterol at the 3´-end of the plus strand via a cleavable linker (TEG, triethylene 
glycol) was already shown to significantly increase targeting efficiency of the modified 
siRNA to human liver cells (Soutschek, Akinc et al. 2004). Therefore, HBV-specific si-
1.2 was coupled at the 3`-end of the plus-strand with cholesterol and labeled 
fluorescently at the 5`-end of the plus-strand with Alexa 488. To investigate the liver 
targeting of modified cholesterol-linked siRNA and additionally compare different 
delivery strategies, cholesterol-conjugated si-1.2 was injected by different methods 
and localized by fluorescent microscopy 6 hours after application (Fig. 22.6). First, 
modified siRNA was complexed before application with jetPEI and then classically 
injected intravenously (Fig. 22.6 a). Second, naked (not complexed with jetPEI) 
modified si-1.2 was classically injected intravenously (Fig. 22.6 b) and third, naked 
modified si-1.2 was injected by hydrodynamic injection (Fig. 22.6 c). All three 
applications led to a comparable accumulation of siRNA in the spleen, but no or only 
minor residues of siRNA were detected in the kidneys. Mice classically intravenously 
injected with complexed modified siRNA revealed an increased amount of siRNA in 
the liver compared to mice treated with jetPei complexed but unmodified siRNA (Fig. 
2.24), although a high amount accumulated outside of hepatocytes (Fig. 22.6 a). In 
contrast, naked modified siRNA, classically injected intravenously, was also 
efficiently delivered into the liver, but additively localized in hepatocytes (Fig. 22.6 b). 
Only little amount of naked modified siRNA injected by hydrodynamic injection ended 
up in the liver (Fig. 22.6 c).  
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Fig. 2.26: Targeting efficiency of cholesterol coupled siRNA to different organs using different 
forms of applications. HBV tg mice were treated with cholesterol-coupled and fluorescently labeled 
(Alexa 633) si-1.2. by a) classical intravenous injection, previously complexed with JetPei b) classical 
intravenous injection, uncomplexed (naked) or c) hydrodynamic injection (HDI), uncomplexed (naked). 
Organs were analyzed for siRNA distribution 6 hours p. inj.. Results are representative for n=2 / group. 
 
 
The results indicate that naked cholesterol-coupled siRNA, injected by classical 
intravenous application, efficiently reaches the liver including hepatocytes. In 
comparison of all investigated applications, cholesterol coupling to 5`-triphosphate 
RNA may represent a powerfull targeting-tool. Nevertheless, the preferred method for 
liver directed targeting, although not optimal, was the classical intravenous injection 
of jetPEI-complexed nucleic acids during this study. 
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2.6.3 IFN-β induction by 3p-siRNA in different liver cell populations 
 
As already stated, the liver consists beside hepatocytes also of non-parenchymal 
cells, such as liver sinusoidal endothelial cells (LSECs) and Kupffer cells. The 
previous described delivery studies revealed that injected nucleic acids partially 
reached the liver, but only to some extent the hepatocytes. A certain proportion 
apparently ended up in other liver cells, likely LSECs or Kupffer cells. To elucidate 
whether 3p-siRNA potentially induced an IFN-I response also in these non-
parenchymal cell types, LSECs and Kupffer cells were isolated beside PHHs from 
fresh human liver specimen and treated with both, 3p-siRNA and si-1.2, respectively, 
poly(I:C) was used as positive control, si-Ctrl as negative control (Fig. 22.7). To 
mimic a potential uptake like in the in vivo situation, RNA-oligonucleotides were 
complexed with “in vivo-jetPEI” and added into the supernatant of the PHHs (Fig. 
22.7 a), LSECs (Fig. 22.7 b) and Kupffer cells (Fig. 22.7 c), respectively. Potent IFN-
β induction was shown 6 hours after application on mRNA levels by qRT-PCR in all 
cell types.  
 
                         
 
Fig. 2.27: IFN-β induction in different liver cell populations after uptake of complexed 3p-siRNA. 
Indicated RNA-oligonucleotides were complexed with JetPei and added to the supernatant of purified 
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liver cell populations. IFN-β expression was determined in a) Primary human hepatocytes (PHHs) b) 
liver sinusoidal endothelial cells and c) Kupffer cells by quantitative RT-PCR analysis 20 hours after 
treatment, relative to GAPDH, normalized to si-Ctrl (HCV-sequence specific siRNA) treated cells. Data 
represent mean values ± SD, n=3.  
 
 
2.7 Initiation of an adaptive immune response against HBV 
 
2.7.1 3p-siRNA induced expression of proinflammatory cytokine in liver cells  
 
It is known that poly(I:C) stimulation of TLR3 leads to a potent expression of 
proinflammatory cytokines like IL-6 in murine non-parenchymal liver cells, in LSECs 
and Kupffer cells (Wu, Lu et al. 2007). Accordingly, it was shown that stimulation of 
RIG-I induces the transcription of proinflammatory cytokines like IL-1, IL-6 and TNF-α 
via the canonical IKK pathway (Dinarello 2000). Secretion of proinflammatory 
cytokines like IL-6 and TNF-α lead to the recruitment of natural killer cells, natural 
killer T cells and T-cells. Accordingly, clearance of HBV is typically associated with 
multispecific CD4+ and CD8+ T cell response (Rehermann 2003).   
Therefore, LSECs and Kupffer cells were stimulated with both, 3p-1.2 and si-1.2, 
poly(I:C) was used as positive control, si-Ctrl RNA as negative control. Based on the 
results of the previous experiment, RNA-oligonucleotides were complexed and 
applied by addition into the supernatant. Cells were tested 6 hours after application 
for secretion of IL-6 and TNF-α into the supernatant by ELISA assay.  
Isolated LSECs and Kupffer cells showed a strong basal expression level of IL-6 
(dotted red line). Nevertheless, application of 3p-1.2 and poly(I:C), respectively, led to 
significant additive induction of IL-6 in LSECs. In contrast, Kupffer cells revealed a 
lower basic induction of IL-6 and only application of 3p-1.2 induced a significant 
additive IL-6 expression (Fig. 2.28 a). Additionally, LSECs and Kupffer cells showed 
significant induction of TNF-α following 3p-1.2 stimulation (Fig. 2.28 b).  
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Fig. 2.28: IL-6 and TNF-α induction in purified liver cell populations after uptake of complexed 
3p-siRNA. Indicated RNA-oligonucleotides were complexed with JetPei and added to the supernatant 
of purified liver cell populations. Liver sinusoidal endothelial cells, LSECs (left panels) and Kupffer 
cells (right panels) were analyzed for a) IL-6 and b) TNF-α expression by ELISA 6 hours after 
treatment. Basic induction indicated by dotted red line. Data represent mean values ± SD, n=3. 
 
 
The results indicate that uptake of 3p-1.2 by liver sinusoidal endothelial cells (LSECs) 
and Kupffer cells induced potent expression of proinflammatory cytokines such as IL-
6 and TNF-α. 
 
 
2.7.2 Induction of an adaptive immune response against HBV after RNA-
oligonucleotide stimulation in vivo 
 
It was shown that application of immune-stimulatory RNA-oligonucleotides led to a 
potent stimulation of an antiviral acting innate immune response against HBV. 
Furthermore it was presumed, due to the previous experiment, that application of 3p-
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siRNA additionally led to the expression of proinflammatory cytokines and potentially 
could be followed by the induction of an HBV antigen specific adaptive immune 
response after several days. Therefore it was investigated in vivo, whether the mice 
previously treated with immune-stimulatory and antivirally active RNA-
oligonucleotides revealed any induction of an adaptive immune response (Fig. 2.29). 
Accordingly, mice treated with 3p-RNA, 3p-1.2, si-1.2 and si-Ctrl as negative control, 
respectively, were analyzed for liver damage by determining serum alanine 
aminotransferase (ALT) levels at day 0, 4, 9 and 15 after injection (Fig. 2.29 a). In 
fact, nearly all treated mice showed significantly elevated ALT levels at day 9 after 
injection, irrelevant of the RNA-oligonucleotide, in comparison to normal ALT values 
at day 4. The ALT levels decreased back to normal ranges at day 15 in almost all 
treated mice.   
Additionally, the livers of mice were analyzed at day 9 and 15 after injection for 
expression of CD8 (Fig. 2.29 b) and IFN-γ (Fig. 2.29 c) on mRNA level by qRT-PCR. 
CD8 is a surface marker of predominately cytotoxic T cells lymphocytes (CTLs). IFN-
γ is a cytokine produced predominately by CD8+ CTLs during antigen specific 
adaptive immune response. The analysis revealed slightly increased overall CD8 
expression in treated mice at day 9 in comparison to day 15. In particular 3p-RNA 
and 3p-1.2 treated mice, respectively, showed an increase in CD8 expression, 
indicating CD8+ T cell infiltration. Furthermore, overall IFN-γ expression was slightly 
increased at day 9 in comparison to day 15, in turn particularly in 3p-RNA and 3p-1.2 
injected mice.  
The results indicate induction of an HBV antigen specific adaptive immune response 
at day 9 after application of both, 3p-RNA and 3p-1.2, but need to be confirmed by 
specific T cell assays like intracellular IFN-γ staining after e.g. peptide stimulation. 
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Fig. 2.29: Induction of an adaptive immune response in HBV tg mice. HBV tg mice were injected 
twice (day 0 and day 3) with indicate RNA-oligonucleotides. a) Alanine aminotransferase (ALT) levels 
in serum of mice at day 4, day 9 and day 15 after treatment. b) Quantitative RT-PCR analysis of CD8 
expression and c) IFN-γ expression in liver of mice at day 9 and day 15 after treatment with different 
RNA-oligonucleotides relative to GAPDH. Data represent mean values ± SD, n=5 (**P<0.01, t-test). 
 
 
To support these results of an inflammatory immune response, the Pathology of 
Helmholtz Zentrum München performed histological analyses of the liver tissues of 
treated HBV tg mice at day 9 and day 15 after injection, respectively (Fig. 2.30). 
Histopathological alterations were classified in changes affecting the portal tracts, 
including liver arteries, -veins and –bile duct (e.g. inflammation, degenerative 
changes of the bile ducts, fibrosis), changes affecting the lobule, which are clear 
anatomical divisions or extensions (e.g. spotty and bridging necrosis, degenerative 
changes of the hepatocytes, fibrosis) and changes affecting the vessels (e.g. 
inflammation, fibrosis, thrombosis). Furthermore, alterations were graded as mild, 
moderate and severe, depending on their frequency and severity.  
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Fig. 2.30: Liver staining (HE and PAS) of RNA-oligonucleotide treated HBV tg mice. HBV tg mice 
were injected with indicated RNA-oligonucleotides. Liver tissue was analyzed by HE and PAS staining 
for alterations along with an adaptive immune response at a) day 9 and b) day 15 after treatment. One 
representative out of n=5 mice per group is shown, 2 mice per group were analyzed. 
 
 
The histological analysis revealed clear symptoms of an inflammatory reaction in the 
liver of si-1.2, 3p-RNA and 3p-siRNA treated mice, respectively, at day 9 after 
injection. Foci of spotty necrosis with apoptotic hepatocytes were found in almost all 
cases of treated animals, except for si-Ctrl (Fig. 2.30 a, middle and right). 
Moreover, infiltration of immune cells resulting in a mild to moderate subendothelial 
inflammation (endothelitis) of the central and portal veins (Fig. 2.30 a, left and right), 
sometimes associated with perivenular necrosis of hepatocytes (Fig. 2.30 a, middle) 
was found only in treated animals.  
Furthermore, in comparison to modest liver tissue with normal portal tracts of si-Ctrl 
treated animals at day 15 (Fig. 2.30 b, left), only small foci of spotty necrosis (Fig. 
2.20 b, middle) and mild subendothelial infiltration of portal veins (Fig. 2.20 b, 
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middle) were found in treated animals at this timepoint. Therefore, we concluded that 
inflammatory changes had ceased at day 15. 
The results indicate, in correlation with previous serological results (ALT values), an 
inflammatory reaction in the liver of si-1.2, 3p-RNA and 3p-siRNA treated animals, 
respectively, at day 9 after treatment and its resolution towards day 15.  	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3 Discussion 
 
About two billion people worldwide (~ 30%) have been infected with HBV and about 
360 million (5 - 7%) live with a chronic state of infection. Estimated 700 000 persons 
die each year due to the acute or chronic consequences of hepatitis B (WHO, 2008). 
Approved therapies of chronic hepatitis B include antiviral active IFN-α and inhibitors 
of viral reverse transcription. Their use leads to suppression of viral replication, but 
with partially limited effectiveness concerning sustained antiviral effects or even 
elimination of the virus. Indeed, following treatment termination, persistent cccDNA is 
able to initiate a new HBV replication cycle (Protzer and Schaller 2000), even after 
serological clearance of viral infection (Werle-Lapostolle, Bowden et al. 2004).	  
Therefore, a lifelong therapy, accompanied by appearance of severe cytotoxic side 
effects and drug-resistant HBV mutants, is indispensable in most cases. This rather 
limited clinical success demonstrates the necessity for the development of new 
therapies, focused on the effective and long-lasting suppression of HBV replication, 
associated with enhanced physiological compatibility. Combinatorial strategies 
targeting simultaneously multiple steps of HBV replication represent a promising tool 
for the treatment of chronic hepatitis B. In this project we developed a novel 
immunotherapeutic approach, combining endogenous IFN-I induced antiviral activity 
against HBV by stimulation of the cytosolic helicase RIG-I with HBV sequence 
specific gene silencing by RNAi in one single molecule.  
The therapeutic aspects of (1) IFN-I induction by RIG-I stimulation in (2) combination 
with siRNA mediated gene silencing targeting HBV replication, as well as (3) options 
for efficient delivery of the designed molecule in vivo and (4) simultaneous initiation 
of an HBV-specific immune response will be consecutively discussed below. 
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3.1 RIG-I dependent induction of IFN-I and interferon stimulated genes by 
3p-RNA suppressed HBV replication in vitro and in vivo  
 
3.1.1 3p-RNA induced IFN-I suppresses HBV replication  
 
Hornung et al. showed in a series of elegant studies that in vitro transcribed 5`-
triphosphated-dsRNA (3p-RNA) strongly induces endogenous IFN-I by stimulation of 
RIG-I (Hornung, Ellegast et al. 2006). We intended to use 3p-RNA to initiate an 
endogenous antivirally active IFN-I response by stimulation of RIG-I to potentially 
suppress HBV replication in this study.  
To test the therapeutic potential of 3p-RNA against HBV in this project, we revealed 
the antiviral effects of transfected 3p-RNA on HBV replication in stably HBV 
expressing HepG2 H1.3 cells and in HBV infected PHHs. Both cell types showed a 
potent reduction of HBV-DNA levels after transfection with 3p-RNA, but not after 
treatment with control RNA. Additionally, HBeAg, HBsAg and HBV pgRNA levels 
were significantly diminished compared to untreated cells, indicating an antiviral 
activity at the level of transcription and posttranscriptionally. In addition, we examined 
the antiviral effect of 3p-RNA in vivo. HBV tg mice revealed a significant decrease of 
HBV-DNA levels in the blood. Furthermore, HBV antigen and intrahepatic 
pregenomic RNA levels were drastically reduced. These results suggest that 
selective engagement of RIG-I by 3p-RNA displays pronounced antiviral activity in 
vitro and in vivo. 
RIG-I, broadly expressed in almost every cell type (Melchjorsen, Jensen et al. 2005) 
was proposed to detect long dsRNA (Yoneyama, Kikuchi et al. 2004) and additionally 
identified as a cellular key sensor of negative-strand RNA viruses (Plumet, Herschke 
et al. 2007; Habjan, Andersson et al. 2008; Takeuchi and Akira 2008). Furthermore, it 
has been demonstrated that RIG-I is essential for the production of antiviral 
interferons in response to RNA viruses that express a phosphorylated RNA genome 
(Kato, Takeuchi et al. 2006). Moreover, the presence of a triphosphate group at the 
5`-end of both, ssRNA and dsRNA is an important molecular feature that is 
recognized by RIG-I (Kim, Longo et al. 2004; Hornung, Ellegast et al. 2006; 
Pichlmair, Schulz et al. 2006; Cui, Eisenacher et al. 2008; Saito, Owen et al. 2008; 
Takahasi, Yoneyama et al. 2008). In contrast, recent work by Kato et al. suggests 
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that long dsRNA of vesicular stomatitis virus (> 300 bp) can substitute for the 
presence of a 5´-triphosphate group (Kato, Takeuchi et al. 2008). In summary, 
stimulation of antivirally active IFN-I can be induced by different RNA-
oligonucleotides serving as RIG-I ligands, the exact structure of the RNA remains 
controversial (Schlee, Hartmann et al. 2009). The antiviral effect of IFN-I on HBV 
replication was described extensively in vitro and in vivo (Guidotti and Chisari 1999; 
Rang, Gunther et al. 1999; Schultz, Summers et al. 1999; McClary, Koch et al. 2000; 
Wieland, Guidotti et al. 2000; Pasquetto, Wieland et al. 2002) and led to approved 
application of exogenous IFN-α in clinical treatment of chronic HBV infection, 
although still inducing severe side effects.  
In search for appropriate HBV model systems we analyzed several hepatoma 
derived cell lines as well as isolated PHHs (Schulze-Bergkamen, Untergasser et al. 
2003) for expression of RIG-I. Previous stimulation of cells with IFN-I is known to 
increase the expression of RIG-I (Bowie and Unterholzner 2008). We detected 
expression of endogenous RIG-I protein in all analyzed liver cells, which could be 
drastically enhanced by addition of exogenous IFN-I. It remains to be elucidated 
whether the expression of RIG-I can also be increased by induction of endogenous 
IFN-I after transfection of 3p-RNA. However, neither HuH7 cells (Nakabayashi, 
Taketa et al. 1982) nor its subline HuH7.5 (Blight, McKeating et al. 2002) revealed 
any induction of IFN-β by 3p-RNA or poly(I:C), respectively. Consistently, it has been 
published that Huh7 cells failed to produce IFN-I via TLR3 or RIG-I signaling 
pathway, explained by insufficient TLR3 expression and by an undefined defect on 
RIG-I receptor level, respectively (Li, Chen et al. 2005; Preiss, Thompson et al. 
2008). This holds also true for HuH7.5 cells, which are highly permissive for 
replication of HCV RNA replicons (Blight, McKeating et al. 2002), but are also devoid 
of proper IFN-induction in absence of TLR3 and due to a point mutation of RIG-I 
within its CARD-like domain (Sumpter, Loo et al. 2005). In contrast, HepG2 cells 
(Hirayama, Kohgo et al. 1993) are known to be competent for IFN-I signaling via RIG-
I stimulation (Preiss, Thompson et al. 2008). Moreover, the use of a stably HBV 
expressing cell line for in vitro investigations was preferred, therefore HepG2 H1.3 
cells (Jost, Turelli et al. 2007; Protzer, Seyfried et al. 2007) were chosen. This cell 
line additionally establishes, in contrast to HepG2 2.15 cells, episomal cccDNA, 
helpful as an accessory replication marker and hardly to affect by antiviral therapy. 
PHHs were selected as an in vitro HBV infection model, which also express cccDNA 
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during HBV replication. In addition, as an in vivo model system, we decided to use 
HBV1.3 –xfs transgenic (tg) mice carrying a genotype D HBV1.3 overlength genome, 
with a frameshift mutation (GC) in the x-gene at position 2916/2917  (Weber, 
Schlemmer et al. 2002). The virus replicating in HBV1.3 –xfs mice is non-infectious in 
vivo as suggested by studies using X-mutated woodchuck HBV (WHV) in 
woodchucks (Chen, Kaneko et al. 1993).  
A dual-luciferase assay performed in RIG-I expressing HEK 293 cells (Aiello, 
Guilfoyle et al. 1979) revealed clear differences in the potency to induce IFN-I via 
RIG-I stimulation of different 3p-RNAs derived from seperate in vitro transcriptions. 
These observations could be explained as a consequence of inefficient 
triphosporylation during reverse transcription by T7 RNA polymerase within diverse 
preparations. Another important conclusion that can be drawn from several 
puplications is that induction of IFN-I by RIG-I stimulation strongly depends on the 
structure and sequence of the 3p-RNA. Interestingly, short-hairpin 3p-RNAs 
synthesized by T7 RNA polymerase do not induce IFN-I (Gondai, Yamaguchi et al. 
2008). The 3p-RNA used in this study includes a GU-rich dsRNA sequence with an 
overhang of one G-nucleotide at the 5`-position of both strands and was already 
shown to strongly induce IFN-I (Hornung, Ellegast et al. 2006). The guanine-base 
overhang increased transcription efficiency, whereas presence of the pyrimidine base 
uracil within the dsRNA sequence was shown to be essential for double-strand 
formation during in vitro transcription by T7 RNA polymerase (Schlee, Roth et al. 
2009). Controversially, it was recently suggested that fully synthetic 5`-triphosphate 
short blunt-end dsRNA structure with out an overhang, as contained in the panhandle 
of negative-strand RNA genomes, confers full RIG-I ligand activity (Schlee, Roth et 
al. 2009). However, it remains to be elucidated whether 5`-triphosphate short blunt-
end dsRNA without an overhang of one G-nucleotide at the 5`-postion on both 
strands would increase IFN-I induction by stimulation of RIG-I in our models.  
3p-RNA has been shown to selectively induce apoptosis in melanoma cell lines by an 
IFN-independent antiviral signaling pathway (Poeck, Besch et al. 2008; Besch, Poeck 
et al. 2009). To exclude toxic effects of 3p-RNA in our cellular system, HepG2 H1.3 
cells were transfected with different concentrations of 3p-RNA. Tolerance of treated 
cells for the 3p-RNA concentration used throughout the study (0.5 µg / ml) was 
confirmed by a cell viability assay determining active metabolism in mitochondria. 
The formed dye was quantitated in a spectrophotometer, absorbance directly 
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correlated with number of living cells. Vitality levels above 100% can be explained 
due to determination by means of linear regression analysis. Identical concentrations 
of Ctrl-RNA were used throughout the in vitro studies. Synthetic dsRNA poly(I:C), 
used as positive control, was transfected in lower concentrations (0.05 µg / ml), due 
to its known toxicity in high concentrations. Neither Ctrl-RNA, nor poly(I:C) showed 
any obvious cytotoxicity at applied concentrations in vitro, but has to be further 
investigated by cell viability analysis or determination of alanine aminotransferase 
(ALT) levels that is predominately secreted by damaged liver cells in detail. 
In addition, toxicity of RNA-oligonucleotides in vivo, complexed with the cationic 
polymer polyethylenimine (PEI) before systemic distribution by intravenous injection, 
was examined by monitoring serum ALT levels. HBV tg mice exhibited unchanged 
ALT levels 6 hours after both applications of 3p-RNA (25 µg per mouse and injection, 
respectively), and also at day 6, comparable to mock treated mice, which 
demonstrated the safety of the therapy in vivo. Surprisingly, several mice treated with 
Ctrl-RNA revealed significantly elevated ALT levels. This apparent discrepancy could 
be explained by a possible contamination of the synthetic Ctrl-RNA by bacterial 
components, such as LPS, which might have elicited an inflammatory response by 
TLR or by complement activation in some of the animals (Zhong, Deaciuc et al. 2006; 
Zhang, Kimura et al. 2007).   
After exclusion of cytotoxic side effects, we analyzed the potency of 3p-RNA to 
stimulate IFN-I expression. We found that 3p-RNA induced a potent IFN-I response 
in vitro and in vivo. The IFN-β response in HepG2 H1.3 cells even remained 
detectable until day 6 after transfection, whereas it was significantly reduced in PHHs 
at this timepoint. Remarkably, IFN-I expression levels in PHHs at day 1 after 
application were comparable with those of HepG2 H1.3 cells at day 3. This result 
indicated that initial IFN-I induction by 3p-RNA was significantly higher in HepG2 
H1.3 cells than in PHHs, possibly as a result of reduced transfection efficiency of 
hardly transfectable PHHs. Since TLR3 expression is known to be diminished in 
HepG2 cells (Preiss, Thompson et al. 2008), its likely that the strong IFN-I induction 
in poly(I:C) treated HepG2 H1.3 cells appeared by stimulation of cytosolic helicase 
MDA-5 (Alexopoulou, Holt et al. 2001; Gitlin, Barchet et al. 2006; Kato, Takeuchi et 
al. 2006). However, the TLR expression pattern of PHHs is not well known and is 
currently characterized in our laboratory.  
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To obtain immunostimulatory activity of 3p-RNA in vivo, HBV tg mice were injected 
twice (day 0 and day 3), related to the experiences of our collaborators Poeck and 
colleagues, who observed comparable IFN-I induction after both applications, each 
peaking 6 hours (unpublished data). Accordingly, we detected high serum IFN-α 
levels 6 hours after the first injection of 3p-RNA. Interestingly, the expression of IFN-
α was already markedly reduced 6 hours after the second injection at day 3 and not 
detectable at day 6 in an ELISA assay. 
Consistent with our data, 2`-5`-oligoadenylate synthetase (OAS), which is known to 
be activated by IFN via dsRNA stimulation (Hovanessian and Justesen 2007; 
Silverman 2007), was induced by 3p-RNA application in our in vitro models. In the 
murine system studied here, only remaining levels of intrahepatic 2`-5`-OAS were 
detectable on mRNA level at day 6 after injection, which was unexpected considering 
the stunning induction of IFN-α detected in the serum of 3p-RNA treated mice 6 
hours after application in comparison to mock treated mice. Reflecting this apparent 
discrepancy, and taking into account that the majority of 3p-RNA was taken up by 
non-hepatocytes, it appears more likely that IFN-α expression is also initiated by 
accessory cells targeted by 3p-RNA after systemic distribution. This was further 
investigated and results revealed that also non-parenchymal cells, such as LSECs 
and Kupffer cells are capable to strongly induce IFN-I. 
After having confirmed IFN-I and 2`-5`-OAS induction in our HBV models, no further 
analysis of IFN-induced ISGs were performed in this study. Many studies aimed at 
defining how interferons act on HBV. Analyzing the different steps of the HBV 
replication cycle it became obvious, that mainly posttranscriptional steps were 
affected (Klocker, Schultz et al. 2000; Robek, Boyd et al. 2004), but at higher doses 
also transcription was controlled. Guidotti et al. showed that RNase L, an enzyme 
induced by 2´-5`-OAS, which is able to degrade viral RNA and cellular RNAs (Floyd-
Smith, Slattery et al. 1981), does not affect HBV replication in vivo, demonstrated in 
RNase L-/- knockout mice (Guidotti, Morris et al. 2002). The group showed in a similar 
study that the IFN induced dsRNA-dependent protein kinase (PKR) could mediate 
the antiviral activity against HBV (Guidotti, Morris et al. 2002). Furthermore, IFN-I 
upregulates the expression of GTPases Mx (Martens and Howard 2006; Haller, 
Staeheli et al. 2007). In addition, it was suggested that the human GTPase MxA 
(myxovirus resistance protein A) exhibits antiviral activity and inhibits HBV replication 
at posttranscriptional level in HuH7 and HepG2 cells (Melen, Keskinen et al. 2000; 
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Gordien, Rosmorduc et al. 2001). Furthermore, Wieland et al. revealed that gene 
expression of the murine GTPases IIGP is strongly upregulated by IFN stimulation 
and is tightly associated with inhibition of HBV replication (Wieland, Vega et al. 
2003). Moreover, IFN-I induced proteins of the APOBEC3 family, which are cellular 
cytidine deaminases, were assumed to be involved in antiviral inhibition of HBV 
replication in hepatoma cell lines (Rosler, Kock et al. 2005; Baumert, Rosler et al. 
2007). Bonvin et al. detected significantly elevated APOBEC3 mRNA levels in PHHs 
stimulated with IFN-I (Bonvin, Achermann et al. 2006). Nevertheless, it has been 
recently demonstrated by Tuarelli and colleagues that IFN-induced viral clearance of 
HBV occurs independently of APOBEC3 in HBV tg mice (Turelli, Liagre-Quazzola et 
al. 2008). It therefore remains to be further elucidated, whether IFN-I stimulated 
expression of antivirally active PKR and GTPases is also involved in the suppression 
of HBV replication in our model systems. 
In addition, we investigated whether the applied RNA-oligonucleotides stimulate the 
induction of type-II interferon (IFN-γ). We were not able to detect hepatocellular 
expression of IFN-γ on mRNA level in our model systems after stimulation with 3p-
RNA or poly(I:C), respectively. Moreover, we were interested whether the IFN 
inducible protein 10, IP-10, which is a chemoattractant for the recruitment of effector 
T cells, macrophages, NK cells and DCs in vivo (Luster, Unkeless et al. 1985; 
Dufour, Dziejman et al. 2002) is expressed after administration of 3p-RNA and 
poly(I:C) in vitro and in vivo. Despite the absence IFN-γ, both ligands induced strong 
expression of IP-10 via IFN-I induction in vitro. Remarkably, RNA-oligonucleotide 
treated mice showed only minor residual expression of IP-10 at hepatocellular mRNA 
level after treatment with Ctrl-RNA at day 6. Nevertheless, it is conceivable that high 
expression of IFN-I in the circulation of the murine system was followed by systemic 
induction of IP-10, as it has been recently described by Harkins et al. (Harkins, 
Szymanski et al. 2008). However, this aspect has to be further investigated. 
In search for the mechanism and to further elucidate the contribution of RIG-I and 
interferon-α/β-receptor (IFNAR) in 3p-RNA-induced expression of IFN-I, we knocked 
down RIG-I and IFNAR expression, respectively, by siRNA transfection in HepG2 
H1.3 cells and PHHs. We observed significantly reduced IFN-β levels in both cell 
types treated previously with siRNA against RIG-I, but astonishingly, only a minor 
reduction of IFN-β expression in cells previously treated with IFNAR specific siRNA. 
Discussion 
	   106	  
Accordingly, it has been shown that hepatoma cell lines such as HuH7 and HepG2 
exhibit only a minor suppression of IFN-I signal transduction after knockdown of 
IFNAR-I in comparison to other hepatoma derived cell lines (Damdinsuren, Nagano 
et al. 2007). Nevertheless, we concluded from these experiments that RIG-I is strictly 
required for 3pRNA-dependent induction of IFN-I. However, a feed-back loop via the 
IFNAR seems to play a minor role in 3p-RNA-mediated suppression of HBV 
replication in vitro and in vivo. For the murine system it would be helpful to cross HBV 
tg mice with RIG-I deficient (RIG-I-/-) (Kato, Takeuchi et al. 2006) or IPS-1 deficient 
(IPS-1-/-) mice (Kumar, Kawai et al. 2006), as well as with common IFNAR deficient 
(IFNAR-/-) mice, respectively, to dissect this. 
 
 
3.1.2 HBV escapes from antiviral activity of IFN 
 
Detailed analysis revealed a reduced antiviral effect in PHHs in comparison to 
HepG2 H1.3 cells. Concurrently, we observed lower induction of 2`-5`-OAS after 
treatment with 3p-RNAs, which indicated a weaker antiviral IFN response due to 
hampered transfection efficacy. Moreover, a diminished IFN-I induction in PHHs 
might go along with an active counteraction of HBV against IFN-induced antiviral 
activity. Active HBV evasion to circumvent or even inactivate IFN-I antiviral 
mechanisms have been described and may be also responsible for limited IFN-I 
efficacy in around 30% of chronic HBV patients.  
It has been shown that HBV developed various strategies to counteract IFN signaling 
pathways. Assumingly, HBV is able to overcome or inhibit mechanisms of antiviral 
effector molecules and may also inhibit IFN signaling pathway. For example it was 
proposed that HBV suppresses IFN-β expression at transcriptional level by direct 
binding of HBV-core protein to the regulatory sequence of the IFN-β gene (Twu, Lee 
et al. 1988; Twu and Schloemer 1989; Whitten, Quets et al. 1991). Furthermore, it 
had been published that expression of the IFN effector protein MxA is inhibited by 
direct binding of the core-protein to regulatory elements of the MxA promotor 
sequence in HepG2 2.15 cells (Fernandez, Quiroga et al. 2003; Guan, Lu et al. 
2007), in HepG2 cells transiently transfected with a recircularized HBV genome 
(Fernandez, Quiroga et al. 2003) and in peripheral blood momonuclear cells (PBMC) 
from HBV chronically infected patients (Fernandez, Quiroga et al. 1997). Confirming 
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previous studies it has been suggested that encapsidation of spliced HBV RNA leads 
to the secretion of circulating HBV defective particles (referred to as dHBV DNA), 
which have been detected at higher level in patients evolving chronicity in 
comparison to those recovering from acute HBV infection (Rosmorduc, Petit et al. 
1995; Soussan, Pol et al. 2008). The dHBV DNA may lead to cytoplasmic 
accumulation of the core-protein, which strongly reduced the antiviral activity of IFN-α 
by inhibition of MxA expression in vitro (Rosmorduc, Sirma et al. 1999). Besides the 
core-protein, other HBV proteins have been proposed to interact with the IFN 
pathway. For instance, it has been demonstrated that 5% of human fibroblasts 
transfected with the terminal protein (TP) domain of the HBV polymerase are 
resistant to IFN and dsRNA stimulation (Foster, Ackrill et al. 1991). Moreover, to 
clarify a potential clinical relevance of this inhibitory effect, expression of TP was 
analyzed in liver cells of patients with chronic hepatitis B. Accordingly, it was 
suggested that TP expression is associated with a failure of hepatocytes to respond 
to IFN therapy (Foster, Goldin et al. 1993). A report by Wu et al. supported these 
results. The authors revealed that TP inhibits expression of several interferon 
stimulated genes, such as ISG15 and adaptor protein MyD88 (myeloid differentiatial 
primary response protein 88) by direct interference with the target promotor activity 
through blockage of STAT1 nuclear import (Wu, Xu et al. 2007). Moreover, it was 
shown that also HBV S- and X-protein are directly involved in inhibition of antiviral 
IFN signaling. A report by Christen et al. indicated that the S- and, or X-protein, 
respectively, could block nuclear import of STAT1 by upregulation of a cellular protein 
phosphatase named pp2A in vitro and in liver biopsies from chronically infected HBV 
patients (Christen, Duong et al. 2007). Additionally, Zhang et al. described that HBV 
X-protein may inhibit cellular proteasome activity, necessary for viral protein 
degradation, and coevally enhances viral replication (Zhang, Protzer et al. 2004). 
Altogether, these reports point to the fact that HBV counteracts IFN-induced 
suppression by interference of different HBV proteins with several actors of the IFN 
signaling pathway and moreover, might enhance simultaneously its own replication 
level. Accordingly, it was recently observed in our group that treatment of HBV 
replication with low concentrations of different types of IFN-α, conventionally used in 
antiviral therapy, led to slightly increased levels of HBV replication markers in vitro 
(Yuchen Xia, unpublished data). Higher dose of IFN, however, can clearly overcome 
the escape mechanisms and show antiviral activity. 
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There is evidence that an additionally escape mechanism of HBV is reflected in the 
direct interaction with PRR signaling cascades. Besides reports of HBV dependent 
modulation of TLR expression (Visvanathan, Skinner et al. 2007; Chen, Cheng et al. 
2008), it was demonstrated that HBV suppress innate antiviral immune response 
elicited by TLR3 and TLR4 stimulation of both, hepatocytes and non-parenchymal 
cells, respectively. Accordingly, the authors found suppression of IFN-β production 
and decreased IFN stimulated gene expression (Wu, Meng et al. 2009). These 
strategies of HBV to counteract antiviral activity of IFN-I could have assisted a 
decreased antiviral effect in PHHs. A better understanding of these mechanisms 
might provide means to enhance and support antiviral treatment with IFN. 
 
 
3.2 3p-siRNA combines RIG-I stimulation and siRNA mediated gene 
silencing and indicates a long lasting and superior anti-HBV effect 
 
3.2.1 HBV-sequence specific siRNAs 
 
To enhance the therapeutic efficiency against HBV we intended to combine the 
antiviral immune regulatory effect of RIG-I stimulation with an RNAi mediated gene-
silencing effect of vulnerable cytosolic HBV-RNA. Therefore, we designed three 
different HBV-sequence specific siRNAs, targeting three different regions within or 
near the common polyadenylation signal region at the 3`-end of HBV-RNAs. The 
targeted regions offer the possibility of interfering with several sensitive sites due to 
overlapping open reading frames (ORFs). RNAi is a powerful tool to inhibit the 
function of HBV target genes and has already been shown to exhibit a potent antiviral 
effect against HBV in vitro (Hamasaki, Nakao et al. 2003; Konishi, Wu et al. 2003) 
and in vivo (Giladi, Ketzinel-Gilad et al. 2003; Klein, Bock et al. 2003; McCaffrey, 
Nakai et al. 2003). Moreover, it has been reported that the highest inhibitory effects 
induced by different siRNAs targeted HBcAg and HBx gene (McCaffrey, Nakai et al. 
2003; Shlomai and Shaul 2003). Accordingly, we designed a siRNA named si-1.1 
that targeted this preferential region of the HBV genome within the overlapping ORFs 
of the X-protein and the precore/core protein and therefore affected all HBV-mRNAs. 
The siRNA named si-1.2 target an alternative region within the X-protein ORF, but 
Discussion 
	   109	  
also affected all HBV-mRNAs transcripts. Another alternative HBV-genome target 
region, the ORF of the polymerase, was directed by siRNA si-1.3, which affects all 
HBV mRNA transcripts except for the 0.7 kb transcript of the X-protein. The HBV 
targeting sequences of all siRNAs are conserved within the different genotypes, 
except the rare genotype F HBV. 
Delivery of siRNA into mammalian cells is known to often induce a non-specific 
innate immune response. The RNA-activated protein kinase (PKR) can be stimulated 
by sequence unspecific double-stranded siRNA (Bridge, Pebernard et al. 2003; 
Sledz, Holko et al. 2003). Therefore, asymmetrical siRNA possessing a standard 3`-
overhang, such as our siRNAs, have become more widely used in an attempt to 
improve RNAi potency (Soutschek, Akinc et al. 2004). However, it was demonstrated 
that blunt-ended RNA, including siRNA, can also bind to and activate RIG-I, when the 
RNA is released into the cytoplasm (Hornung, Guenthner-Biller et al. 2005; Marques, 
Devosse et al. 2006). Moreover, delivered siRNA can interact with sequence-
unspecific TLR3 and sequence-specific TLR7 or TLR8, respectively, as the RNA 
traffics through the endosomal compartment (Akashi, Miyagishi et al. 2005; Judge, 
Sood et al. 2005). These “off-target” effects lead to the production of IFN-I, as well as 
proinflammatory cytokines and induce NFκB activation. Nevertheless, in 
consideration of our intention to combine siRNA mediated gene silencing of HBV with 
the immuno-stimulatory activity of 3p-dsRNA, endogenous IFN response is rather 
desired. Accordingly, we resigned any stabilizing chemical modifications of the siRNA 
for nuclease degradation resistance, for example substitution of the 2`-OH group in 
the ribose sugar backbone to a 2`-O-methyl (2`OMe) group, as they were used for 
HBV siRNA treatment in vivo (Morrissey, Lockridge et al. 2005). It was shown that 2`-
OMe modified siRNAs are recognized with high affinity by TLR7/8, but do not induce 
downstream signaling (Sioud, Furset et al. 2007). 2`-OMe modification of the siRNA 
is sufficient to abrogate siRNA-mediated interferon induction also in vivo (Judge, Bola 
et al. 2006). It has to be further investigated, whether application of unmodified 
siRNA had any attenuating impact on siRNA stability and efficiency in vitro or in vivo. 
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3.2.2 HBV-sequence specific 3p-siRNAs efficiently suppress HBV replication  
 
5`-triphosphate groups were coupled to siRNAs during in vitro transcription and 
resulting oligonucleotides were termed 3p-1.1, 3p-1.2 and 3p-1.3. Combination of 
siRNA mediated gene silencing with additional antiviral approaches was already 
shown to exhibit greater inhibitory effects on HBV replication. For example, it was 
shown that combination of siRNA with lamivudine exerted a pronounced inhibition of 
HBV replication in HepG2 2.15 cells (Li, Xu et al. 2007). Moreover, a very recent 
report by Vincent et al. described the enhanced inhibitory effect by the combination of 
CpG-induced cytokines with lamivudine against HBV replication in HBV infected 
differentiated HepaRG cells (Vincent, Lucifora et al. 2009). Concerning our 
combinatory approach of IFN-I induction by RIG-I stimulation and siRNA mediated 
gene silencing, it has been lately shown by our collaborators Poeck et al. that 3p-
siRNA efficiently turns gene silencing and RIG-I activation against melanoma (Poeck, 
Besch et al. 2008). The particular advantage using a combinatorial therapeutic 
strategy of immunostimulatory and siRNA over conventional monotherapy using 
nucleos(t)ide analogues is that the immunostimulatory 3p-component targets 
specifically HBV replication, whereas the siRNA gene silencing component acts 
independently from HBV replication and will be thus less subjected due to 
development of resistance. A limited half-life period and absence of cytotoxic side 
effects of systemically applied 3p-siRNA would prefer our combinatory molecules 
before other HBV treatment strategies in development, such as redirected T-cell 
therapy. 
To demonstrate the therapeutic efficiency of our new molecules, we first showed a 
clear induction of IFN-β in 3p-1.2 treated HepG2 H1.3 cells, whereas cells treated 
with si-1.2 elicited no IFN-β expression. Next, we tested the potency of all three 3p-
siRNAs to induce IFN-I. As expected, 2`-5`-OAS levels were strongly induced in both, 
HepG2 H1.3 cells and HBV infected PHH. Consistent with the upregulation of IFN-I 
and 2`-5`-OAS by all three 3p-siRNAs, we observed a significant reduction of 
progeny HBV DNA copies, as well as HBeAg and HBsAg levels. Similar results were 
obtained in HBV-infected primary cells. Remarkably, also cccDNA levels, which 
indicate HBV persistence and are hardly affected by any anti-HBV drug, were 
decreased after application of 3p-siRNAs in both in vitro models. Nevertheless, 
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comparing the antiviral effects of all three 3p-RNAs, the equally potent IFN induction 
did not lead to the same strong antiviral effect, suggesting a combinatorial antiviral 
effect of RIG-I stimulation with variable potent siRNA mediated gene silencing. 
To test the efficacy against different HBV genotypes, PHHs were infected with 
isolated virus from stably HBV producing hepatoma cell line HepG2 2.15 several 
days before treatment. HepG2 2.15 cells express genotype A HBV in comparison to 
HepG2 H1.3 cells, which replicate genotype D HBV. Comparable reduction efficiency 
of HBV replication markers in HepG2 H1.3 and HBV infected PHHs indicated that the 
RNAi component of 3p-siRNA was also functional against genotype D HBV. To 
further sustain this result we tested the therapeutic efficiency of 3p-siRNAs also in 
HepG2 2.15 cells. Surprisingly, the transfected 3p-siRNAs revealed none or only 
minor residual expression of 2´-5´-OAS at day 6 after application, fitting to the 
reduced sensitivity of HepG2 2.15 cells against IFN (Guan, Lu et al. 2007). 
Nevertheless, probably independent of IFN-I induction, progeny HBV DNA-, HBeAg- 
and pgRNA levels, respectively, were significantly reduced. These results supported 
effective siRNA dependent HBV gene silencing of genotype A HBV and moreover, 
independent of the fact that HepG2 2.15 cells replicated HBV approximately twice as 
high as HepG2 H1.3 cells. It remains to be further elucidated, whether 2`-5`-OAS 
levels were already strongly diminished on day 6 or if RIG-I expressing HepG2 2.15 
cells showed no triphosphate induced IFN-I response at all. 
To analyze whether immunostimulation and RNAi-mediated gene silencing acted 
synergistically to suppress HBV replication, we compared the primarily used 3p-RNA 
with our new 3p-siRNAs in HepG2 H1.3 cells. We observed strongly reduced viremia, 
as well as cccDNA and HBV-protein levels, respectively, after treatment with the 
original 3p-RNA. Intriguingly, all three 3p-siRNAs revealed an even more pronounced 
reduction of HBV-DNA levels compared to 3p-RNA alone. Nevertheless, comparing 
all in vitro results, 3p-1.2 indicated the most promising antiviral effects and was used 
for further experiments.  
To prove the sustained antiviral effects of 3p-siRNA, we compared the antiviral 
efficacy of 3p-RNA with 3p-1.2 over a prolonged period of 16 days in HepG2 H1.3 
cells. Because HBV replication is attenuated until the cell layer is confluent, we 
detected only low progeny HBV-DNA and HBeAg levels at day 0.5. In correlation to 
increasing hepatocellular differentiation (Quasdorff, Hosel et al. 2008), HBV 
replication increased constantly until day 10. Application of both, 3p-1.2 and si-
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1.2decreased HBV-DNA and HBeAg levels at all timepoints. Yet, 3p-1.2 showed a 
significantly more prolonged antiviral response than si-1.2 or 3p-RNA alone. Thus, 
our data demonstrated that the early antiviral response until day 6 is comparable 
between all therapeutic oligonucleotides, but IFN mediated reduction of HBV 
replication by 3p-RNA and 3p-1.2 decreased over time. Therefore, 3p-RNA was 
equally active at early timepoints, but 3p-1.2 was superior over time due to its gene 
silencing activity. These results confirmed the superior antiviral activity by the 
combination of immunostimulation and HBV gene silencing in one single molecule in 
vitro. In addition, we excluded hampered siRNA binding to HBV-RNA due to 
appearance of mutations by RNAi selection pressure in 3p-1.2 or si-1.2 treated cells. 
These observations indicated a combinatory antiviral effect of IFN-I induction by RIG-
I stimulation and siRNA mediated HBV gene silencing in vitro, superior than each 
mechanism alone. 
In vivo, both molecules, 3p-RNA and 3p-1.2, induced comparable IFN-α levels, 
determined 6 hours after the first injection in the sera of mice. 3p-RNA and 3p-siRNA 
elicited comparable reduction of hepatocellular HBV-DNA and HBV pgRNA levels at 
day 6 after application. In contrary and consistent with our in vitro data, 3p-1.2 
showed a significantly stronger effect than 3p-RNA on HBV pgRNA at day 9, pointing 
to an effective combinatory antiviral mechanism of 3p-1.2 in vivo. Remarkably, the 
antiviral effect of 3p-RNA and 3p-1.2 on HBV viremia remained until day 15. As 
previously described, HBV RNA-containing capsids are preferentially targeted by 
IFN-I (Schultz, Summers et al. 1999; Wieland, Guidotti et al. 2000). Consistently, 3p-
RNA and 3p-siRNA induced IFN-I exhibited a strong impact on cytoplasmic core 
protein expression at day 9, which persisted until day 15.  
Surprisingly, si-1.2 treatment alone showed only minor reduction of HBV replication 
markers in vivo over time. This observation suggested that all RNAs, including the 
siRNAs, were not effectively delivered to hepatocytes to fully elicit their gene 
silencing component after systemic administration. Nevertheless, the in vitro 
experiments confirmed that gene silencing is an important key function of 3p-1.2. 
Likewise, the lower antiviral response induced by si-1.2 in vivo highlighted the 
importance of inducing an innate immune response. In fact, detailed analysis 
revealed that even PEI complexed 3p-siRNA is systemically distributed. More than 
the liver, the lymphatic glands and the spleen expressed IFN-I after intravenous 
injection of 3p-1.2, likely via stimulation of endosomal TLRs and RIG-I in immune 
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cells (Applequist, Wallin et al. 2002; Heil, Hemmi et al. 2004; Hornung, Ellegast et al. 
2006). In addition, fluorescently labeled si-1.2 complexed with PEI was enriched 
predominantly in the spleen, and to reduced extend in liver. This indicate that liver 
cells played only a subordinary role in antiviral IFN-I induction by systemic 3p-siRNA 
application. Remarkably, the results showed that also unphosphated si-1.2 induced 
IFN-I in lymphatic glands and in the spleen, although to a minor extent, referred as 
an “off-target” effect by stimulation of TLRs or RIG-I, respectively (Akashi, Miyagishi 
et al. 2005; Hornung, Guenthner-Biller et al. 2005; Judge, Sood et al. 2005; Marques, 
Devosse et al. 2006). 
 
 
3.3 Liver targeting of modified siRNAs using different applications in vivo 
 
Due to the poor hepatocellular uptake of siRNA and to improve the effect of 3p-
siRNA based combinatory therapy we wanted to improve hepatocyte targeting. 
Different groups already followed up several strategies in this context, using delivery 
vehicles or chemical modifications and bioconjugations. The most widely used 
vehicles for this purpose are based on positively charged (cationic) agents that 
complex with, or encapsulate, the negatively charged nucleic acid. The cationic 
polymer PEI (polyethylenimine), used in this study for 3p-RNA application (Poeck, 
Besch et al. 2008), could not yield the desired hepatocyte targeting. Importantly, such 
delivery vehicles are typically taken up into cells by endocytosis, and are 
concentrated in endosomal compartments prior to releasing the nucleic acid into the 
cytoplasm (Robbins, Judge et al. 2009). This fact could contribute to the limited 
observed gene silencing efficiency of both, si-1.2 and 3p-siRNA in vivo. Alternatively, 
hydrodynamic injection (HDI) was shown to deliver nucleic acids more efficiently to 
the liver (Giladi, Ketzinel-Gilad et al. 2003; Klein, Bock et al. 2003; Morrissey, 
Blanchard et al. 2005; Huang, Wu et al. 2006). Using this injection technique we 
observed an increase of fluorescently labeled si-1.2 in liver cells and simultaneously 
a decrease in spleenocytes, compared to si-1.2 after conventional intravenous 
administration. Nevertheless, this approach seemed rather promising, because 
structure and vitality of liver cells seemed to be negatively affected by HDI, due to the 
rapid intravenous injection of a large volume under high pressure. 
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In addition, chemical modifications by bioconjugation are used to increase liver 
directed targeting. Conjugated cholesterol to the 3`-end of the sense-strand was 
shown to significantly increase the levels of hepatocellular uptake (Soutschek, Akinc 
et al. 2004). We observed that cholesterol-conjugation to fluorescently labeled si-1.2 
drastically increased the hepatocellular uptake particularly by hepatocytes after 
conventional injection, in comparison to unmodified si-1.2. Previous complexation 
with PEI even increased the targeting efficiency. Application of cholesterol-coupled 
si-1.2 by HDI showed no accessory targeting effect. An antagonizing attribute might 
be the limited stability of uncomplexed siRNA (Braasch, Jensen et al. 2003; 
Czauderna, Fechtner et al. 2003), which is exposed to drastic shear forces during 
HDI. In summary, the data showed promising prospects to further enhance 
hepatocelluar uptake of 3p-siRNA by bioconjugation with cholesterol. Nevertheless, it 
remains to be investigated in more detail, whether 5`-triphosphated siRNA could be 
stabilized by sugar backbone modifications and moreover, modified by 3`-cholesterol 
coupling, or whether stoechiometric limitations might drop this approach. However, 
various considered alternative approaches could further enhance hepatocyte specific 
targeting of 3p-siRNA. Morrissey et al. incorporated chemically modified siRNAs 
against HBV into a specialized liposome to form a stable nucleic acid lipid particle 
(SNALP). After intravenous administration significant improvement of efficacy 
combined with a longer half-life were observed in the liver of treated animals 
(Morrissey, Blanchard et al. 2005; Morrissey, Lockridge et al. 2005). Furthermore, we 
considered the use of recombinant adeno-associated viral (rAAV) vector as a delivery 
vehicle. AAV-8 pseudotype shows high natural liver tropism and was already used in 
preclinical evaluations as a vector for hepatocyte specific delivery approaches (Gao, 
Alvira et al. 2002; Grimm, Zhou et al. 2003). Alternatively, antibody-mediated delivery 
is an effective method of targeting siRNA to liver cells. Wen et al. constructed a 
fusion protein containing a single chain of the human variable fragment (scFv) 
against HBsAg, coupled to HBV-sequence specific siRNA. The modified siRNA was 
specifically delivered into HBsAg-positive cells and effectively inhibited HBV gene 
expression in vitro and in vivo (Wen, Liu et al. 2007). Thus, efficient delivery of 3p-
siRNA into hepatocytes remains the main goal of further investigations.  
Previous described delivery studies revealed that injected complexed nucleic acids 
only partially reached the liver and only to some extent the hepatocytes. A certain 
proportion apparently ended up in non-parenchymal cells (NPCs) such as LSECs or 
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Kupffer cells. Therefore, we wanted to elucidate the contribution of these cells, 
beside heaptocytes, in 3p-siRNA mediated induction of IFN-I. To mimic a potential 
uptake like in the in vivo situation, PEI-complexed 3p-1.2. was added to all isolated 
cell types and a potent IFN-β induction could be shown in all cases. These results 
clearly indicated the potency of NPCs to contribute to an anti-HBV response via 
stimulation of endogenous IFN-I and ISGs, as it was already shown by Wu and 
colleagues (Wu, Lu et al. 2007). It has to be further investigated, whether other cell 
types are contributed to the strong IFN-I expression after systemic distribution of 
triphosphated RNA-oligonucleotides in vivo. 
 
3.4 Application of immune-stimulatory RNA-oligonucleotides initiates an  
adaptive T cell response against HBV 
 
Further investigations of LSECs and Kupffer cells revealed that both cell types 
additionally expressed the proinflammatory cytokines IL-6 and TNF-α, respectively, 
after treatment with 3p-1.2., and in contrast to PHHs. It was already shown that 
hepatoma cells are defective for induction of Il-6 and TNF-α after stimulation with 
transfected poly(I:C), acting as a TLR3 or MDA-5 ligand (Wu, Lu et al. 2007; Preiss, 
Thompson et al. 2008). It has to be further investigated whether this is probably also 
applied for RIG-I stimulation of PHHs. Nevertheless, we assumed that expression of 
proinflammatory cytokines might be an indicator for the induction of an HBV antigen 
specific adaptive immune response after several days.  
A cytolytic clearance of HBV infection is dependent on adaptive T cell response by 
cytotoxic CD8+ T cells (CTLs), which inhibit viral replication and kill infected cells 
(Guidotti, Ishikawa et al. 1996). The elimination of cccDNA containing hepatocytes is 
essential for the clearance of HBV infection. HBV tg mice are immunologically 
tolerant to HBV antigens. Nevertheless, it was shown that the HBV tg mice used in 
this study are not completely xenotolerant (Quasdorff, Hosel et al. 2008). The study 
demonstrated that HBV envelope proteins were not expressed during the embryonic 
phase of development and thus probably do not induce tolerance by deletion of T 
cells. HBV replication only starts after birth. This enables appearance of an adaptive 
T cell response in HBV tg mice.  
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In fact, a major part of mice treated with 3p-RNA or 3p-1.2, respectively, revealed 
enhanced levels of IFN-γ and CD8 mRNA in the liver and significantly elevated ALT 
levels at day 9 after application, indicating a CD 8 T cell influx into the liver. A similar 
picture was obsereved in a very recent study during early stages of HBV infection in 
patients (Fisicaro, Valdatta et al. 2009). Moreover, histological analysis of liver tissue 
confirmed appearance of an inflammatory reaction in treated mice at this timepoint. A 
clear shift towards resolution of the inflammatory changes indicated by decrased ALT 
levels, as well as diminished expression of CD8 and IFN-γ could be observed at day 
15. It is conceivable that an accessory adaptive T cell response, induced after RNA-
oligonucleotide application, might additionally enhance the antiviral activity. However, 
this needs to be proven by the analysis of liver associated lymphocytes. It was 
observed that the expression of MHC I on HBV infected hepatocytes, required for 
effective presentation of HBV specific antigens on the cell surface to stimulate 
cytotoxic T-cell response, was significantly diminished (Chen, Tabaczewski et al. 
2005). In contrast, it was shown that IFN-I modulates a number of immunoregulatory 
functions involving interactions between cells. This multiple-cell response includes 
the IFN-I induced expression of MHC-I antigens, (Samuel 2001), which is also 
increased after application of 3p-RNA or 3p-siRNA, respectively (Poeck, Besch et al. 
2008). An IFN-I induced increase of antigen presentation could stimulate the 
direction of the adaptive immune response by priming T helper cells and cytotoxic T 
cells (Biron 1999), which might result in complete elimination of HBV replication. 
Detailed characteristics have to be examined, but it is conceivable that an optimized 
induction of IFN-I by RNA-oligonucleotides could even assist the cytolytic adaptive 
immune response against HBV. 	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4 Material and Methods 
 
4.1 Biotic and abiotic material 
All solutions were prepared with deionised water from the Ultra Pure Water System 
Easy Pure UV/UF (Werner Reinstwassersysteme, Wilhelm Werner GmbH, 
Leverkusen, Germany). At a resistance of 16 Mega Ohm or more obtained water is 
valid as desalted and is comparable to double-distilled water (ddH2O). 
 
4.1.1 Consumable items 
Cell culture flasks     Nunc, Wiesbaden, Germany 
Cell culture dishes     Nunc, Wiesbaden, Germany 
Cell culture well plates    Nunc, Wiesbaden, Germany 
Cell strainer      Nunc, Wiesbaden, Germany 
Centrifuge vials (15 / 50ml)  Falcon, BD GmbH, Heidelberg, Germany 
Chamber Slides LabTekII, RS Glass Nunc, Wiesbaden, Germany 
Cryo vials      Nunc, Wiesbaden, Germany 
Cuvettes      Sarstedt, Nümbrecht, Germany 
ELISA 96-well-plates   Maxisorb, Nunc, Wiesbaden, Germany 
Filter paper Whatman 3MM  Biometra, Göttingen, Germany 
Freezing Container    Nalgene, Nunc, Wiesbaden, Germany 
Perfusion cutlery    BD Valu-SetTM, Heidelberg, Germany 
Pipetts, single use    Sarstedt, Nümbrecht, Germany 
Hyperfilm ECL     GE Healthcare, Buckinghamshire, UK 
Pipette tipps      Starlab GmbH, Ahrensburg, Germany 
Reaction vials     Eppendorf, Hamburg, Germany 
Reflotron® ALT stripes     Roche Diagnostics, Mannheim, Germany 
Saran folie      Roth, Karlsruhe, Germany 
Tissue paste Histoacryl®   Braun, Melsung, Germany 
Syringes     Heiland Med GmbH, Hamburg, Germany 
Ultra centrifuge-tubes, polyallomer Beranek Laborgeräte, Weinheim, Germany  
Nylon membrane, positively charged Roche Diagnostics, Mannheim, Germany 
PVDF membrane     Amersham, Buckinghamshire, UK 
X-ray film     Biomax MR-Film, Kodak, Germany 
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4.1.2 Chemicals 
Acidic acid      Roth, Karlsruhe, Germany 
Acryl amide      Sigma, Deisenhofen, Germany 
Agarose SeaKem LE    Cambrex Bio Science, Rockland, USA 
Ammonium acetate    Merck, Darmstadt, Germany 
Ammoniumpersulfate    Roth, Karlsruhe, Germany 
Aqua-Phenol (pH 4,5)   Roth, Karlsruhe, Germany 
Bradford Reagent     Sigma, Deisenhofen, Germany 
Bromphenol blue     Merck, Darmstadt, Germany 
BSA (Bovines serum albumine)   Serva, Heidelberg, Germany 
Caesium chloride    Roth, Karlsruhe, Germany 
Collagen      Serva, Heidelberg, Germany 
1,4-Diazabicyclo[2,2,2]octane 98%  
(DABCO)     Sigma Aldrich Chemie GmbH, Steinheim, 
      Germany 
DEPC (Diethylpyrocarbonate)   Roth, Karlsruhe, Germany 
Developer G153 A + B   Agfa Geveart NV, Mortsel, Belgium  
Dimethylsulfoxide (DMSO)   Merck, Darmstadt, Germany 
Ethanol      Roth, Karlsruhe, Germany 
Ethylenedinitrilotetraacedic acid  
(EDTA)      Roth, Karlsruhe, Germany 
Ethidium bromide     Merck, Darmstadt, Germany 
Formaldehyde     Roth, Karlsruhe, Germany 
Formamide      Roth, Karlsruhe, Germany 
Glycerine (Glycerol)   Roth, Karlsruhe, Germany 
Glucose      Sigma, Deisenhofen, Germany 
Glutaraldehyde     Sigma, Deisenhofen, Germany 
Hydrochloric acid     Roth, Karlsruhe, Germany 
Isopropanol      Roth, Karlsruhe, Germany 
Methanol      Roth, Karlsruhe, Germany 
Milk powder      Sigma, Deisenhofen, Germany 
Mowiol 4-88 reagent   Calbiochem, La Jolla, CA, USA  
NP-40      Roth, Karlsruhe, Germany 
Paraformaldehyde    Merck, Darmstadt, Germany 
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Polyethylenglycol (PEG) 6000  Serva Electrophoresis, Heidelberg, Germany 
Ponceau S      Roth, Karlsruhe, Germany 
Potassium      Roth, Karlsruhe, Germany 
Potassium chloride     Merck, Darmstadt, Deutschand 
Potassium acetate     Merck, Darmstadt, Germany 
Potassium dihydrogenphosphate  Roth, Karlsruhe, Germany 
Rapid Fixer G354    Agfa Geveart NV, Mortsel, Belgium 
RNALater      Quiagen, Hilden, Germany 
Roti-Phenol (pH 7,5)    Roth, Karlsruhe, Germany 
Saccharose      Sigma, Deisenhofen, Germany 
Sodium acetate     Merck, Darmstadt, Germany 
Sodium chloride     Roth, Karlsruhe, Germany 
Sodium citratdihydrate    Roth, Karlsruhe, Germany 
Sodium dihydrogenphosphate   Roth, Karlsruhe, Germany 
Sodium hydroxid     Roth, Karlsruhe, Germany 
Sodium dodecylsufate (SDS)   Merck, Darmstadt, Germany 
Spermidine-HCl     Sigma, Deisenhofen, Germany   
Sucrose      Sigma, Deisenhofen, Germany 
Tetramethylethylendiamine (TEMED) Sigma, Deisenhofen, Germany 
Tissue-Tak® Tec     Sakura Finetec, Torrance, USA 
Tris-Base      Roth, Karlsruhe, Germany 
Tris-HCl      Roth, Karlsruhe, Germany 
Triton X-100      Roth, Karlsruhe, Germany 
Trizol reagent    Invitrogen, Karlsruhe, Germany 
Tween 20      Roth, Karlsruhe, Germany 
Virkon disinfectant     Tetenal AG & Co KG, Norderstedt, Germany 
Yeast extract     BD Microbiology Systems, Sparks, USA 
 
4.1.3 Kits 
4.1.3.1 Cell isolation 
Kupffer cells     Pierce, Rockford, IL, USA 
LSECs     Miltenyi, Bergisch Gladbach, Germany 
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4.1.3.2 DNA labelling 
Rediprime DNA Labeling System  Amersham, Buckinghamshire, UK 
 
4.1.3.3 ELISA 
Human IFN-γ     BD Microbiology Systems, Sparks, USA 
Human IL-6      BD Microbiology Systems, Sparks, USA 
Mouse IFN-α     Biosource, Solingen, Germany 
Murex HBsAg Version 3   Abbott, Wiesbaden, Germany 
 
4.1.3.4 In vitro transcription (IVT)  
Silencer siRNA construction Kit  Ambion, Huntington, UK 
T7 promotor primer    Metabion Int. AG, Martinsried, Germany 
 
4.1.3.5 Luciferase detection 
Dual Luciferase reporter Assay  Promega GmbH, Mannheim, Germany 
 
4.1.3.6 Nucleic acid isolation 
High pure RNA isolation kit   Roche, Mannheim, Germany 
MinElute PCR Purification Kit  Qiagen, Hilden, Germany 
Mini Quick Spin™ Oligo Column  Roche, Mannheim, Germany 
Nucleospin Tissue Kit    Macherey-Nagel, Düren, Germany 
Nucleospin RNA II    Macherey-Nagel, Düren, Germany 
PCR Purification Kit   Qiagen, Hilden, Germany 
QIAquick Gel Extraction Kit  Qiagen, Hilden, Germany 
QIAamp DNa Blood Mini Kit  Qiagen, Hilden, Germany 
QIAamp MinElute Virus Spin Kit  Qiagen, Hilden, Germany 
 
4.1.3.7 Plasmid preparation 
QIAprep Miniprep, Maxiprep,  
EndoFree Maxiprep Kit   Qiagen, Hilden, Germany 
 
4.1.3.8 PCR reaction mix 
PuRetaq ready-to-go PCR Beads Amersham, Buckinghamshire, UK 
PCR DNA Amplification Kit   Roche Diagnostics, Mannheim, Germany 
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4.1.3.9 Real time PCR 
DNA Amplification Kit SYBR® Green Roche Diagnostics, Mannheim, Germany 
First-strand cDNA synthesis  
qRT-PCR, Superscript III   Invitrogen, Karlsruhe, Germany 
LightCycler® 1.5:  
Cycler® Capillaries (20µl)    Roche Diagnostics, Mannheim, Germany 
LightCycler® 480II: 
96-microtiter plates    Roche Diagnostics, Mannheim, Germany 
 
4.1.3.10 Transfection reagent 
FuGENE 6®     Roche Diagnostics, Mannheim, Germany 
Lipofectamin 2000®    Invitrogen, Karlsruhe, Germany 
HiPerFect®     Qiagen, Hilden, Germany 
 
4.1.3.11 Nucleic acid complexation 
invivo-jetPEI ®    Polyplus transfection, New York, NY, USA 
 
4.1.3.12 Radioactive probes  
Rediprime II Random Prime Labelling  
System     Amersham, Buckinghamshire, England 
 
4.1.3.13 Western blot 
ECL Western Blotting Detection   
Reagents      Amersham, Buckinghamshire, UK 
Enhanced Chemiluminescence  Pierce, Rockford, USA 
 
4.1.3.14 XTT-Test 
XTT - Cell Proliferation Kit II   Roche Diagnostics, Mannheim, Germany 
 
4.1.4 Cell culture  
4.1.4.1 Cell lines and primary cells 
HEK 293   - human embryonic kidney cell line (Aiello, Guilfoyle et al. 1979) 
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HepG2 H1.3 - stably HBV producing hepatoma cell line, containing one copy of a 
1.3-fold overlength HBV genome, genotype D, which establishes 
HBV cccDNA as additional transcription template (Jost, Turelli et al. 
2007; Protzer, Seyfried et al. 2007) 
HepG2.2.15   - stably HBV producing hepatoma cell line, containing four copies of a  
      1.1-fold HBV genome, genotype A (Sells, Zelent et al. 1988) 
HuH7    - human hepatoma cell line (Nakabayashi, Taketa et al. 1982) 
HuH7.5   - human hepatoma cell line, point mutation in CARD-domain of RIG-I 
      (Blight, McKeating et al. 2002) 
Kupffer cells   - liver macrophages, isolated from fresh liver specimen 
LSEC - liver sinusoidal epithelial cells, isolated from fresh liver specimen     
PHH    - primary human hepatocytes, isolated from fresh liver specimen  
      (Schulze-Bergkamen, Untergasser et al. 2003) 
 
4.1.4.2 Consumable cell culture items  
Collagenase     Worthington Biochemical Corporation,  
      Lakewood, NJ, USA 
Dimethylsulfoxid (DMSO)    Merck, Darmstadt, Germany 
Dulbeccos MEM     Gibco, BRL, Eggenstein, Germany 
Ethyleneglycolbis (2-aminoethyl)   
-tetraacetic acid (EGTA)   Roth, Karlsruhe, Germany 
Fetal Calf serum (FCS)    Biochrom AG, Berlin, Germany 
Glutamine      Gibco, BRL, Eggenstein, Germany 
HBSS      Gibco BRL, Eggenstein, Germany 
HEPES      Gibco BRL, Eggenstein, Germany 
Hydrocortisone     Sigma, Deisenhofen, Germany 
Inosine      Serva, Darmstadt, Germany 
Insulin      Serva, Darmstadt, Germany 
Non essential amino acids (NEAA) Biochrom AG, Berlin, Germany 
RPMI 1640     Gibco, BRL, Eggenstein, Germany 
Sodium pyruvate    Gibco BRL, Eggenstein, Germany 
Trypsine      Gibco, BRL, Eggenstein, Germany  
Universal type-I interferon   PBL Interferon Source, Piscataway, NJ, USA 
Williams Medium E    Gibco, BRL, Eggenstein, Germany 
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4.1.4.3 Antibiotics  
Ampicilline      Sigma, Deisenhofen, Germany 
Geniticine (Neomycine) G418  Invitrogen, Karlsruhe, Germany 
Gentamycine     Gibco BRL, Eggenstein, Germany 
Penicilline/Streptomycine   Biochrom AG, Berlin, Germany  
 
4.1.4.4 Cell culture media 
Cell freezing medium    Dulbeccos MEM  500 ml 
      FCS                      20% 
      DMSO     10%  
HEK 293 cultivation medium  Dulbeccos MEM  500 ml 
      FCS                      10 %  
  Glutamine, 200 mM     1.1 %  
  P/S, 5000 U/ml     1.1 % 
HepG2.2.15 / HepG2 H1.3 cultivation  
medium     Dulbeccos MEM  500 ml 
      FCS                      10 % 
 Glutamine, 200 mM     1.1 %  
 P/S, 5000 U/ml     1.1 % 
 NEAA, 100 x      1.1 % 
HepG2 2.15 virus production medium PHH medium  250 ml 
 Williams E medium  250 ml 
 FCS                      5 % 
 Glutamine, 200 mM     0.5 %  
 P/S, 5000 U/ml     0.5 % 
 NEAA, 100 x      0.5 % 
HuH7 / HuH7.5 cultivation medium Dulbeccos MEM  500 ml 
      FCS                      10 % 
 Glutamine, 200 mM     1.1 %  
 P/S, 5000 U/ml     1.1 % 
 NEAA, 100 x      1.1 % 
LSECs cultivation medium   PHH medium  500 ml  
 FCS    5 % 
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Kupffer cells medium   RPMI     500 ml 
 FCS    5 % 
Primary human hepatocytes, PHH 
- Preperfusion medium    HBSS, Ca/Mg-free  500 ml  
 EGTA, 100 mM  0.5 % 
 Heparine, 5000 U/ml 0.2 %  
- Collagenase medium    Williams Medium E  250 ml 
 CaCl2, 1 M   0.36 %  
      Gentamycine, 10 mg/ml 1 %  
 Collagenase typeIV  200 mg 
- Wash medium     Williams Med E  500 ml 
      Glutamine, 200 mM  1.1 % 
 Glucose, 5%   1.2 %   
 Hepes, 1 M, pH 7.4  2.25 % 
 P/S,5000U/ml  1.2 % 
- PHH medium     Wash medium  500 ml  
 Gentamycin, 10 mg/ml 1 %   
          Hydrocortison             0.1 % 
      Insulin    0.45 mg 
      DMSO    1.75 % 
      Inosine, 82.5 mg/ml  0.4 %   
 
 
4.1.5 Oligonucleotides for in vitro transcription (IVT) 
T7 promotor:  5´ CTATAGTGAGTCG 3´ 
 
DNA-template:           5´ AAGCTGACCCTGAAGTTCATCCC 3´ 
3p-RNA:  5´ppp GAAGCUGACCCUGAAGUUCAUCCC 3´  
                    3´ UUCGACUGGGACUUCAAGUAGGGG ppp 5´ 
 
DNA-template:            5´ TTTCACCTCTGCCTAATCA 3´ 
3p-1.1:  5´ ppp GUUUCACCUCUGCCUAAUCA 3´ 
                                          3´ AAAGUGGAGACGGAUUAGU ppp 5´ 
 
Material and methods 
 
 125 
DNA-template:           5´ CGACCTTGAGGCATACTTC 3´ 
3p-1.2:  5´ ppp GCGACCUUGAGGCAUACUUC 3´   
             3´ GCUGGAACUCCGUAUGAAGG ppp 5´   
 
DNA-template:        5´ CTATTAACAGGCCTATTGA 3´  
3p-1.3:  5´ ppp GCUAUUAACAGGCCUAUUGA 3´ 
             3´ GAUAAUUGUCCGGAUAACTG ppp 5´ 
 
 
 
Fig. 4.1: Schematic representation of triphosphated siRNA   
 
 
4.1.6 siRNAs (Eurogentec, Leiden, Belgium) 
Ctrl-RNA  
polyA-RNA (Polyriboadenosine)  5´ AAAAAAAAAAAAAAAAAAA 3´ 
  
siRNAs 
si-1.1 (3105 - 3124): HBV target 5´ TTTCACCTCTGCCTAATCA 3´  
                       sense  5´ UUUCACCUCUGCCUAAUCAdTdT 3´ 
             antisense 3´ UGAUUAGGCAGAGGUGAAAdTdT 5´  
 
si-1.2:  (2973 - 2992) HBV target 5´ CGACCTTGAGGCATACTTC 3´ 
      sense  5´ CGACCUUGAGGCAUACUUCdTdT 3´ 
     antisense 5´ GAAGUAUGCCUCAAGGUCGdTdT 3´  
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si-1.3: (2241 – 2260) HBV target 5´ CTATTAACAGGCCTATTGA 3´ 
      sense  5´ CUAUUAACAGGCCUAUUGAdTdT 3´ 
      antisense 5´ TCAAUAGGCCUGUUAAUAGdTdT 3´ 
 
si-Ctrl (HCV):    sense  5´ CUGAUAGGGUGCUUGCGAGdTdT 3´ 
      antisense 5´ CUCGCAAGCACCCUAUCAGdTdT 3´ 
      
4.1.7 PCR Primer (Invitrogen, Karlsruhe, Germany) 
Amplification primer 
HBV -2595- fw    5´ GAGCAAACATTATCGGGACT 3´ 
HBV -3081- rev    5´ GACCAATTTATGCCTACAGC 3´ 
 
Sequenzing primer 
HBV -2595- fw    5´ GAGCAAACATTATCGGGACT 3´ 
 
4.1.8 Quantitative real time PCR primers (Invitrogen, Karlsruhe, Germany) 
HBV primers 
HBV rcDNA1745 fw   5´ GGAGGGATACATAGAGGTTCCTTGA 3´ 
HBV rcDNA1844 rev   5´ GTTGCCCGTTTGTCCTCTAATTC 3´ 
HBV pgRNA 383 fw   5´ CTCCTCCAGCTTATAGACC 3´ 
HBV rpgRNA 705 rev   5´ GTGAGTGGGCCTACAAA 3´ 
HBV cccDNA 92 fw    5´ GCCTATTGATTGGAAAGTATGT 3´ 
HBV cccDNA 2251 rev   5´ AGCTGAGGCGGTATCTA 3´ 
  
mitochondrial DNA primers 
mitoDNA 8686 fw    5´ CCCTCTCGGCCCTCCTAATAACCT 3´ 
mitoDNA 8796 rev    5´ GCCTTCTCGTATAACATCGCGTCA 3´ 
 
Human primers 
human IFN-β fw    5´ GCCGCATTGACCATCT 3´ 
human IFN-β rev    5´ AGTTTCGGAGGTAACCTG 3´ 
human 2`-5`-OAS fw   5´ CAGTTAAATCGCCGGG 3´ 
human 2`-5`-OAS rev   5´ AGGTTATAGCCGCCAG 3´ 
human IFNAR fw    5´ ATTTACACCATTTCGCAAAGC 3´ 
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human IFNAR rev    5´ CACTATTGCCTTATCTTCAGCTTCTA 3´ 
human GAPDH fw    5´ GGTATCGTGGAAGGACT 3´ 
human GAPDH rev    5´ GGGTGTCGCTGTTGAA 3´ 
 
Mouse primers 
mouse IFN-β fw    5´ TTACACTGCCTTTGCCA 3´ 
mouse IFN-β rev    5´ GCGTAGCTGTTGTACTTC 3´ 
mouse 2`-5`-OAS fw   5´ CAGTGGATTGGACACTCT 3´ 
mouse 2`-5`-OAS rev   5´ AGCACTTGAATGTTCACC 3´ 
mouse CD8 fw    5´ GGATTGGACTTCGCCTG 3´ 
mouse CD8 rev    5´ CAAGTATGCTTTGTGTCAAAGA 3´ 
mouse IFN-γ fw    5´ ATGGTGACATGAAAATCCTG 3´ 
mouse IFN-γ rev    5´ GTGGACCACTCGGATGA 3´ 
mouse GAPDH fw    5´ ACCAACTGCTTAGCCC 3´ 
mouse GAPDH rev    5´ CCACGACGGACACATT 3´ 
 
4.1.9 Primers for PCR amplification of purified HBV-DNA (Invitrogen) 
HBV-2595 fw       5` GAGCAAACATTATCGGGACT 3` 
HBV-3081 rev      5` GACCAATTTATGCCTACAGC 3` 
 
4.1.10 Sequencing primer of purified HBV-DNA (Invitrogen) 
HBV-2595        5` GAGCAAACATTATCGGGACT 3` 
 
4.1.11 Enzymes 
DNase I      Fermentas, St. Leon Rot, Germany 
Exo-Minus Klenow DNA polymerase  Epicentre Biotechnologies, USA 
Hind III restriction enzyme (hc. 10 U/µl) Roche Diagnostics, Mannheim, Germany 
Other restriction endonucleases   Fermentas, St. Leon Rot, Germany 
RNaseA 10 mg/ml     Roche Diagnostics, Mannheim, Germany 
RNAse free DNase    Quiagen, Hilden, Germany 
Proteinase K     Roth, Karlsruhe, Germany 
Proteinase K inhibitor “Complete”  Roche Diagnostics, Mannheim, Germany 
T7 RNA polymerase   Fermentas, St. Leon Rot, Germany 
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4.1.12 Weight- and Length standards 
4.1.12.1 DNA standards 
SmartLadder, 0.2-10 kb    Eurogentec, Liege, Belgium 
SmartLadder, 0.1-2 kb    Eurogentec, Liege, Belgium 
4.1.12.2 Protein standards 
Prestained Protein ladder    Invitrogen, Karlsruhe, Germany 
 
4.1.13 Antibodies 
4.1.13.1 Primary antibodies Western Blot 
core-protein- Rabbit anti core (H800)     kindly provided by H. Schaller   
      (ZMBH, University of Heidelberg, Germany) 
L-protein - Goat anti HBsAg Antibody  Murex HBsAg ELISA, Version 3 
Mouse anti RIG-I – Alme-1   Alexis biochemicals, Axxora, Lörrach,  
      Germany  
Rabbit anti -actin     Sigma, St. Louis, MO, USA 
 
4.1.13.2 Secondary antibodies Western Blot 
Goat anti rabbit, HRP-conjugated  Sigma, Deisenhofen, Germany  
Goat anti mouse, HRP-conjugated  Sigma, Deisenhofen, Germany 
Donkey anti goat, HRP-conjugated  Sigma, Deisenhofen, Germany 
 
4.1.13.3 Histology 
Polyclonal rabbit anti hepatitis B  
core antigen     Diagnostic Biosystems, CA, USA  
 
4.1.14 Radioactive [32P] dCTP  Amersham, Buckinghamshire, England 
 
4.1.15 Mouse strain 
HBV transgenic mouse strain HBV1.3 -xfs was kindly provided by Prof. H. Schaller, 
ZMBH, University of Heidelberg, Germany. The mouse genome contains a genotype 
D HBV1.3 overlength genome, with a frameshift mutation (G/C) in the x-gene at 
position 2916/2917 (Weber, Schlemmer et al. 2002). 
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4.1.16 Technical equipment 
4.1.16.1 Instruments 
Dot blot fraction recovery system  Beckman, München, Germany 
Biocycler Thermocycler T3  Biometra, Göttingen, Germany 
Blot chamber MiniProtean®3 Cell  BIO-RAD Laboratories, Hercules, USA 
Dot blot apparatus Minifold I  Schleicher & Schuell, Dassel, Germany 
ELISA Reader MRX Revelation  Dynex, Gaithersburg, USA 
Film processor Curix 60   Agfa Geveart NV, Mortsel, Belgium 
Flow cytometer FACSCanto™   BD Biosciences, Heidelberg, Germany 
Gel chambers     BIO-RAD Laboratories, Hercules, USA 
Heating block Thermomixer comfort Eppendorf, Hamburg, Germany 
Incubator      Heraeus Holding GmbH, Hanau, Germany 
LightCycler® 1.5 and 480 II  Roche Diagnostics, Mannheim, Germany 
Luminometer     Berthold Technologies, Bad Wildbad,  
      Germany 
pH-Meter      WTW, wissenschaftlich technische  
      Werkstätten, Uniklinik Köln / MRI München 
Cryostate CM 3050S   Leica Microsystems, Wetzlar, Germany 
Pipetboy Swift Pet®   Abimed, Langenfeld, Germany 
Phosphoimager, Molecular Imager FX BIO-RAD Laboratories, Hercules, USA 
Phosphoscreen-cassette    Amersham, Buckinghamshire, England 
Photometer Smart Spec 3000  BIO-RAD Laboratories, Hercules, USA 
Photometer Nanodrop   Implen, München, Germany 
Photo system for agarose gels   BIO-RAD Laboratories, Hercules, USA 
Gel-doc 2000     BIO-RAD Laboratories, Hercules, USA 
Power Supplies Pack300   BIO-RAD Laboratories, Hercules, USA 
Refrigerators and freezer    Liebherr, Lientz, Germany 
Rocking platform WT12   Biometra, Göttingen, Germany 
Shaker      Innova 4230, New Brunswick Scientific, USA 
Sterile hood (cell cultur)    Heraeus Holding GmbH, Hanau, Germany 
UV-Oven GS Gene LinkerTM   BIO-RAD Laboratories, Hercules, USA 
ALT measurement, Reflotron®  Roche Diagnostics, Mannheim, Germany 
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4.1.16.2 Centrifuges 
Centrifuge 5417C / 5417R   Eppendorf, Hamburg, Germany 
Megafuge 1.0 / 1.0 R   Heraeus Holding GmbH, Hanau, Germany 
Sorvall RC 50 Plus     Kendro, Langenselbold, Germany 
XL 70      Beckman, München, Germany 
Scales Kern 440-47   Sartorius AG, Göttingen, Germany 
 
4.1.16.3 Microscopes 
Fluorescence microscope IX81    Olympus, Hamburg, Germany  
Confocal microscope FluoView1000 Olympus, Hamburg, Germany 
 
4.1.16.4 Software 
Autoradiography    Quantity One, 4.2.1, BIO-RAD   
      Laboratories, Hercules, USA 
Fluorescence microscopy   Cell P, AnalySIS, Soft Imaging   
      System GmbH, Münster, Germany 
Light Cycler      Probe Design Analysis and Rel Quant,     
 Roche Diagnostics, Mannheim, Germany 
Luminometer     Magellan Software, Tecan, Grödig, Austria 
Data processing     Microsoft MS Office 2008 for Mac,  
      Word and Excel 12.1.3, Microsoft,  
      Redmont, USA 
      Apple Macintosh OS-X, Cupertino, CA, USA 
Graphic programmes    Adobe Photoshop CS3 10.0.1, Adobe  
      Illustrator, CS3 13.0.2, Adobe, San Jose, 
      USA 
 Prism 5, 5.0a, for Mac OS X, Graphpad, La 
Jolla, CA, USA  
 Power Point 2008 for Mac, 12.1.3, Microsoft, 
Redmont, USA 
Statistical Analysis    Prism 5, 5.0a, for Mac OS X, Graphpad, La 
      Jolla, CA, USA Bibliography  
      EndNote X2, Thomson, San   
      Francisco, CA, USA 
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4.2 Methods 
 
4.2.1 Molecular biology methods 
 
4.2.1.1 In vitro transcription (IVT) 
Chemically synthesized RNA oligonucleotides were purchased from Eurogentec 
(Leiden, Belgium). In vitro-transcribed RNAs were synthesized using the Silencer 
siRNA construction Kit (Ambion, Huntingdon, UK) or according to the following 
protocol: Using partially overlapping single stranded DNA oligonucleotides, a double-
stranded DNA template was constructed using Exo-Minus Klenow DNA polymerase. 
The obtained templates contained a T7 RNA polymerase consensus promoter 
sequence (5´ CTATAGTGAGTCG 3´). 20 pmol of the DNA template were incubated 
with dNTP-Mix (2.5 mM each dATP, dCTP, dGTP and dTTP), 30 U T7-RNA 
polymerase, 40 U RNase inhibitor, 0.3 U yeast inorganic pyrophosphatase in a buffer 
containing 40 mM Tris-HCl pH 8.0, 10 mM DTT, 2 mM spermidine-HCl (Sigma) and 
20 mM MgCl2. In vitro transcription was carried out overnight at 37 °C. The DNA 
template was digested using DNase I (Fermentas) and subsequently RNAs were 
purified using the High pure RNA isolation kit with the following modifications: Binding 
buffer was 2.0 M guanidine thiocyanate in 70 % ethanol and wash buffer was 
substituted by 100 mM NaCl, 4.5 mM EDTA, 10 mM Tris HCl in 70 % ethanol. After 
elution, excess salts and NTPs were removed by passing the RNAs through a Mini 
Quick Spin™ Oligo Column. Size and integrity of RNAs was checked via gel 
electrophoresis.  
 
4.2.1.2 Alexa 488 and cholesterol coupled siRNA 
Si-1.2 was labeled at the sense-strand with 5`-Biotin or 5`-Biotin plus 3`-cholesterol, 
respectively (Eurogentec).  Si-RNAs were incubated for 1 h at 37°C in the dark with 
Alexa-488 coupled strepatavidin, 1 µg / µg siRNA (S21375, Invitrogen, Karlsruhe, 
Germany). Thereby, Alexa-488-strepatavidin was linked to biotin at the 5`-end of the 
siRNA sense-strand. Fluorescently labeled siRNAs were precipitated (10% v/v 3M 
NaAc pH 5 and 400% v/v EtOH) at -20°C over night. Solution was centrifuged at 
13.000 rpm for 30 min at 4°C. The siRNA pellet was washed once with 75% EtOH 
and solved in ddH2O. Concentration was determined via OD measurement. 
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Fig. 4.2: Schematic representation of fluorescently labeled and/or choslesterol coupled si-1.2. 
 
4.2.1.3 DNA and RNA quantification 
To calculate the concentration of a DNA (or RNA) preparation, the absorption at 260 
nm and 280 nm was determined with a photometer (Nanodrop). This technique relies 
on the characteristic of nucleic acids to absorb UV light with a wave-length of 260 
nm.  Absorption at 260 nm (OD260) of 1 equals a DNA concentration of 50 µg/ml (40 
µg/ml). The ratio of the absorption at 260 nm and 280 nm allows estimating the purity 
of the DNA (or RNA) and should range between 1.8 and 2.0. The absorption was  
normalized to ddH2O.   
 
4.2.1.4 Gelelectrophoresis 
DNA (or RNA) molecules are negatively charged, with the charge being proportional 
to the molecular weight. Therefore they can be separated according to their size in 
an electric field. Electrophoresis was performed in 0.8 - 2 % agarose gels. The 
agarose was dissolved in 1 x TAE buffer, and ethidium bromide was added to a final 
concentration of 0.5 µg/ml, after the agarose was cooled. Ethidium bromide 
intercalates into dsDNA. This results in a complex, which fluoresces when exposed to 
UV light (254 nm to 366 nm). Emission of 590 nm light allows the visualization of the 
DNA, with a detection limit of approximately 20 ng dsDNA (or RNA). The polymerized 
gel was covered with TAE buffer and electrophoresis was performed with a constant 
voltage of 30 to 120 V. The samples were mixed with 1x DNA (or RNA) sample buffer 
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to firstly ballast the DNA (or RNA) with glycerol, and to secondly mark the separation 
front with bromphenol blue. In addition to the samples a DNA (or RNA) standard with 
defined DNA (or RNA) sizes was loaded on the gel.   
 
4.2.1.5 Polymerase chain reaction  
PCR is a method to amplify specific DNA sequences located between 2 primers. 
These are complementary to the 5` and 3` ends of the sequence. The polymerase 
specifically amplifies the sequence in repeated amplification rounds. A master-mix 
was prepared with the following contends per reaction: 
 
Reagent   Concentration 
Polymerase buffer   4 µl 
Pfu polymerase   2 µl  
Primer fw    5 pmol 
Primer rev    5 pmol 
ddH2O    12 µl  
 
150 to 300 ng template DNA or ddH2O were added per reaction. The Thermocycler 
was programmed as follows: 
 
Step        Temperature  Time 
1. Initial denaturation 94°C   2 min      
2. Denaturation  94°C   30 sec 
3. Annealing   60°C   30 sec 
4. Elongation  72°C   90 sec 
5. Final elongation  72°C   5 min 
 
Steps 2 to 4 were repeated 30 times. The final elongation step is necessary to allow 
the complete amplification of the sequence fragments.    
 
4.2.1.6 DNA sequencing 
DNA sequencing was performed by GATC Biotech AG, Konstanz, Germany. 
Therefore, 30 µl of both, 10 - 50 ng / µl PCR-product and 10 pmol / µl sequencing 
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primer, respectively were dispatched separately. Taq-polymerase and 
didesoxynucleosidtriphosphates (ddNTPs) were provided by the company.   
 
4.2.1.7 cDNA synthesis 
To circumscribe RNA into cDNA the reverse ranscription kit `First-strand cDNA 
synthesis qRT-PCR, Superscript III` (Invitrogen) was used according to manufactures 
instructions. 
 
4.2.1.8 Quantitative real time polymerase chain reaction (qRT-PCR) / Light 
cycler© PCR) 
Real time PCR detection techniques make a kinetic quantification possible. PCR 
amplification depends mostly on the template concentration. However, reaction 
efficiency is also important: In high efficient reactions with low template 
concentrations the same plateau can be reached as in reactions with high template 
concentrations but low reaction efficiency. Therefore, end point quantification 
analyses are sometimes not accurate. The advantage of real time PCR is the 
measurement in the log-linear phase of constant amplification. This allows the 
precise quantification of the amount of starting material. For fluorescence detection 
the SYBR Green I Dye was used. This fluorescent dye intercalates only in dsDNA. 
The fluorescence intensity of this DNA-SYBR green complex is much higher than the 
intensity of the dye alone. Therefore, during annealing and elongation phases the 
fluorescent signal increases. The signal intensity is directly proportional to the DNA 
amount, and the highest signal is obtained at the end of the elongation phase. In the 
used LightCycler® systems 1.5 and 480 II, respectively, in which the PCR reaction 
takes place, a rapid thermal transfer is guaranteed. The fluorescence intensity is 
measured at the end of each elongation phase at a certain temperature in a single 
optical unit. The LightCycler PCR is very sensitive with a detection limit of 1 to 10 
copies for plasmid DNA per sample. For genomic DNA the detection of a single-copy 
gene of 3 pg DNA is estimated. Different quantification methods are available with 
the LightCycler© System. Absolute quantification is performed with an external 
standard curve of known concentrations of the target DNA. The relative quantification 
expresses the target gene concentration in relation to a reference gene, usually a 
house keeping gene or mitochondrial DNA. Standard curves of both target and 
reference gene are used to obtain the concentrations. The template concentration is 
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determined with so-called crossing points. These points are defined as the cycle 
numbers, in which all amplifications exhibit the same fluorescence intensity. The 
identification of specific DNA products is possible using melting curve profiles. The 
melting temperature of dsDNA depends on length, GC contend and sequence. Thus, 
every sequence has a specific melting curve profile. Within the PCR reaction, the 
melting curve is obtained by steadily increasing temperatures while the fluorescence 
is monitored.       
This sensitive PCR technique was used to detect absolute amounts of HBV rcDNA, 
as well as relative amounts of HBV pgRNA, IFN-β, IFN-γ, 2`-5`-OAS, IFNAR and 
CD8, relativated to the housekeeping gene GAPDH, as well as HBV cccDNA relative 
to mitochondrial DNA. Quantification was performed relative to an internal calibrator 
dilution row or to an external plasmid HBV DNA standard (rcDNA) on a Light Cycler© 
instrument 1.5 or 480 II with the LightCycler FastStart DNA Masterplus SYBR Green I 
(Roche). This reaction mix contains the Taq-DNA-polymerase, reaction buffer, MgCl2 
and dNTPs. The following master-mix was prepared per reaction:                 
 
Reagent        Vol. 
LightCycler FastStart DNA Masterplus SYBR Green I  10 µl 
Primer fw        1 µl            
Primer rev        1 µl 
ddH2O        6 µl  
 
2 µl template DNA or ddH2O (negative control) were added to the mix. The light 
cycler instrument was basically programmed as followed: 
 
Step    Temperature  Time 
1. Initial denaturation    95°C  5 min      
2. Denaturation     95°C  15 sec 
3. Annealing      60°C  4 sec 
4. Elongation      72°C  25 sec 
5. Detection      88°C  2 sec 
 
Targeting gene dependent modifications of the program were performed. 
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4.2.1.9 Isolation of progeny HBV-DNA from cell supernatant 
HBV rcDNA was isolated from cell supernatant or mouse serum with QIAamp 
MinElute Virus Spin Kit (Qiagen) according to the manufacturers instructions. 
 
4.2.1.10 Protein precipitation 
Cells were washed with ice cold PBS and for whole cell protein isolation treated with 
SDS lysis buffer (15mM TRIS-HCl pH 6.8, 2.5% Glycerol, 0.5% SDS (10%) and 1 
tablet proteinase-inhibitor `Complete`(Roche)) for 10min. Lysates were centrifuged at 
11.000 rpm in table top centrifuge and supernatants were used for Western blot 
ananlysis. 
 
4.2.1.11 Calculation of protein concentrations 
To determine total protein concentrations the BCATM Protein Assay Kit (Pierce) was 
used. This assay is based on the reduction of Cu2+ to Cu+ by proteins in an alkaline 
medium, combined with the colorimetric detection of Cu+ with a reagent containing 
bicinchonic acid (BCA). The complex formed by the chelation of 2 BCA molecules 
with 1 Cu+ exhibits a strong absorbance at 562 nm. The absorbance is linear with 
increasing protein concentrations over a working range of 20 to 2000 µg / ml. The 
reaction was performed according to the manufacturers introductions, and an 
albumin protein dilution series served as protein standard.  
 
4.2.1.12 SDS-page gel electrophoresis 
Protein samples were mixed with WB sample buffer (2ml glycerol, 2ml 10% SDS, 
0,25% bromphenol blue, 0.5 M TRIS-base and 1ml 10% SDS, added to 10ml with 
H2O, 5 v/v β-mercaptoethanol were added freshly before use) and boiled for 10 min 
at 100°C. The indicated amount of protein was transferred to a 12.5 % SDS gel. 
(Resolving gel, 12.5%: 6.25 ml Acrylamid, 40%, 5 ml Tris, 1.5 M, pH 8.8, 8.55 ml 
H2O, 230 µl SDS, 10%, 20 µl TEMED, 100 µl, APS, 10%; Stacking gel, 5%: 0.375 ml 
Acrylamid, 40%, 1.2 ml Tris, 0.5 M, pH 6.8, 3.325 ml H2O, 50 µl SDS, 10%, 4 µl 
TEMED, 50 µl APS, 10%). As a standard for protein size a pre-stained marker 
(Fermentas) was added. The proteins were separated by electrophoresis in a blot 
chamber (MiniProtean®3 Cell, BIO-RAD) with constant amperage (25 mA per gel).   
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4.2.1.13 Western blot analysis 
The proteins were transferred with transfer-buffer (25 mM TRIS, 192 mM Glycin, 20% 
methanol) from the SDS gel onto a methanol-activated PVDF membrane (Roche) 
using a semi-dry transfer cell (BIO-RAD). The amperage was calculated with the 
following formula: 1.2 mA/cm² of the gel for 1 h transfer. After protein transfer the 
membrane was blocked in blocking solution (5% w/v milk powder in PBS) for 1 h at 
RT or over night at 4°C and probed for 2 h at RT or over night at 4°C with the 
indicated antibody (H800 1:2000, goat anti HBsAg Ab and Alme-1 1:1000, anti β-
actin Ab 1:5000) in antibody solution (10 mm TRIS, 5% w/v milk powder, 2% v/v 
BSA, 0.1 % Tween-20, pH 7.6). After 6 washing steps with PBS-Tween (0.5% v/v) 5 
min each, the respective secondary HRP-conjugated antibody (1: 8000) was added 
in antibody solution and incubated for 1 h at RT. Blots were again washed 6 times, 5 
min each with PBS-Tween (0.5% v/v). The detection was performed with the 
Enhanced Chemiluminescence detection kit (Amersham). If re-probing of the 
membrane with another antibody was necessary, the membrane was previously 
stripped with 0.2 M NaOH for 10 min. PDVF membranes were re-activated in 
methanol, and blocking and antibody incubation were performed as previously 
described.  
 
4.2.1.14 ELISA assay HBsAg 
The HBsAg ELISA (Murex, Abbott) detects different epitopes of the HBsAg. It was 
performed according to the manufacturers’ instructions. The readout was in dual 
frequencies at 450 nm and, as a reference wavelength, 620 nm in a plate reader.  
   
4.2.1.15 ELISA assay human IFN-γ and IL-6 and mouse IFN-α    
 ELISA assays were performed with undiluted cell supernatant or mouse sera 1:25 
diluted according to manufacturers instructions. 
 
4.2.1.16 Preparation of total RNA with Trizol® 
Total RNA of murine liver cells was isolated out of 50 mg liver tissue by lysis in 1ml 
Trizol® reagent (Invitrogen). Isolation was performed according to manufacturers 
instructions.  
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4.2.1.17 Separation of total liver cell RNA and Northern blot analysis 
Extracted total-RNA was separated in a vertical 1% agarosegel. 1,5 g agarose was 
boiled in 15 ml autoclaved 10x E-Puffer (300 mM NaH2PO4-2H2O, 50 mM EDTA) and 
105 ml DEPC-H2O. After cooling down to 60°C, 30 ml formaldehyd (37%) were 
added. Agarose was transferred into the gel chamber. 25 µg of total-RNA were mixed 
on ice with 10 µl 10x E-Puffer, 15 µl formaldehyde and 40 µl formamide for 
denaturation. Samples were boiled 10 min at 65°C, placed on ice and 5 µl loading 
buffer were added to each sample. Gel electrophoresis was performed in 1 x E-Puffer 
at 80-100 V for 4 - 5 h at 4°C. Afterwards, the gel was washed 2x in H2O and 
incubated for 4 min in 10 x SSC. Transfer onto a positively charged nylon-membrane 
was performed with 10 x SSC via capillary forces during 12 - 16 h.  Membrane was 
washed for 5 min with 2 x SSC and then dried at RT for 10 min. RNA was cross-
linked to the membrane under UV light at 125 mJ / cm2. Membrane was stored at RT 
until hybridization with radioactive labeled HBV-genome specific probe. 
 	  
4.2.1.18 Preparation of genomic DNA 
Total DNA extraction from cultured HepG2 H1.3 cells or from liver tissue of mice, 
respectively, was performed by phenol / chloroform extraction. 1 x 107 cells or 50 mg 
of homogenyzed liver tissue were lyzed in 1 ml proteinase K buffer (100 mM Tris pH 
8,5; 5 mM EDTA; 0,2 % SDS; 200 mM NaCl) and 20 µl Proteinase K (20 mg/ml) 
under rotation at 37°C over night. Then, 1 ml of phenol was added, the suspension 
mixed and centrifuged 5 min at 5000 rpm and 4°C. Nucleic acids were solved due to 
their hydrophilic residues in the aqueous phase, whereas proteins accumulated in the 
interphase. Upper aqueous phase was transferred in a new reaction tube and 1ml of 
a mixture of phenol-chloroform (1:1) was added. After centrifugation for 5 min at 5000 
rpm and 4°C the upper aqueous phase was again transferred to a new tube and 1 ml 
chloroform was added in order to remove residual phenol. After centrifugation for 5 
min at 5000 rpm and 4°C the DNA containing upper aqueous phase was transferred 
to a new reaction tube and precipitated. Therefore, 600 µl of ice-cold isopropanol was 
added and incubated at 4°C for 30 min. Precipitated nucleic acids was pelleted by 
centrifugation at 14.000 rpm for 20 min and afterwards washed with 250 µl of 70 % 
ethanol. After repeated centrifugation the pellet was air-dried and resolved in 500  µl 
ddH2O. Then, RNA was digested with 2,5 µl of RNAse A (60mg / ml) for 2 h at 37°C. 
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Precipitation was repeated, DNA was resolved in 200 µl ddH2O and stored at -20°C 
until further experiments. 
 
4.2.1.19 Separation of total liver cell DNA and Southern blot analysis 
Before separation, the genomic DNA was digested with high concentrated (10 U / µl) 
restriction enzyme Hind III over night at 37°C, which affected the HBV-DNA. Isolated 
HepG2 2.15 DNA as size control was additionally restricted with EcoR I, an HBV-
genome single-cutter restriction enzyme, for 3 h at 37°C to perform linearization of 
the HBV-genome. DNA was separated in a vertical agarose-gel (0.8% w/v agarose in 
1x TAE buffer) at 35 V for 16 h. After separation, the gel was washed with ddH2O, 
incubated for 15 min with 0.4 M NaOH to denature the DNA and then incubated with 
0.2 M HCl for 5 min for depurination of the DNA. Transfer onto a positively charged 
nylon-membrane was performed with 0.4 M NaOH via capillary forces during 12 - 16 
h.  for neutralization, membrane was washed for 3 min with 2 x SSC and then dried 
at RT for 10 min. DNA was cross-linked to the membrane under UV light at 125 mJ / 
cm2. Membrane was stored at RT until hybridization with radioactive labeled HBV-
genome specific probe. 
 
4.2.1.20 Radioactive HBV-genome specific probes 
25 ng of HBV-DNA (isolated of HBV-wt plasmid) or GAPDH-DNA, respectively, were 
primed with desoxy-cytosine-tri-phosphates [(α32P) dCTP] by random-priming with 
Rediprime II DNA Labeling System (Amersham), according to manufacturers 
instructions. 
 
4.2.1.21 Hybridization with radioactive labeled probes 
Northern- or southern blot membranes were incubated at 65°C for 3 h with Church-
buffer (6 x SSC, 5 x Denhardts solution; Denhardts solution: 1% w/v Ficoll 400, 1% 
w/v Polyviynlpyrrolidon, 1% w/v BSA) and 50 µl (10 µg / ml) salmon-sperm to block 
unspecific binding sites. Radioactive probe was denatured at 100°C for 5 min, cooled 
on ice and then added to the buffer solution. Hybridization was performed over night 
at 65 °C. Then, membranes were washed at 65°C for 15 min each with pre-warmed 
washing buffer I (2 x SSC, 0.1% SDS), washing buffer II (1 x SSC, 0.1% SDS) and 
washing buffer III (0.5 x SSC, 0.1% SDS). Membranes were air-dried for 10 min, 
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radioactive signal was quantified via X-ray film or phosphoscreen after different 
timepoints with a phosphoimager (BIO-RAD). 
 
 
4.2.2 Cell biology methods 
All procedures were carried out under sterile conditions using sterile solutions and 
equipments. All cells were cultivated in a humidified incubator at 37°C containing 5% 
CO2.   
 
4.2.2.1 Eukaryotic cell lines 
Cells were incubated at 37°C and 5% CO2. The human hepatoma cell lines HuH7, 
HuH7.5 were maintained in complete DMEM medium and passaged at a ratio of 1:5 
when confluent. HepG2 H1.3 and HepG2.2.15 cell were cultivated in complete 
DMEM or, for virus production, in a 1:1 mixture of PHH medium and complete 
Williams E medium. HEK 293 cells were kept in complete DMEM and passaged at a 
ratio of 1:5 when confluent.  
 
4.2.2.2 Isolation of primary human hepatocytes (PHHs) 
PHH were isolated from fresh surgical liver specimen from patients undergoing partial 
hepatectomy. The procedure was approved by the local Ethics Committee, with 
obtained consent of the patients. Protocol was performed as previously described 
(Schulze-Bergkamen, Untergasser et al. 2003). The pre-perfusion medium, perfusion 
medium, and the PHH medium were warmed to 37°C prior to the perfusion, and the 
wash medium was cooled to 4°C. The healthy liver tissue piece was placed on a 
kidney dish. A large branch of the port vein was canulated, and the canula was fixed 
with tissue paste. The two-step collagenase perfusion started with 500 ml pre-
perfusion medium, with a flow rate between 20 and 40 ml/min. For a satisfactory 
result it is important that the whole tissue is evenly perfused. At cut surfaces with high 
medium passage, the large vessels were occluded with tissue paste. The medium 
was discarded after traversing the liver tissue. After 15 to 20 min, perfusion was 
continued with 250 ml perfusion medium containing freshly added collagenase type 
IV (Worthington). 100 ml of the collagenase perfusion medium were kept and 
perfusion was continued with this remaining amount of medium. Collagenase 
treatment was performed for 15 to 20 min, depending on liver section size. As soon 
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as the tissue softened and liver cells appeared in the medium, the liver was cut into 
small peaces and the tissue was scratched off with a scalpel. If collagenase digestion 
was incomplete, the suspension was transferred to a sterile beaker and stirred for 10 
min at 37°C. The cell suspension was filtrated through double-layered gaze and a 70 
µm cell strainer. After centrifugation in 50 ml Falcon tubes for 5 min at 50 x g at 10°C, 
the pellet was re-suspended in 40 ml wash medium. Supernatant was used for 
isolation of LSECs and Kupffer cells. The wash step was repeated 3 times. The cells 
were re-suspended in PHH medium and the cell number and viability was 
determined. The cells were seeded on collagenised cell culture dishes at a density of 
to 8 x 105 cells per ml in PHH medium supplemented with 10% FCS. After 3 h the 
medium was exchanged to remove non-adherent cells. One day post seeding, the 
cells were kept in medium containing 5% FCS. From day 2 post seeding the cells 
were cultivated in FCS-free medium and were usable for experiments. 
 
4.2.2.3 Isolation of LSECs and Kupffer cells 
Seperation of human Kupffer cells (KCs) and liver sinusoidal endothelial cells 
(LSECs) from human liver non-parenchymal cell (NPC) suspension (in 1. supernatant 
of PHH cell isolation described above) was performed as followed: Kupffer cells: 
Suspension of cells were centrifuged with 300 rcf, 10 min, at 4°C. Pellet was washed 
with PBS and again centrifuged with 300 rcf, 10 min, at 4°C. Simultaneously, density-
Gradient was prepared: 20 ml 9% OptiPrep diluted with PBS over 10 ml 16% 
OptiPrep. Pellet was resuspended in 20 ml PBS and the suspension carefully applied 
on the density gradient. Gradient was centrifuge with 800 rcf, 25 min, at RT, with 
deactivated break. NPCs were now separated into two bands: the upper band 
contained the ITO cells, the lower band the KCs and LSECs. The lower band was 
collected, cells resuspended with PBS in a 50 ml reaction tube and centrifuged with 
300 rcf, 10 min, at 4°C. Then, cell pellet was resuspended in PHH medium, the 
volume depended on the size of the pellet. LSECs and Kupffer cells were separated 
as followed. Cells were counted, and dispersed (5x105 cells / ml) for 12-well plate 
range. For the adherence step of KCs, cell suspension was incubated for 20 min in 
humidified incubator at 37°C containing 5% CO2 without the possibility of shaking. 
KCs adhered to the plastic surface. Medium was taken of and collected (contained 
LSECs). Each well was washed three times with warm PBS, the supernatant was 
collected each time.  Adherent KCs were incubated with RPMI medium in a 
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humidified incubator at 37°C containing 5% CO2 for further experiments. All 
supernatants from the washing steps were collected in a 50 ml reaction tube for 
isolation of LSECs:  
Collected supernatants were centrifuged at 300 rcf, 5 min, at RT. Supernatant was 
dispersed and the pellet resuspended in an adjusted volume of LSEC medium. Cells 
were counted and 20 µl FcR blocking reagent (Miltenyi) per 107 cells was added. 
Suspension was mixed gently and incubated for 5 min at 4°C. Afterwards, 20 µl 
CD31 magnetic beads (Miltenyi) pro 107 cells were added, suspension was mixed 
gently and incubated for 15 min at 4°C. 1 ml LSEC medium per 107 cells was added 
and centrifuged with 300 rcf, 5 min, at RT. Pellet was resuspended in 1 ml LSEC 
medium. Miltenyi MS column in the magnetic field were prepared. MS column was 
equilibrated with 500 µl LSEC medium. Cell suspension was applied onto the column 
and afterwards washed 3x with LSEC medium. Then, the column was removed from 
the magnet and CD31 positive cells squeezed out using 1 ml LSEC medium and the 
stamp. Separated cells were counted and applied in collagenized wells with LSEC 
medium. Cells were incubated in a humidified incubator at 37°C containing 5% CO2 
for further experiments. 
 
4.2.2.4 Transfection of cells 
All cell types cell were transfected with the indicated RNA-oligonucleotides using 
HiPerFect® (Qiagen) according to the manufacturers protocol: Cells were plated 
immediately prior to transfection in fresh medium to obtain a 40 to 60% confluent 
monolayer at the following day. 1 µg RNA-oligonucleotide was used per 3.125 x 105 
cells, except poly(I:C), due to cytotoxicity, only 1/10 was used (1 µg per 3.125 x 106 
cells). The RNA-oligonucleotide was mixed with serum free medium and 8,75 µl 
HiPerFect per µg RNA-oligonucleotide. After 10 min incubation the solution was 
added drop wise to the cells. Inoculums were left on the cells over night. Fresh 
medium was applied at the next day.      
 
4.2.2.5 Production of wild type HBV  
For the production of wtHBV the HepG2.2.15 cell (genotype A) line was used. This 
cell line contains 1.1 fold over-lengths HBV genomes stably integrated into the 
cellular genome. Therefore, they permanently produce HBV, which can be harvested 
in the supernatant of the cells. The cells were cultivated until confluent in complete 
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DMEM medium. Then the medium was exchanged to 50% PHH medium and 50% 
complete Williams E medium. Every 2 to 3 days the virus-containing medium was 
collected and cell debris was removed by centrifugation at 1000 rpm for 10 min. The 
supernatant was transferred to centrifugal filter devices (Centricon Plus-70, Biomax 
100, Millipore Corp.) The first centrifugation was performed at 3500 x g for 1 h. In this 
step, the virus particles are captured in a filter. Because of the exclusion limit of 100 
kDa, serum proteins flow through, while proteins larger than 100 kDa are kept. In a 
second, invert centrifugation step, performed at 1000 x g for 3 min, the filter system 
was turned upside down, to elute the virus. The virus containing concentrate was 
filled to 1 ml with PBS and a final concentration of 10% glycerol. The virus 
concentrate was stored in 100 µl aliquots at -80°C until further use. The titer of the 
produced wtHBV was measured as enveloped, DNA-containing viral particles. A 
CsCl density-gradient, followed by dot blot analysis, was performed as outlined 
below. 
 
4.2.2.6 Caesium chloride density gradient 
In the context of a virus production different types of particles are obtained in the 
preparation: nacked DNA, unenveloped DNA-containing capsids, and enveloped 
virions. Their different densities enable to separate them in a density gradient. DNA is 
centrifuged down to the bottom, because of the very small size. DNA-containing 
capsids sediment at a density of 1.3 g/l while intact virions can be found in the 1.22 
g/l fraction. The CsCl density gradient ultra centrifugation was performed with the 
SW-60 swing bucket rotor. In SW-60 polyallomer vials (Beranek Laborgeräte) 500 µl 
of CsCl solutions with the following densities were carefully layered one upon the 
other: 1.4 g/l, 1.3 g/l and 1.15 g/l. On top of the CsCl solutions 500 µl of a 20% 
sucrose solution was layered, and the sample was applied. The vials were filled up 
with PBS and tared on micro scales. Ultra-centrifugation was performed at 55.000 
rpm at 20°C for 4 h to over night. The first 12 density fractions from the bottom were 
collected with a Dot Blot Fraction recovery system (Beckman). Each fraction 
contained a volume of approximately 175 µl. The fractions were subjected to 
quantitative dot blot analysis.       
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4.2.2.7 Dot blot analysis 
To quantitatively and qualitatively analyze the produced wtHBV, a DNA dot blot was 
performed. The DNA fractions, obtained by CsCl density centrifugation, were dotted 
to a nylon membrane in a dot blot aperture. A HBV DNA standard ranging from 8 pg 
to 1000 pg was added. Samples and standard were washed once with 200 µl PBS 
and the membrane was transferred to a 3 mm Whatman paper. Following 
denaturation in Soak 1 (0.5 MNaOH, 1 M NaCl ), renaturation in Soak 2 (0.5 M Tris, 
pH 7.4, 3 M NaCl) was performed. Then the DNA was cross-linked at 125 mJ / cm2 
to the membrane in a UV oven. The membrane hybridized with a 32P-labelled HBV 
DNA probe at 65°C over night, as previously described. After wrapping the 
radioactive membrane in seran wrap, the DNA was quantified with a phospho-imager 
(BIO-RAD). 
 
4.2.2.8 HBV-infection of PHHs 
Infection of PHHs with HBV was performed in medium containing 5% PEG 8000. The 
cells were incubated over night with HBV at a MOI of 100 virions/cell. After over night 
inoculation, cells were washed 3 times with PBS. Cells were further cultivated in fresh 
medium, and cell culture medium was collected at indicated time points. To monitor 
infection, HBsAg and HBeAg were determined using commercial immuno-assays 
(Axsym®, HBeAg 2.0, HBsAg V2, Abbott Laboratories, HBsAg ELISA, Abbott).        
 
4.2.2.9 Dual-luciferase assay 
First, 2x105 HEK 293 cells were plated per 24-well-plate and incubated over night. At 
day 1 cells were transfected (Fugene6, according to manufacturers instructions) with 
a) 100 ng/well of plasmid p125, containing ORF of Firefly-Luciferase under IFN-β 
promotor (nt-125 - nt-55) and b) 10 ng/well of plasmid pRL-TK, containing ORF of 
Renilla luciferase, used as internal control for transfection efficiency. To enhance 
RIG-I expression, 1000U / ml medium of universal type-I IFN  (PBL) was added 
appropriate 8 h after transfection for 16 – 20 h (until day 2) to supernatant of cells. 
Therefore medium was changed previously to P/S free HEK 293 medium. At day 2 
3p-RNA oligonucleotides were transfected (Lipofectamine 2000, according to 
manufacturers instructions) into cells. At day 3 cell lysates were prepared for 
lufirease detection assay. Supernatant of cells was discarded and 100 µl of 1x 
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passive lysis buffer / well was added. For lysis (4.2.2.5.1) cells were incubated for 20 
min at RT on a shaker platform. 
Plasmids and dual luciferase kit were kindly provided by Dr. Katharina Eisenächer, 
AG PD Dr. med. Anne Krug, II. Medizinische Klinik und Polyklinik (Gastroenterology), 
MRI München.  
 
4.2.2.10 Luciferase detection 
Firefly (Photinus pyralis) and Renilla (Renilla reniformis) luciferase are enzymes that 
convert their substrate Beetle luciferin into oxyluciferin (Firefly) or coelenterazine into 
coelenteramide (Renilla). In this reaction light is emitted proportional to the enzyme 
concentration. To quantify the light emission the Firefly-Luciferase Assay system 
(Promega) was used, according to to manufacturers instructions. HEK 293 cells were 
lysed in 100 µl lysis buffer per well at day 3 post transfection. 80 µl LAR II buffer 
(luciferase assay buffer + luciferin) was added into a cuvette and 20 µl of lysate was 
added. After mixing by pipetting for 5 seconds the samples were transferred to a 
luminometer (Berthold Technologies). After 5 sec the light emission of Firefly 
luciferase expression was measured for 10 sec in a luminometer (measurement I). 
After quantifying the firefly luminescence 80 µl of Stop & Glow was added, which 
stopped the reaction and simultaneously the initiated the renilla luciferase reaction by 
adding its substrate (Coelenterazien). Samples were mixed by vortexing. Renilla-
Luciferase expression was measured according to measurement of Firefly-Luciferase 
(measurement II). The luminescence (RLU) of measurement I were set as relative 
value to RLU of measurement II and normalised to mock transduced cells, serving as 
negative control. The RLU determined in these samples were defined as 1, the other 
values were adapted proportionally. 
 
4.2.2.11 Cytotoxicity assays XTT 
Viability of HepG2 H1.3 cells after transfection of RNA oligonucleotides in triplicate 
was tested with XTT - Cell Proliferation Kit II (Roche), according to manufacturers 
instructions at indicated timepoints from 24h up to 16 days. 25µl XTT labeling mixture 
was added to each well and incubated for 2 h.  
The cell viability assay determining cleavage of tetrazolium salts (XTT) to formazan 
by the "succinate-tetrazolium reductase" system. This system belongs to the 
respiratory chain of mitochondria, and is only active in metabolically active cells. The 
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assay is based on the cleavage of the tetrazolium salt XTT in the presence of an 
electron-coupling reagent, producing a soluble formazan salt. This conversion only 
occurs in viable cells. Cells grown in a 96-well tissue culture plate are incubated with 
the XTT labeling mixture for approximately 2 - 20 hours. After this incubation period, 
the formazan dye formed is quantitated using a scanning multi-well 
spectrophotometer (ELISA reader). The absorbance revealed directly correlates to 
the cell number.  
 
 
4.2.3 Mouse experiments 
Animal experiments were approved by the ethics committee of the Bezirksregierung 
Köln and were performed in accordance with the German animal protection law. HBV 
tg mice used in this study were of comparable weight and age. 
 
4.2.3.1 Bleeding of mice and serum preparation 
Mice were bleeded retro bulbar or sacrificed, respectively. After scarification mice 
fixed and blood was extracted from the heart muscle with a syringe. Blood was 
centrifuged for 10 min at 6000 rpm and RT. Serum supernatant was added to a new 
reaction tube and stored at -20°C for further analysis of ALT levels or determination 
of viral DNA and antigen load. 
 
4.2.3.2 Determination of ALT activity 
The liver specific enzyme alanine aminotransferase (ALT) is secreted by apoptotic 
hepatocytes into the blood. The concentration is therefore a highly specific marker for 
liver damage. Determination of ALT activity in the blood was used to specify the 
grade of liver inflammation in mice. Analysis was performed with 32 µl of fresh mouse 
serum on Reflotron® stripes in Reflovet® automat.  
 
4.2.3.3 Classical and hydrodynamic intravenous injection 	  
All mouse studies were conducted at animal facility of IMMIH in Köln under S2 
conditions and animal care guidelines (authorized by Regierung von Köln). RNA 
oligonucleotides (25g/mice/injection) were intravenously injected after complexation 
with in vivo-JetPEI (Polyplus) in a total volume of 200 µl (5% glucose), according to 
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manufacturers instructions. Injection was repeated after 3 days and antiviral effects 
were analyzed 6 to 15 days after first injection.  
Alternatively, mice were injected by hydrodynamic injection (HDI). By HDI the nucleic 
acid is intravenously injected in a high volume of buffer (8% of body weight) during 5 
– 10 seconds under high pressure into the tail vein of the mice. By an averaged 
bodyweight of 20 g per mouse the siRNA is diluted in 1,6 ml of PBS, which reflects 
~50% of the blood volume. 
 
4.2.3.4 Organ perfusion 
Mice were sacrificed and perfused with 50 ml buffered paraformaldehyd (PFA, 4%) 
via left ventricle, vena portae or the vena cava, respectively. Fixed organs were 
removed and stored in buffered PFA (4%) over night. To remove H2O, organs were 
then stored in 25% sucrose solution at 4°C over night. For tissue-slices organs were 
completely embedded in Tissue-Tak® Tec. After freezing at -80°C over night organ 
slices of 8µm were cut in a cyrostate (Leica) and embedded on object-slides. Organ-
slices were mounted with Mowiol/Dabco. A cover slip was sealed on the slide with 
nail polish. The slides were stored at 4°C and analyzed by fluorescence microscopy. 
 
4.2.3.5 Fluorescence microscopy 
Examination was performed on an Olympus IX81 microscope or on an Olympus 
FluoView1000 confocal microscope.        
 
4.2.3.6 Histology 
Mice were sacrificed and organs were removed. Organ samples were treated with 
formalin. Pathology Helmholtz-Center Munich embedded the pieces in paraffin for 
blinded histological examination. Two-µm-thick sections were cut and stained with a) 
haematoxylin and eosin (H&E) and periodic acid-Schiff (PAS) or b) polyclonal rabbit 
anti hepatitis B core antigen antibody. The histopathological alterations were 
classified for a) in: -changes affecting the portal tracts (e.g. inflammation, 
degenerative changes of the bile ducts, fibrosis); - changes affecting the lobule (e.g. 
spotty and bridging necrosis, degenerative changes of the hepatocytes, fibrosis); - 
changes affecting the vessels (e.g. inflammation, fibrosis, thrombosis). The 
histopathological alterations were graded as mild, moderate and severe depending 
on their frequency and severity. Focal lesions (e.g. spotty necrosis) were counted 
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through the whole tissue specimen. The histopathological core-staining was 
classified in: nuclear positivity; the intensity was comparable in all samples, the 
localization was always diffuse. As well as in cytoplasmic positivity; the localization, 
intensity and distribution (diffuse: around most central venules; multifocal: around 
multiple central venules; focal) were determined.  
 
4.2.4 Statistical analysis 
For statistical analysis, the data were subjected to unpaired, two-tailed Student’s t-
test and statistical significance was determined confidence intervals of 95%. 
 
 
4.2.5 HBV sequence 
Read from ASCII file hpb ayw.gbo; HBV -3182 nt- (ayw)-Galibert; AccNo. J02203;  
ori set to core ATG. 
Targeting sequences of siRNAs si-1.1, si-1.2 and si-1.3 are marked 
 
ATGGACATCGACCCTTATAAAGAATTTGGAGCTACTGTGGAGTTACTCTCGTTTTTGCCTTC
TGACTTCTTTCCTTCAGTACGAGATCTTCTAGATACCGCCTCAGCTCTGTATCGGGAAGCCT
TAGAGTCTCCTGAGCATTGTTCACCTCACCATACTGCACTCAGGCAAGCAATTCTTTGCTGG
GGGGAACTAATGACTCTAGCTACCTGGGTGGGTGTTAATTTGGAAGATCCAGCGTCTAGAGA
CCTAGTAGTCAGTTATGTCAACACTAATATGGGCCTAAAGTTCAGGCAACTCTTGTGGTTTC
ACATTTCTTGTCTCACTTTTGGAAGAGAAACAGTTATAGAGTATTTGGTGTCTTTCGGAGTG
TGGATTCGCACTCCTCCAGCTTATAGACCACCAAATGCCCCTATCCTATCAACACTTCCGGA
GACTACTGTTGTTAGACGACGAGGCAGGTCCCCTAGAAGAAGAACTCCCTCGCCTCGCAGAC
GAAGGTCTCAATCGCCGCGTCGCAGAAGATCTCAATCTCGGGAATCTCAATGTTAGTATTCC
TTGGACTCATAAGGTGGGGAACTTTACTGGGCTTTATTCTTCTACTGTACCTGTCTTTAATC
CTCATTGGAAAACACCATCTTTTCCTAATATACATTTACACCAAGACATTATCAAAAAATGT
GAACAGTTTGTAGGCCCACTCACAGTTAATGAGAAAAGAAGATTGCAATTGATTATGCCTGC
CAGGTTTTATCCAAAGGTTACCAAATATTTACCATTGGATAAGGGTATTAAACCTTATTATC
CAGAACATCTAGTTAATCATTACTTCCAAACTAGACACTATTTACACACTCTATGGAAGGCG
GGTATATTATATAAGAGAGAAACAACACATAGCGCCTCATTTTGTGGGTCACCATATTCTTG
GGAACAAGATCTACAGCATGGGGCAGAATCTTTCCACCAGCAATCCTCTGGGATTCTTTCCC
GACCACCAGTTGGATCCAGCCTTCAGAGCAAACACCGCAAATCCAGATTGGGACTTCAATCC
CAACAAGGACACCTGGCCAGACGCCAACAAGGTAGGAGCTGGAGCATTCGGGCTGGGTTTCA
CCCCACCGCACGGAGGCCTTTTGGGGTGGAGCCCTCAGGCTCAGGGCATACTACAAACTTTG
CCAGCAAATCCGCCTCCTGCCTCCACCAATCGCCAGTCAGGAAGGCAGCCTACCCCGCTGTC
TCCACCTTTGAGAAACACTCATCCTCAGGCCATGCAGTGGAATTCCACAACCTTCCACCAAA
CTCTGCAAGATCCCAGAGTGAGAGGCCTGTATTTCCCTGCTGGTGGCTCCAGTTCAGGAACA
GTAAACCCTGTTCTGACTACTGCCTCTCCCTTATCGTCAATCTTCTCGAGGATTGGGGACCC
TGCGCTGAACATGGAGAACATCACATCAGGATTCCTAGGACCCCTTCTCGTGTTACAGGCGG
GGTTTTTCTTGTTGACAAGAATCCTCACAATACCGCAGAGTCTAGACTCGTGGTGGACTTCT
CTCAATTTTCTAGGGGGAACTACCGTGTGTCTTGGCCAAAATTCGCAGTCCCCAACCTCCAA
TCACTCACCAACCTCTTGTCCTCCAACTTGTCCTGGTTATCGCTGGATGTGTCTGCGGCGTT
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TTATCATCTTCCTCTTCATCCTGCTGCTATGCCTCATCTTCTTGTTGGTTCTTCTGGACTAT
CAAGGTATGTTGCCCGTTTGTCCTCTAATTCCAGGATCCTCAACAACCAGCACGGGACCATG
CCGGACCTGCATGACTACTGCTCAAGGAACCTCTATGTATCCCTCCTGTTGCTGTACCAAAC
CTTCGGACGGAAATTGCACCTGTATTCCCATCCCATCATCCTGGGCTTTCGGAAAATTCCTA
TGGGAGTGGGCCTCAGCCCGTTTCTCCTGGCTCAGTTTACTAGTGCCATTTGTTCAGTGGTT
CGTAGGGCTTTCCCCCACTGTTTGGCTTTCAGTTATATGGATGATGTGGTATTGGGGGCCAA
GTCTGTACAGCATCTTGAGTCCCTTTTTACCGCTGTTACCAATTTTCTTTTGTCTTTGGGTA
TACATTTAAACCCTAACAAAACAAAGAGATGGGGTTACTCTCTAAATTTTATGGGTTATGTC
ATTGGATGTTATGGGTCCTTGCCACAAGAACACATCATACAAAAAATCAAAGAATGTTTTAG
AAAACTTCCTATTAACAGGCCTATTGATTGGAAAGTATGTCAACGAATTGTGGGTCTTTTGG
GTTTTGCTGCCCCTTTTACACAATGTGGTTATCCTGCGTTGATGCCTTTGTATGCATGTATT
CAATCTAAGCAGGCTTTCACTTTCTCGCCAACTTACAAGGCCTTTCTGTGTAAACAATACCT
GAACCTTTACCCCGTTGCCCGGCAACGGCCAGGTCTGTGCCAAGTGTTTGCTGACGCAACCC
CCACTGGCTGGGGCTTGGTCATGGGCCATCAGCGCATGCGTGGAACCTTTTCGGCTCCTCTG
CCGATCCATACTGCGGAACTCCTAGCCGCTTGTTTTGCTCGCAGCAGGTCTGGAGCAAACAT
TATCGGGACTGATAACTCTGTTGTCCTATCCCGCAAATATACATCGTTTCCATGGCTGCTAG
GCTGTGCTGCCAACTGGATCCTGCGCGGGACGTCCTTTGTTTACGTCCCGTCGGCGCTGAAT
CCTGCGGACGACCCTTCTCGGGGTCGCTTGGGACTCTCTCGTCCCCTTCTCCGTCTGCCGTT
CCGACCGACCACGGGGCGCACCTCTCTTTACGCGGACTCCCCGTCTGTGCCTTCTCATCTGC
CGGACCGTGTGCACTTCGCTTCACCTCTGCACGTCGCATGGAGACCACCGTGAACGCCCACC
AAATATTGCCCAAGGTCTTACATAAGAGGACTCTTGGACTCTCAGCAATGTCAACGACCGAC
CTTGAGGCATACTTCAAAGACTGTTTGTTTAAAGACTGGGAGGAGTTGGGGGAGGAGATTAG
GTTAAAGGTCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCAGCACCATGCA
ACTTTTTCACCTCTGCCTAATCATCTCTTGTTCATGTCCTACTGTTCAAGCCTCCAAGCTGT
GCCTTGGGTGGCTTTGGGGC 
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6 List of abbreviations 
   
2`-5`-OAS   2`-5`-oligoadenylate synthetase 
3p    5`-Triphosphated  
A    Adenine 
aa    Amino acid 
ALT    Alanine aminotransferase  
Ab    Antibody 
APS    Ammonium persulphate 
bp    Base pair 
C    Cytosine 
cccDNA   Covalently closed circular DNA form of HBV 
cDNA    CopyDNA, to mRNA complementary DNA 
C-terminal   Carboxy-terminal 
Ctrl    Control 
d    Day 
ddH2O   Double distilled water 
DNA    Desoxyribonucleic acid 
ds    Double-stranded 
EDTA   Ethylenedinitrilotetraacedic acid 
e.g.    exempli gratia 
EIA   Enzyme immuno-assay 
ELISA   Enzyme linked immunoabsorbent assay 
Enh    Enhancer 
EtBr    Ethidiumbromide 
FCS    Fetal calf serum 
G    Guanine 
GAPDH   Glyceraldehyde 3-phosphate dehydrogenase 
h    Hour 
HBeAg   HBV e-antigen 
HBsAg   HBV s-antigen  
HBV    Hepatitis B virus 
HCC    Hepatocellular carcinoma 
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HRP    Horse radish peroxidase 
IFNAR   Interferon α/β receptor 
Ig    Immunoglobulin 
IL-6    Interleucin-6 
IFN    Interferon 
IP-10    Interferon-inducible protein 10    
IVT    In vitro transcription 
kb    Kilo base 
kDa    Kilo Dalton 
l    Liter 
L-protein  Large surface protein of HBV envelope 
LPS    Lipopolysaccharide 
mA    Milli-ampere 
MDA-5   Melanoma differentiation associated gene-5  
µg    Microgram 
mg    Milligram 
MHC    Major histocompatibility complex 
Min   Minute 
µl    Microliter 
ml    Milliliter 
µM    Micromolar 
mM    Millimolar 
MOI    Multiplicity of infection; infection ratio in number of virus per cell  
M-protein  Middle surface protein of HBV envelope 
mRNA   Messenger RNA 
n    Number 
ng    Nanogram 
nM    Nanomolar 
N-terminal   Amino-terminal 
nt    Nucleotide 
OD    Optical density 
ori    Origin of replication 
ORF    Open reading frame 
P     P-value 
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PAGE   Polyacrylamide gel electrophoresis 
PCR    Polymerase chain reaction 
pgRNA   Pregenomic RNA template of HBV 
PHH    Primary human hepatocytes 
PolyA    Polyriboadenosine 
Poly(I:C)   Polyinosinic-polycytidylic acid 
preS1   C-terminal domain of HBV L-protein 
preS2   C-terminal domain of HBV M-protein 
p.inf.    After infection 
p.inj.    After injection 
p.tr.    After transfection 
qRT-PCR   Quantitative real-time polymerase chain reaction 
rcDNA   Relaxed circular DNA: partial double-stranded HBV-genome  
RIG-I    Retinoic acid inducible gene I 
RLU    Relative light units  
RNA    Ribonucleic acid 
Rpm   Rounds per minute 
RT   Room temperature 
scFv    Single chain fragment of the variable region  
SD    Standard deviation 
sgRNA   Subgenomic RNA template of HBV 
S-protein  Small surface protein of HBV envelope 
ss    Single-stranded 
SVP    Subviral particle 
T    Thymine 
TAE    Tris-acetate-EDTA buffer 
TBS    Tris buffered saline 
Tg    Transgenic 
TLR    Toll-like receptor 
TNFα    Tumor necrosis factor α 
U    Uracil 
U    Units 
v/v   volume per volume 
w/v    weight per volume 	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